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Abstract 
 
 
 Pseudomonas aeruginosa expresses type IV pili, which are polymeric fibrous surface 
appendages extending from the poles of the cell that function in adhesion and surface 
motility.  The monomeric pilus subunit, pilin, of P. aeruginosa 1244 is glycosylated with an 
oligosaccharide that is structurally identical to the O-antigen repeating unit of this organism.  
Work presented here identifies the pilin structures necessary for glycosylation.   Results 
suggested that the C-terminal Ser of pilin is the major glycosylation recognition feature, and 
this residue cannot be substituted at its carboxyl group.   While no other specific recognition 
features are present, the pilin surface must be compatible with the reaction apparatus for 
glycosylation to occur.  Further work was conducted to investigate glycan substrate 
recognition in the 1244 pilin glycosylation reaction.  Data suggested that the pilin 
glycosylation substrate recognition features lie within the reducing-end moiety of the O-
repeat, and structures of the remaining sugars are irrelevant.  Additional research was carried 
out to assess the role of the P. aeruginosa 1244 pilin glycan in pathogenesis.  Competition 
index analysis using a mouse respiratory model comparing strain 1244 and the pilO isogenic 
knockout strain, 1244G7 indicated that the presence of the pilin glycan allowed for 
significantly greater survival in the lung environment.  This suggested that the pilin glycan is 
a significant virulence factor and may aid in the establishment of infection.  As the pilin 
glycan and the O-subunit are structurally identical, mice were immunized with strain 1244 
glycosylated pili to test if vaccination with these fibers provided O-antigen-specific 
protection.  Using either the mouse respiratory or the thermal injury model, protection from 
challenge with a pilus-deficient O-antigen-producing 1244 mutant was observed.  These 
results provide evidence that the pilin glycan stimulates a protective response that targets the 
O-antigen, suggesting that this system could be utilized as a means to develop numerous 
protective anti-gram-negative bacterial bioconjugate vaccines.   
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Chapter 1. Introduction 
 
 1.1.  Pseudomonas aeruginosa.  P. aeruginosa is a gram-negative, rod shaped 
bacterium ubiquitously distributed in the environment.  Other defining characteristics of this 
organism include the capability to grow at 41°C, the ability to oxidize gluconate, and also the 
capability to reduce nitrate to nitrogen gas (147).  P. aeruginosa has been isolated from soil, 
plants, sinks, faucets, bedpans, catheters, respirators, and bladder irrigation devices (22, 23). 
This organism is one of the most prevalent facultative pathogens, and has an extremely broad 
host specificity, as it is capable of causing diseases to a wide variety of hosts, including 
plants, nematodes, and insects, as well as humans (53, 110, 111, 120, 150, 181, 229).  In part, 
its success as a pathogen is associated with this organism’s versatility due to its minimal 
growth requirements, capability to use a wide variety of compounds as energy sources, as 
well as its natural resistance to many antibiotics and heavy metals (22).  By forming biofilms 
– many layers of cells embedded in an extracellular slime – P. aeruginosa furthers its 
resistance to anti-microbial agents such as commercial disinfectants commonly used in 
hospitals (57, 169, 215).  Notably, the genome of P. aeruginosa is large (220), exceeding 
6000 kb in most strains (137),  providing this organism with the potential for producing a 
complex proteome (more than 5500 annotated proteins) larger than some simple eukaryotes 
such as the fission yeast, Schizosaccharomyces pombe, and the microsporidian, 
Encephalitozoon cuniculi (231).  
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 1.2.  P. aeruginosa as a pathogen.  P. aeruginosa thrives as an opportunistic 
pathogen.  For instance, this organism is the most commonly isolated gram-negative 
bacterium from nosocomial infections (22, 236),  and the second most encountered pathogen 
following surgery, third in medicine, and among the most frequent organisms isolated from 
pus, sputum, and blood from septicemic patients (214). This organism commonly colonizes 
respirators, catheters, and prosthetic implants, which may lead to successful host colonization 
(22).  Individuals afflicted with cystic fibrosis, severe burns, or compromised immune 
systems are most at risk to acquire an oftentimes-lethal P. aeruginosa infection.  
 The collaborative effort of multiple virulence factors contributes to this organism’s 
success as a pathogen.  Once a P. aeruginosa infection is established, antibiotic treatment of 
the diseased individual does not always result in successful eradication because P. 
aeruginosa is intrinsically resistant to antibiotics (3, 175, 250).  The low permeability of the 
outer membrane, the production of periplasmic β-lactamases, and the presence of numerous 
multidrug resistance pumps (187) all contribute significantly to the antibiotic resistance of 
this organism.  In addition to producing protein machines responsible for the nullification 
and expulsion of antibiotics, this organism synthesizes cell surface components to aid in 
successful host infection and colonization.   The outer membrane of P. aeruginosa is 
primarily composed of lipopolysaccharide (LPS).  LPS (Fig. 1.1) is highly immunogenic, 
mediates entry into eukaryotic cells, and protects P. aeruginosa against host defenses (83).  
Other surface structures involved in virulence of P. aeruginosa are type IV pili (Fig. 1.2).  
Type IV pili mediate attachment to host cells, which is a key contributor to the pathogenicity 
of P. aeruginosa (221).  The absence of pili considerably decreases the virulence of P.  
 3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. P. aeruginosa 1244 lipopolysaccharide based on the predicted 
lipid A (180), core oligosaccharide (190), and serotype O7 (127) repeating 
unit (IATS).  This image was drawn using ChemDraw software. 
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aeruginosa (230).  Interestingly, pilus mediated adhesion stimulates transcription of several 
immune-specific host cell genes, indicative of an intricate host/pathogen relationship 
between metazoa and Pseudomonads throughout evolution (105).   
 During the establishment of a P. aeruginosa infection, this organism unleashes an 
arsenal of proteases, hemolysins, cytotoxins, phospholipases, and exotoxins resulting in 
extensive damage to host tissue.  Numerous toxins, such as ExoS, ExoT, and ExoU are all 
exported by the type III secretion system.  The direct delivery of these toxins into the 
cytoplasm allows these enzymes to alter the host cell molecular biology, resulting in 
extensive tissue damage.  For example, ExoS is an ADP-ribosyltransferase that interacts with 
various eukaryotic intracellular proteins such as the intermediate filament vimentin, and 
several GTP-binding proteins, ultimately leading to morphological changes and cell death 
(101, 106).  Additionally, proteases such as elastase and alkaline protease, produce 
hemmorrhagic lesions, necrosis, and destruction of non-specific host defenses (214).  
Phospholipase C and rhamnolipids have distinctive detergent-like qualities, which result in 
the break-down of pulmonary surfactant, and cause hemolysis (181).   
 Another prominent virulence factor that P. aeruginosa extrudes to host cells is 
exotoxin A.  Exotoxin A is delivered via the type II secretion pathway, enters cells by 
receptor-mediated endocytosis, and ADP-ribosylates elongation factor 2 (96) by way of 
ribosome mimicry (117).  This impedes protein synthesis, which results in cell death.  
Exotoxin A can kill a number of cells associated with the immune system, such as 
polymorphonuclear leukocytes and macrophages (96). 
 In chronic infections P. aeruginosa has established long-term colonization, usually by 
way of fortification to protect itself from host defenses by forming a biofilm.  In a mature 
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biofilm, a massive aggregation of bacterial cells is embedded in an exopolysaccharide 
matrix.  In addition to polysaccharides, nucleic acids and proteins have been discovered in 
this coating (172).  The extracellular matrix inhibits phagocytosis and increases the 
organism’s resistance to anti-microbial agents.  Interestingly, the presence of sub-inhibitory 
levels of aminoglycoside antibiotics have been shown to induce the formation of P. 
aeruginosa biofilms (100).  P. aeruginosa biofilms are commonly detected in the lungs of 
cystic fibrosis patients (236).  While embedded in a biofilm, P. aeruginosa undergoes 
various cell surface transformations with respect to gene expression and LPS production.  In 
most instances, isolates from cystic fibrosis patients either partially or completely lack the 
LPS O-antigen (187) and do not secret common virulence factors associated with acute 
infection (84).  
 
1.3.  Pilin/pilus structure.  Pili (also commonly referred to as fimbriae) are 
proteinaceous, fibrous appendages that protrude from the cell surface of many gram-negative 
bacteria. The type IV pilus is composed primarily of a polymer of the 15-16 kDa monomeric 
subunit, pilin, which is encoded by the gene, pilA (Table 1.1) (87).  These pili are categorized 
as ‘type IV’ due to similarities in the pilin subunit primary sequence (221).  Additionally, 
type IV pilin subunits contain a positively charged leader sequence (Fig. 1.3), which is 
cleaved prior to pilus assembly.  This cleavage is coupled to the N-methylation of the newly 
exposed N-terminus of the mature pilin subunit (156).  In addition, all type IV pilins contain 
a C-terminal disulfide bond (47).  Type IV pilins are divided into two subcategories, referred 
to as type IVa or IVb, based on differences in primary structure, and pilin length (47).  The 
leader sequence of type IVa pilins is shorter (5-6 amino acids) than that of the type IVb pilins  
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Table 1.1 Select genes and products involved in assembly, disassembly, or functionality of 
type IV pili.  Genes are partitioned by relative chromosome location.  This information was 
gathered from the Pseudomonas genome project website at www.pseudomonas.com.  
 
Gene  Product/ Product    Location on 
name          aternate name function    chromosomea 
pilA  pilin, PilA pilus monomer   5,069,531 – 5,069,082 
pilO  PilO, TfpO pilin glycosyltransferase  behind pilA in strain 1244 
pilB  PilB  pilus biogenesis motor  5,069,763 – 5,071,463 
pilC  PilC  pilus biogenesis motor  5,071,567 – 5,072,691 
pilD  PilD, XcpA prepilin peptidase   5,072,695 – 5,073,567 
pilS  PilS  two-component sensor kinase 5,093,378 – 5,094,970 
pilR  PilR  two-component response regulator 5,094,985 – 5,096,332 
 
 
pilQ  PilQ  secretin protein   5,677,858 – 5,675,714  
pilP  PilP  lipoprotein, associates with PilQ 5,678,436 – 5,677,912  
pilM  PilM  unknown, possibly pilus   5,680,713 – 5,679,649  
     localization 
 
 
pilZ  PilZ  necessary for pilus assembly 3,320,030 – 3,319,674 
fimV  FimV  putative peptidoglycan binding 3,498,205 – 3,495,446 
     protein 
 
pilT  PilT  pilus retraction motor  436,570 – 437,604  
pilU  PilU  important for twitching motility 437,782 – 438,930 
pilG-I  PilG-I  important for taxis-mediated  449,639 – 451,045  
     twitching 
 
 
aLoci of all genes were based on the chromosome of PAO1, however, this strain does not possess pilO. 
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(15-30 amino acids).  In addition, the mature pilin sequence of type IVa pilins contains fewer 
residues than type IVb pilins, averaging 150 amino acids compared with 190, respectively.  
Following cleavage of the leader sequence, the newly exposed N-methylated residue is 
always Phe for the type IVa pilins, but varies for the type IVb pilins (47).  Interestingly, type 
IVa pili are produced by many gram-negative bacteria that have broad host ranges including 
P. aeruginosa, Neisseria spp., Dichelobacter nodosus, Moraxella spp., Eikenella corrodens, 
Azoarcus sp., and Bdellovibrio bacteriovorus (47).  The type IVb pili, by comparison, have 
been discovered only to be produced by bacteria that colonize the human intestine, including 
Vibrio cholerae, Salmonella enterica, and the enteropathogenic and enterotoxigenic E. coli 
(47). 
 
 
 
 
 
 
 
 
 
 
 
 
 
N C
Variable 
Region
Constant
Region
DSL
Type IV Pilin 
Subunit Structure:
Leader
DSL
Variable 
Region
Figure 1.3. Structure of the 
proteinaceous type IV pilin subunit.  
Disulfide loop is abbreviated as DSL.  
The leader sequence, which is cleaved by 
PilD, is colored in pink.  The conserved 
α-helical domain is shown in red, and the 
variable β-sheet region is colored in cyan.  
The crystal structure shown is pilin 
produced by P. aeruginosa PAK (48, 89, 
123). 
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Type IV pili have been discovered in numerous gram-negative bacteria (156), 
however the pili of P. aeruginosa, Neisseria sp., and V. cholerae are most commonly 
studied.  Ordinarily, type IV pili are 6-8 nm in diameter, and can extend to lengths of several 
μm (157).  In Pseudomonas, and other rod-shaped cells, pili are localized to the poles where 
pilin polymerization involves non-covalent interaction between subunits yielding a helical 
arrangement, with 4-5 subunits per turn (29, 48), which constitutes the crux of the pilus fiber.  
Pilin is usually 145-160 amino acids in length and may be additionally modified aside from 
the initial N-methylation.  Such post-translational modifications include glycosylation, 
phosphorylation, or the covalent addition of phosphocholine or phosphoethanolamine (32, 
73, 91, 218).   
The monomeric pilin subunits from various organisms all have a similar predicted 
tertiary structure (Fig. 1.3), regardless of the lack of identity in a majority of the amino acid 
sequence (47, 48, 73, 89, 123, 171).  The strongest sequence similarity between pilins of 
different bacterial strains exists in the N-proximal region (Fig. 1.3).  This region, which is 
adjacent to the N-terminal leader sequence, contains a series of conserved hydrophobic 
amino acids.  Beyond this domain, pilin sequences are divergent, but they terminate in a 
distinctive disulfide loop region (DSL) adjacent to the C-terminus (Fig. 1.3).   
The 3-dimensional structure for the type IV pilin subunit 
(http://www.scripps.edu/~lisac/) was produced via crystallographic and/or X-Ray EM 
analyses of native pilin monomers from N. gonorrhoeae (171), V. cholerae (48), and P. 
aeruginosa  PAK (48, 89, 123).  These models reveal two distinct regions.  The first region, 
appearing as a long ‘stem-like’ structure is the hydrophobic α-helical segment that 
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corresponds to the amino proximal conserved region, and consists of approximately one third 
of the pilin primary structure (Fig. 1.3).  This segment of the pilin monomer is adjoined to a 
region consisting of curved antiparallel β-sheets that fold over the C-terminal portion of the 
large α-helix.  The β-sheet region terminates in the carboxy-terminal DSL structure found in 
all type IV pilins (Fig. 1.3).   
 
 1.4.  P. aeruginosa pilus biosynthesis.  Assembly of pilin subunits into type IV pili is 
an elaborate, multistage process involving the collaboration of over 30 gene products (Table 
1.1).  The specific role of many of the products of these genes still remains uncertain, 
although much progress has been made in recent years concerning the elucidation of pilus 
biogenesis.  P. aeruginosa as well as N. gonorrhoeae have been used commonly as model 
organisms for studying type IV pilus biosynthesis in which these two organisms have 
demonstrated many similarities (247).  Genes involved in pilus biosynthesis are usually 
clustered together on bacterial chromosomes (156, 157).  As previously mentioned, in P. 
aeruginosa, the major pilus structural gene, pilA, encodes the pilin subunit in the form of a 
pre-pilin.  Normal expression of pilA requires the σ54 subunit of RNA polymerase which is 
encoded by rpoN.  RpoN is also necessary for normal expression of flagella and various 
virulence factors, and also acts as a global negative control on the quorum-sensing machinery 
of P. aeruginosa (97).  Mutants lacking a functional rpoN gene do not produce pili unless 
complemented with a plasmid containing the pilA gene behind an active promoter (182).  
Two positive regulators of pilA transcription, PilR and PilS (Table 1.1), are constituents of a 
two-component signaling pathway controlling pilA expression (99, 109).  pilR  encodes a 
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transcriptional activator that has homologous regions to members of a response regulator 
class (109, 221), while PilS appears to be a sensor kinase that is involved in a signal 
transduction pathway stimulating pilin synthesis (99, 221).  Furthermore, a functional crc 
gene, the global carbon metabolism regulator, is required for pilA expression (223).  Distinct 
environmental factors regulating pilus biosynthesis have not been determined, although it is 
known that culture agitation is not conducive for piliation (125) suggesting that pilus 
biosynthesis may be influenced by a physical signal.  Also, quorum sensing genes have been 
implicated to be involved with the down-regulation of pilA gene expression in a mature 
biofilm (57, 245).  The global gene regulator, RetS has been found to upregulate genes 
associated with acute infection, such as those involved in piliation, as well type II and III 
secretion while the presence of RetS downregulates biofilm associated genes (84).  The RetS 
counterpart, GacS, stimulates biofilm formation, associated with chronic infections, while it 
inhibits expression of the aforementioned acute infection-associated genes (84). 
 Upstream of pilA is a region containing the genes pilB, pilC and pilD (Table 1.1) 
which encode accessory proteins that process and assemble pilin subunits into functional pili 
(Fig. 1.4) (165).  PilD is a multi-functional protein responsible for cleavage of the leader 
sequence of pre-pilin as well as functioning as the N-methyltransferase after cleavage (166).  
In addition, PilD is responsible for processing components of the type II secretion apparatus 
of gram-negative bacteria (166).  An archaeal homolog of PilD, referred to as PibD, mediates 
the maturation of secretory proteins in Sulfolobus solfataricus, and can process various 
precursor proteins of E. coli when heterologously expressed (4), indicating the phylogenic 
conservation of PilD-like processing.  There is little known about the function of PilC in 
pilus biogenesis.  What is known is that PilC is an integral inner membrane-associated 
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protein required for piliation.  Mutants lacking either pilB or pilC display a buildup of mature 
pilin subunits in the cytoplasmic membrane, emphasizing their roles in pilus assembly (221).   
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Figure 1.4.  LPS and pilus biosynthetic pathways of P. aeruginosa 1244. O-antigen repeating units 
are constructed on the cytoplasmic face of the cell membrane on a carrier lipid, referred to as 
undecaprenyl phosphate (Und-P), by sequential addition of nucleotide-activated sugars.  WbpL 
catalyzes the transfer of initial O-subunit sugar, β-D-FucNAc (F), to Und-P.  Subsequently, xylose 
(X) is transferred to the carrier-lipid-bound FucNAc, followed by the addition of pseudaminic acid 
(P) to complete the O7 subunit.  Wzx is essential for the translocation of the carrier lipid-linked O-
repeat to the periplasmic face of the cell membrane, where Wzy catalyzes polymerization of the O-
antigen.  The size of the O-antigen chain length is regulated by Wzz, and the O-ligase, WaaL 
mediates the transfer of the entire O-antigen to the core polysaccharide.  The entire LPS molecule 
is transferred to the exterior of the outer membrane by an unknown mechanism.  Pilin is 
transcribed and its α-helix is embedded in the cell membrane.  By a poorly understood process, the 
globular β-sheet region is flipped to the periplasm where PilO mediates glycosylation by 
transferring a single O-subunit from the carrier lipid to Ser148 of pilin.  PilD cleaves the leader 
sequence of pilin.   Piliation/ depiliation is mediated by the PilBC/ PilTU pilus motor.  Pili are 
extruded through the PilQ assemblages in the outer membrane.  Mutating genes that act early on in 
O-antigen biosynthesis (wbpM and wbpL) abolished pilin glycosylation, confirming that the pilin 
glycan arises from the O-subunit metabolic pathway. 
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 The specific mechanism by which pilin subunits congregate into fibers is unknown. 
As the pilus extends through the periplasm, it must pass through the peptidoglycan.  
Although the mechanism underlying this process is poorly understood, FimV (Table 1.1) 
contains a putative peptidoglycan-binding domain, which contributes to the passage of the 
pilus through the cell wall (156). A secretin protein complex, consisting of PilQ, is crucial 
for the expression of extracellular type IV pili.  PilQ monomers conform into a multimeric 
pore in the outer membrane through which the pilus extends (19, 39, 154). In N. 
gonorrhoeae, PilQ (Table 1.1) has been shown to require PilP, a lipoprotein, in order to form 
into a stable oligomer (65).  Negative-stain transmission electron microscopy of the N. 
meningitidis PilQ assemblages revealed the three dimensional confirmation of this protein 
complex which revealed that the PilQ secretin contains a cavity, 10 nm deep, and 6.5 nm 
wide at the top, tapering to a closed point.  These results suggest that PilQ is a gated pore 
whereby pilus extension or retraction may be regulated (Fig. 1.4).  Structural studies have 
shown that PilQ interacts with the secreted pilus in a specific fashion, and that PilQ is not 
simply a hole, allowing passage of the pilus through the outer membrane.  Furthermore, this 
secretin is capable of substantial conformational changes upon interaction with the pilus 
substrate (40).  
 As mentioned previously, if a rod-shaped gram-negative bacterium expresses type IV 
pili, they are usually present at the cell poles.  Identification of proteins involved in polar 
localization of the type IV pilus machinery has been elusive.  The protein CpaE of 
Caulobacter crescentus is responsible for pilus localization in this organism, but does not 
have a representative in the pilus biosynthetic machinery of P. aeruginosa.  Due to its 
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homology to cell division protiens, PilM has been proposed to direct the location of piliation 
to the cell poles (156), however, this has yet to be experimentally tested. 
 Interestingly, many of the components of the type IV pilus biosynthesis machinery 
are homologous to proteins involved in the general type II secretory pathway (67, 164, 179).  
The type II secretion pathway of P. aeruginosa is responsible for the extracellular release of 
several toxins and hydrolytic enzymes such as elastase (13) and exotoxin A (146).  Type II 
secretion requires the involvement of the Xcp secreton complex (67).  Durand, et al., have 
shown that the XcpT pseudopilin, when overexpressed, can be assembled into a pilus similar 
to the bundle forming pili of enteropathogenic E. coli (67) indicating similar mechanisms 
behind driving type II secretion and piliation. 
 
 
 1.5.  Functions of P. aeruginosa pili. The type IV pili are involved in a variety of 
functions, including the mediation of a type of short-range surface motility referred to as 
‘twitching’ (24, 93).   Twitching motility involves pilus polymerization (extension), pilus-
tethering (adhesion), depolymerization (retraction), followed by release of the surface.  This 
phenomenon was directly observed by labeling cells with an amino-specific fluorescent dye 
followed by visualization via total internal reflection microscopy (209).  For time-lapse 
twitching motility movies, see www.rowland.harvard.edu/labs/bacteria/movies_paeru.html. 
 Although it is apparent that the extension and retraction of the pilus provides the 
motive force behind twitching, the mechanism of this process is poorly understood.  One of 
the most studied pilus motor proteins, PilT (Fig. 1.4; Table 1.1), is essential for pilus 
retraction (6, 244) as it is involved in the energy-requiring depolymerization step.  
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Additionally, PilU (Table 1.1) was thought to be involved in pilus retraction, as strains 
harboring mutant forms of this protein are hyperpiliated.  However, PilU mutants are 
susceptible to pilus-specific bacteriophage, a phenotype that requires pilus retraction, 
indicating that PilU is not essential for pilus depolymerization (38, 244).  PilT from Aquifex 
aeolicus, which is homologous to that of P. aeruginosa, was purified and shown to be a 
thermostable NTPase indicating its role as a pilus motility motor providing energy needed to 
polymerize/depolymerize pilin subunits (94).  The PilT motor of N. gonorrhoeae exudes a 
force of ~100 pN, making it the most powerful molecular motor on record (151).  
Presumably, these proteins, along with PilB and PilC (Fig. 1.4) make up at least part of the 
pilus motor (119).  Pilus assembly also requires PilZ, (Table 1.1) which is transcriptionally 
coupled to a sigma subunit gene of DNA polymerase III (156). 
 The ability to direct twitching motility allows pathogenic bacteria to attach to host 
tissue and draw themselves closer to the cell surface, thereby promoting the formation of 
microcolonies.  Functional pili have been shown to be essential for P. aeruginosa-mediated 
epithelial cell injury as well as for the establishment of ocular infection (42, 90, 120) 
underlying their importance for pathogen success.  Furthermore, twitching motility 
additionally contributes to the pathogenicity of P. aeruginosa by providing the necessary cell 
movement for early stages of biofilm formation in a static system (57, 169), which allows 
microcolonies to tumble and aggregate into larger masses.  Notably, in dynamic systems with 
flowing liquid, pilus mediated adhesion, but not twitching motility is essential for biofilm 
formation (37). 
 Studies indicated that chemical cues may influence twitching motility.  Putative gene 
products of P. aeruginosa have shown sequence similarity with chemotaxis-associated 
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proteins of Myxococcus xanthus (54) suggesting that they may be functionally similar.  PilG-
J (Table 1.1) are involved in a signal-transduction network controlling pilus biogenesis and 
twitching motility (54).   Furthermore, P. aeruginosa has been shown to exhibit directed 
twitching motility up a phosphatidylethanolamine gradient, indicating a chemotactic or 
chemokinetic response (122).  Additional regulatory studies have suggested that twitching 
motility is dependent on quorum sensing by the las and rhl systems (80) although this has 
been refuted as lasI, lasR, rhlI, and rhlR mutants all exhibit normal twitching (14). 
 In conjunction with directing twitching motility, the type IV pilus can act as an 
adhesive appendage, anchoring bacterial cells to host tissues.  This adhesion is believed by 
many to be a mediated by the pilus tip-exposed DSL, located in the variable C-terminal 
region of pilin subunits.  The DSL has been proposed to be buried (at least partially) along 
the shaft of the pilus fiber, but exposed at the tip (141).  The P. aeruginosa PAK pilus fiber 
has been predicted to consist of a single-start left-handed helix containing approximately 5 
pilin subunits per turn (89, 171).  The tip-exposed DSL region binds specifically to N-acetyl-
galactosamine, β-1-4 linked to galactose residues (133) found on gangliotetraosylceramide 
(asialo-GM1 and asialo-GM2) receptors of host cells (26, 43, 55, 56, 107, 108).  Although 
substantial data supports specific binding between the DSL of pilin and asialo-GM1, 
Schroeder et al. provided data suggesting that asialo-GM1 is not a major receptor for clinical 
isolates of P. aeruginosa provoking skepticism of this interaction (198).  Recent evidence 
has indicated that the pilin DSL region is also responsible for non-specific adhesion events 
associated with pilus tethering necessary for twitching motility (79).  Further DSL binding 
ability is demonstrated as pili of P. aeruginosa were shown to bind DNA in a specific, 
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concentration dependent manner (238).  This binding depends upon the presence of an intact 
fiber, and is mediated through DNA interaction with the pilus tip.  Insight into the 
understanding of pilus adhesion may be gained from a mutational analysis of the DSL.  
 Type IV pili have also been shown to play a role in the natural transformation of some 
bacteria (66, 219).  For example, a pilus-deficient mutant of Legionella pneumophila was not 
competent for DNA transformation, however this mutation was complemented by 
introduction of a cosmid which restored the production of type IV pili (219).  Type IV pilus-
dependent natural competence has also been observed in N. gonorrhoeae and H. influenzae 
(66). 
 
 1.6.  Lipopolysaccharide (LPS) of P. aeruginosa.  The cellular ultrastructure of 
Gram-negative bacteria is comprised of cytoplasm, a cell membrane, periplasm which 
contains the cell wall or peptidoglycan, and the outer membrane (Fig. 1.5).  The major 
component of the exterior surface of the gram-negative bacterial outer membrane is LPS 
(Figs. 1.1 & 1.5).  Because LPS is the dominant external structure of gram-negatives, early 
research concentrated on the role of LPS as a virulence factor and stimulation of the immune 
system to target this molecule by vaccination (187).  More recently, studies have broadened 
to include analysis of the chemistry, genetics, and biosynthesis of LPS in relationship to its 
serotype specificity, serum resistance properties, as well as its immunogenicity (12, 15, 30, 
31, 49, 82, 127, 128, 145, 158, 187, 188). 
 The LPS of P. aeruginosa is composed of three distinct regions (Figs. 1.1 & 1.5): An 
O-antigen (O-polysaccharide) composed of repeating sugar units; a core polysaccharide; and 
a lipid A region.  Two distinct types of LPS are commonly expressed on the outer membrane 
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of P. aeruginosa: A-band and B-band.  A-band LPS is that which contains the 'common 
antigen' and is comprised of short, neutral repeating D-rhamnose moieties.  A-band LPS is 
common among the bulk of P. aeruginosa serotypes (143).  The immunodominant antigen of 
P. aeruginosa is the B-band LPS, which contains the heteropolymeric 'O-antigen', and it is 
the basis for classification of organisms into serogroups and subgroups based on the variation 
in the O-antigen repeating units (83, 138).  According to the International Antigenic Typing 
System (IATS), there are at least 20 distinct serotypes of P. aeruginosa (147, 148).  This 
system expanded upon the schema of Habs which contained 12 serogroups each with a major  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5.  The P. aeruginosa 1244 pilin glycan is identical to this organism’s O7 O-
antigen subunit.  A P. aeruginosa cell (center) with B-band LPS (top) expressing a type IV 
pilus composed of glycosylated pilin subunits (left).  Pilin subunits are shown as purple 
spheres.  Green circles represent the pilin glycan/ O-subunit trisaccharide.  Arrows indicate 
glycosydic bond sites for O-antigen polymerization (black and red) and glycan attachment to 
Ser148 of pilin (red).  This figure was created using Adobe Illustrator.  Erica S. Jewell 
originally photographed the scanning electron micrograph depicted in this figure. 
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heat-stable specific antigen (147).  Prior to the widely accepted IATS, several P. aeruginosa 
serotyping systems existed including the Fisher system which was based on protective 
antigens, Verder and Evans based a schema on heat-stable and heat-labile antigens, and the 
Lanyi-Bergan system was based on major and minor somatic antigens (127, 147).   
 Clinical and environmental isolates of P. aeruginosa exhibit either a ‘smooth’ or 
‘rough’ LPS phenotype.  Strains that have polymerized O-antigen repeating units attached to 
the core-lipid A are referred to as a smooth LPS, whereas strains lacking an O-antigen results 
in a rough LPS phenotype.  Smooth LPS contributes toward, and is essential for acute 
virulence.  For example, in a study using a burned mouse infection model, a rough LPS 
mutant strain lacking O-polysaccharide was shown to have a LD50 of more than 1000-times 
higher than that of the smooth-LPS wild type strain (52).  
 
  1.6.1. O-antigen.  The outermost portion of the LPS of most gram-negative 
cells is the O-antigen.  This polysaccharide is the major cellular component contacting the 
extracellular environment, and may be 10-12 nm in length (127, 147).  In P. aeruginosa, the 
O-antigen polysaccharide consists of repeated subunits of sugars, which are usually di-, tri-, 
or tetrasaccharides (127, 147).  When LPS is subjected to gel electrophoresis followed by 
silver staining or Western blotting using LPS-specific sera (Fig. 1.6) a characteristic ladder 
can be observed due to the varying sizes of LPS O-antigen polymers.  Some examples of 
carbohydrate moieties present in P. aeruginosa O-antigens are N-acetylated hexoses such as 
FucNAc, QuiNAc, and GlcNAc; sugar acids such as Man(2NAc3NAc)A and 
Pse(5NAc7NFm); and common sugars such as glucose and rhamnose (127).  
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 O-antigen biosynthesis (Fig. 1.4) begins with the construction of individual O-antigen 
repeating units (O-subunits; O-repeats) on the cytoplasmic face of the cell membrane (72).   
Before becoming a part of the LPS, these oligosaccharides are constructed on a carrier lipid 
referred to as undecaprenyl phosphate (Und-P) by sequential addition of nucleotide-activated 
sugars (72).   In P. aeruginosa, WbpL (Fig. 1.4) is the enzyme that catalyzes the transfer of  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
initial O-subunit sugar, β-D-FucNAc, to Und-P (59).  In strain PA103, this is subsequently 
followed by the addition of α-L-FucNAc mediated by a previously uncharacterized 
Figure 1.6.  Western blot of P. aeruginosa LPS demonstrating the 
characteristic ladder-like appearance.  Each 'rung' of the ladder 
represents an addition of a single O-subunit.  Cell extract of P. aeruginosa 
1244N3 was run on a 16% tris/glycine gel and electroblotted onto 
nitrocellulose paper.  The blot was probed with O-antigen specific 
monoclonal antibody, 11.14 (33). 
15.5 
20.7 
27.4 
Mr (x10-3) 
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transferase, and finally the glucosyltransferase, WbjA, mediates the addition of a β-D-Glc 
moiety to complete the O11 subunit (58).  In strain 1244, the transferases that mediate O-
subunit assembly beyond the initial β-D-FucNAc have not yet been elucidated (Fig. 1.4).  
Wzx (Fig. 1.4), which is a putative flippase, is essential for the translocation of the 
undecaprenyl pyrophosphate (Und-PP) linked O-repeat to the periplasmic face of the cell 
membrane, where Wzy (Fig. 1.4) mediates O-antigen polymerization (59).  The size of the 
O-antigen chain length is regulated by Wzz (Fig. 1.4) (187), and the O-ligase, WaaL (Fig. 
1.4), catalyzes the transfer of the entire O-antigen to the core polysaccharide (1).  As 
previously shown, a Wzy mutant strain is incapable of synthesizing polymerized O-antigen, 
however, these cells do produce a core that contains a single O-antigen repeating unit (59).  
This LPS phenotype is referred to as a core + 1 (59).  Interestingly in strain PA103, mutation 
of the β-D-Glc-transferase, wbjA, yielded cells that produced a core containing an incomplete 
O-subunit, and possessed a core + 2/3 phenotype (58).  Collectively, these mutant LPS 
phenotypes suggest that polymerization of the O-antigen and complete assembly of the 
individual O-subunit are not necessary for core-O-antigen ligation (58). 
 
  1.6.2. Lipid A. The lipid A region (Figs. 1.1 & 1.5) of LPS (commonly 
referred to as endotoxin) is composed of a phosphorylated diglucosamine moiety substituted 
with fatty acids and is responsible for the major virulence associated with LPS.  Lipid A 
induces the release of host inflammatory mediators by binding to the TLR4 (toll-like receptor 
4) of macrophages.  This subsequently triggers the biosynthesis of TNF-α and IL1-β, which 
stimulate non-specific host defenses against bacterial infections.  In mammalian hosts, 
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excessive LPS stimulation of the immune system leads to elevated levels of activated and 
recruited immune cells which results in septic shock and even death (149).  Although toxic, 
lipid A of P. aeruginosa has been shown to be less virulent than that of enteric organisms, 
presumably by virtue of the presence of a greater number of pentaacyl rather than hexaacyl 
chains (134). 
 Similarly to O-antigen construction, lipid A biosynthesis begins in the cytoplasm.  
LpxA catalyzes the acylation reaction in which a 10-carbon acyl chain is linked to C-3 of 
nucleotide activated (UDP) GlcNAc (180).  This liposaccaride is modified by a deacetylation 
reaction, mediated by LpxC, followed by a second acylation catalyzed by LpxD yielding the 
product, UDP-2,3-diacylglucosamine (180).  This substance is cleaved at its pyrophosphate 
bond by the phosphatase LpxH to form 2,3-diacylglucosamine-1-phosphate which condenses 
with another UDP-2,3-diacylglucosamine molecule (mediated by LpxB) generating a β 1Æ6 
disaccharide (180).  The kinase, LpxK, then phosphorylates the 4-C of the saccharide at the 
oxidizing end.  The 3-deoxy-D-manno-octulosonic acid (KDO) domains of the core 
oligosaccharide are attached to this disaccharide (180). 
 
  1.6.3. Core oligosaccharide. The two regions of the core oligosaccharide (the 
inner and outer core) link the lipid-A to the O-polysaccharide (Fig. 1.1).  The inner core is 
composed of L-glycero-D-manno-heptose and KDO, while the outer core is made up of 
hexose sugars, such as D-glucose, D-galactosamine, and L-rhamnose (Fig. 1.1) (155).  The 
outer core region of P. aeruginosa LPS appears to be important for successful host 
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colonization, as it likely acts as a bacterial adhesin for association and entry of this bacterium 
into corneal cells during the infection stage of keratitis (187).  
 Two KDO moieties are transferred to the disaccharide lipid A by the bifunctional 
enzyme, WaaA (180).  The lipid A-KDO2 molecule serves as the acceptor on which the core 
oligosaccharide is constructed by sequential addition of nucleotide activated sugar 
precursors.  As O-antigen / core-lipid A ligation takes place in the periplasm, the core-lipid A 
must first be translocated to this subcellular compartment.  The process in which this occurs 
is poorly understood, however MsbA has been implicated to act as a translocase that acts in 
the inner membrane (180).  This enzyme has been hypothesized to act as a flippase, or 
possibly a pump that ejects lipid A and phospholipids directly to the outer membrane (180).  
 
1.7.  Protein glycosylation.  Since the discovery of glycosylated archaeal S-layer 
proteins (160) numerous examples of protein glycosylation in prokaryotes have been 
recorded (18, 195, 213, 225, 235).  These findings demonstrate that this protein modification 
is ubiquitously distributed among all biological kingdoms.  Among glycosylation systems, 
much diversity exists in the number of glycosylation sites on a target protein.  Accordingly, 
the carbohydrate compositions of protein glycans differ immensely from one glycosylation 
system to the next. Proteins intended for glycosylation may be modified at a single or 
multiple sites along the polypeptide chain (213, 225) in which the glycan may consist of one 
carbohydrate moiety, or multiple saccharides.  When the glycan is an oligosaccharide, 
assembly of this sugar can either take place by sequential addition of each moiety to the 
target protein, or by synthesis prior to glycosylation (213, 225).  In the latter instance, the 
entire pre-assembled glycan is transferred en bloc.  A number of protein/carbohydrate 
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linkages have been described involving many of the amino-acid functional groups and most 
of the common sugars (such as glucose and galactose (213)) in addition to unusual 
prokaryotic sugars (for instance, bacillosamine and pseudaminic acid (225)).  In both 
eukaryotic and prokaryotic protein glycosylation, carbohydrates are usually bound to the 
peptide chain via the amide nitrogen of an Asn residue (N-linked) or via the functional 
hydroxyl group of Ser or Thr (O-linked).  An example of a glycoprotein exhibiting an 
uncommon glycosylation linkage is the cytokine, interleukin 12, in which a mannose moiety 
is linked to C-2 of the indole ring of a Trp residue (213).  Apart from the N-linked 
glycosylation system in Campylobacter jejuni (71, 225, 227, 232, 251), not much is known 
of glycan biosynthesis and of the enzymatic transferases of prokaryotic glycosylation 
systems. 
 Work from our laboratory that indicated that P. aeruginosa 1244 pilin is glycosylated 
(32) was one of the first examples offering solid evidence in the field of non-S-layer surface 
protein glycosylation in a bacterial pathogen.  Among gram-positive bacteria, Streptococcus 
sanguis, S. mutans, and Mycobacterium tuberculosis have been shown to possess 
glycosylated surface proteins (36, 62, 69).  Many gram-negative bacteria express surface 
glycoproteins as well.  For example, E. coli produces glycosylated adhesins (17, 144) and an 
auto-transporter protein, Ag43 (204).  Chlamydia trachomatis expresses a glycosylated outer 
membrane protein (135).  Campylobacter species, C. crescentus, Aeromonas caviae, 
Helicobacter pylori, as well as several P. aeruginosa strains glycosylate their flagellin (8, 25, 
63, 176).  Along with P. aeruginosa, N. meningitidis, and N. gonorrhoeae, have been shown 
to express glycosylated pilin (32, 171, 217, 218). 
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 C. jejuni is a prevalent food-borne pathogen.  The flagella of this organism direct 
swimming motility, and are virulence factors required for successful colonization of the host 
intestinal tract and eventual invasion into epithelial cells.  The major structural component of 
C. jejuni flagella, referred to as flagellin, is O-glycosylated at 19 Ser/Thr residues with 
pseudaminic acid moieties or derivatives (176, 226).  H. pylori also expresses glycosylated 
flagellin in which neuA/flmD genes are involved in the glycosylation of FlaA (118).  
Interestingly, only extracellular flagellin appears to be glycosylated, suggesting that 
glycosylation may be linked to secretion.  
 In addition to flagellin O-glycosylation, C. jejuni possesses an N-linked glycosylation 
system in which PglB transfers an oligosaccharide to an acceptor protein.  Twenty-two 
proteins from this organism have been discovered to be N-glycosylated (176), containing a 
glycan, which is heptasaccharide containing various GalNAc moieties, as well as other rarely 
encountered sugars such as bacillosamine (176).  Mutants of C. jejuni that have impaired 
general protein glycosylation have a reduced ability to adhere to and colonize epithelial cells 
of mouse intestinal tracts (176).  Interestingly, the C. jejuni N-linked glycosylation system is 
capable of utilizing O-antigen as a glycan source when co-expressed with LPS biosynthetic 
genes in an E. coli waaL mutant strain (71).   
 
 1.8.  1244 pilin glycosylation 
  1.8.1.  Characterization of the glycan.  Work from our laboratyr has 
determined that P. aeruginosa 1244 expresses glycosylated pilin (32, 33, 41, 60).  
Verification of pilin glycosylation was determined by reacting this glycoprotein with a sugar-
specific reagent followed by treatment with a substance that forms a covalent bond with 
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oxidized sugars.   Pilin glycosylation was confirmed by Western blot analysis using a 
primary antibody specific for the substance that covalently bound to the oxidized sugar (32).  
This phenomenon of pilin glycosylation required expression of pilO, a gene that is part of an 
operon which also contains pilA, the structural gene of the pilin subunits (32).  Glycosylated 
P. aeruginosa 1244 pilin had a noticeably higher apparent molecular weight when compared 
to the nonglycosylated form of pilin, as determined by Western blotting probed with a pilin-
specific monoclonal antibody (32).  To confirm the presence of additional covalently bound 
material to pilin, this protein was subjected to matrix-assisted laser desorption ionization-
time of flight (MALDI-TOF) mass spectrometry (35).  While the molecular weight of 1244 
pilin, predicted from the gene product of 1244 pilA, should have a molecular weight of 
15,649 (35), MALDI-TOF indicated that this pilin had a mass of 16,340 (± 25) (33) 
indicating the presence of covalently bound material.  Furthermore, isoelectric focusing 
suggested that strain 1244 pilin had a pI of 4.75 for glycosylated pilin while the pI for the 
nonglycosylated form of pilin was 6.25 (32) suggesting that the pilin modification introduced 
substantial negative charge.  Monoclonal antibody (Mab) 11.14, specific for serotype O7 
LPS, was cross reactive with the LPS of 1244 and the glycosylated pilin, indicating the 
presence of a shared epitope between these two structures (33).  Mab 11.14 did not react with 
non-glycosylated pilin, suggesting that the glycan molecule of the glycosylated pilin may 
share structural similarities or common epitopes with the LPS (33).  Furthermore, Mab 11.14 
inhibited twitching motility of strain 1244, confirming that the epitope was present on native, 
functional pili, and was not an artifact of preparation. 
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   Prior to structural analysis, general physical and chemical characteristics of 
glycosylated pilin were obtained by digesting this molecule with proteinase K / pronase 
followed by subjugation to analytical thin layer chromatography.  This revealed the presence 
of a single orcinol-reactive compound, confirming the presence of a sugar.  This saccharide 
was purified to homogeneity via gel filtration and preparative thin layer chromatography (33) 
and was found to contain three unidentified sugars and serine.  Additionally, this substance 
eluted in the 400-800 molecular weight range as determined by a calibrated Sephadex G-25 
column.  This isolated glycan-containing molecule was referred to as the pilin aminoglycan.  
The purified aminoglycan was shown to carry the Mab 11.14 specific epitope by analysis of 
blocking ELISA experimentation, which indicated competition between pure aminoglycan 
and the O-antigen of the LPS as well as the native pili from P. aeruginosa 1244 (33).  
Together, these results indicated that the aminoglycan contained the shared pilin/LPS 
epitope, suggesting structural semblance between the pilin glycan and the LPS O-repeating 
unit of P. aeruginosa 1244. 
 
  1.8.2.  Structural analysis of the 1244 pilin aminoglycan. P. aeruginosa 
1244 belongs to the O-antigenic group O7, a serogroup which is equivalent to Lanyi-Bergan 
7a, 7b, 7c (138, 147).  Because the O-antigen structure of a P. aeruginosa strain belonging to 
this very serogroup had previously been determined (127, 128), insight was gained toward 
the structural analysis of the 1244 pilin glycan.  The 1-D NMR proton spectrum of pure pilin 
aminoglycan was consistent with that presented for the 7a, 7b, 7c antigen (33) supporting the 
hypothesis that the pilin glycan is structurally identical to the O-antigen repeating unit (Fig. 
1.5).  Using 2-D NMR, proton assignments gave further confirmation, providing linkage data 
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while indicating the presence of serine protons.  The sequence of the glycosyl residues was 
resolved by a ROSEY NMR spectrum, tandem MS/MS analysis, and methylation analysis 
(33).  Taken in concert, results suggested that the structure seen in Fig. 1.7 is that of the pilin 
aminoglycan.  In addition, no indication of LPS or protein contamination was detected 
(limits of detection were 0.5 ng of LPS / μg of pilin) in the preparation of the aminoglycan. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Altogether, these results suggest that the P. aeruginosa pilin glycan is structurally 
equal to the O7 (Lanyi-Bergan 7a, 7b, 7c) O-antigen repeating unit of this organism’s LPS 
(Fig. 1.7).  The pilin glycan is a trisaccharide covalently bound via the N-acetyl-fucosamine 
C-1 to the β-carbon of a pilin serine residue.  The mass of the glycan was calculated to be 
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Figure 1.7. Structure of the P. aeruginosa 1244 pilin aminoglycan.  This trisaccharide is linked to 
Ser148 of pilin. 
 28
666.5, which corresponds to the difference between the predicted pilin masses (putative 
glycosylated versus non-glycosylated), and the mass as determined by MALDI-TOF.  This 
finding indicates that, apart from N-terminal methylation, glycosylation with the O-antigen 
repeating unit structure is the only other 1244 pilin modification.  Furthermore, the absence 
of non-modified pilin and variable glycosylation size isoforms (as determined by MALDI-
TOF and Western blot) suggests that each pilin monomer is glycosylated with, and only with, 
the addition of a single trisaccharide glycan. 
 
  1.8.3.  Identification of glycosylated pilin residue.  Because the aminoglycan 
contained a Ser bound to the O-antigen repeating unit, this indicated that the 1244 pilin 
glycan was covalently bound to a Ser.  In order to determine the specific site of 
glycosylation, pilin peptide fragments were produced by endopeptidase treatment with GluC, 
and the specific fragment that contained the glycan was identified by Western blot analysis 
using a glycan-specific antibody.  N-terminal sequencing of these fragments indicated that 
the glycan was present between residue 75 and the C-terminus (41).  Further sequencing of 
these peptides revealed that serines 75, 81, 84, 105, 106, and 108 were not modified.  
To determine if one of the remaining pilin serines was the site of glycosylation, pure 
pilin samples were subjected to a trypsin digestion (41).  Because this procedure yields 
peptide fragments too small for detection by immunoblotting, the products of this treatment 
were separated by gel filtration using a Superdex Peptide column.  Fractions were assayed by 
orcinol spot test to test for the presence of sugars, in which carbohydrate-positive material 
was determined to be present in the 400-800 molecular weight range.  By using high 
performance thin layer chromatography to analyze pooled fractions, an orcinol-positive 
 29
compound was detected that had Rf values indistinguishable with those of the pure pilin 
aminoglycan.  Moreover, the estimated size of the material isolated was consistent with the 
mass of 771, the mass of the pilin aminoglycan (33).  The proximity of Ser148 to Lys147 
indicated that this Ser is the only pilin residue that could produce the aminoglycan 
subsequent to trypsin digestion (41). 
 In order to confirm that Ser148 was the location of the glycan, site-directed 
mutagenesis was utilized to mutate the codon for this residue to Ala, thereby eliminating the 
putative glycosylation site (41).  Glycosylation was abolished when Ser148 was mutated to 
Ala, but was unaffected when Ser118 was mutated. Thus, these results support the trypsin 
digestion data and indicate that the pilin glycan is bound to residue 148, the C-terminal 
amino acid of the strain 1244 pilin protein.  The proximity of the 1244 pilin glycan to the 
DSL region suggests that this nearby structure may contain important components for 
interaction with the glycosylation machinery (Fig. 1.8). 
 
1.8.4.  Metabolic origin of the pilin glycan.  DiGiandomenico et al. showed 
that strain 1244 mutants lacking functional wbpM or wbpL genes (Fig. 1.4) (both involved in 
the initial steps of O-antigen biosynthesis) did not synthesize O-antigen, and produced only 
non-glycosylated pilin (60).  The wbpM gene product encodes a bifunctional UDP-GlcNAc 
C6 dehydratase/C4 reductase that is necessary for the production of the nucleotide precursor 
UDP-QuiNAc (30, 49).  This sugar nucleotide is converted into UDP-FucNAc by a  
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subsequent epimerization step, which is the precursor for the first sugar residue of the 
serotype O7 O-antigen subunit.  WbpL is a bifunctional glycosyltransferase, required for the 
initiation of both A-band and B-band LPS synthesis (188).  This transferase initiates 
assembly of single O-antigen units by the transfer of FucNAc from UDP-FucNAc to Und.  
DSL 
Figure 1.8.  Predicted surface of the P. aeruginosa 1244 pilin DSL.  The tertiary structure of 
1244 pilin was generated by homology modeling.  Molecular surface of the DSL was generated 
by DS Viewer Pro software.  Ser148, the pilin glycosylation site, is adjacent to the DSL. 
Ser148 
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Both the wbpL and wbpM mutants were defective in O-antigen biosynthesis as determined by 
Western blotting using an O-antigen specific primary antibody as a probe.  These mutants 
produced functional pili, as determined by the ability to carry out twitching motility, as well 
as the sensitivity to a pilus-specific phage.  However, neither mutant was able to produce 
glycosylated pilin.  Complementation with plasmids containing functional wbpM or wbpL 
genes completely restored the both O-antigen biosynthesis and pilin glycosylation. 
 Expression of a cosmid clone harboring the LPS serotype O11 O-antigen biosynthetic 
gene cluster from P. aeruginosa PA103 in P. aeruginosa 1244 (LPS serotype O7) resulted in 
the production of strain 1244 pilin that contained glycans equivalent to both O7 and O11 O-
antigens (60).  The presence of the O11 repeating unit was confirmed by MALDI-TOF mass 
spectrometry.  In a similar experiment, expression of the O-antigen biosynthesis gene-cluster 
from E. coli O157:H7 in strain 1244 yielded the production of pilin that contained both the 
endogenous Pseudomonas, O7 antigen, as well as the E. coli O157 O-antigen (60).  It is 
evident that PilO is responsible for catalyzing the glycosylation of P. aeruginosa pilin 
because the cloned pilAO operon produced glycosylated strain 1244 pilin in eight 
heterologous P. aeruginosa strains (60).  When a plasmid that encoded 1244 pilA, but not 
pilO was expressed in these strains, 1244 pilin produced was unmodified.  Altogether, these 
results suggest that the pilin glycan of P. aeruginosa 1244 is a product of the O-antigen 
biosynthetic pathway.  Furthermore, the structural variance of the O-antigens used by the 
1244 pilin glycosylation machinery suggests that the glycan substrate specificity for this 
reaction is low (60). 
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1.8.5. Pilin glycosylation pathway. As the pilin glycan and the O-antigen 
subunit originate in the same metabolic pathway, analysis of LPS biosynthetic mutants may 
reveal the location in the O-antigen pathway, as well as the cellular location of pilin 
glycosylation.  Because a mutant lacking a functional wbpL gene was unable to support pilin 
glycosylation, it appears as if this modification does not occur through the sequential 
attachment of individual O-antigen sugars to pilin, but rather through attachment of a 
completely fabricated repeating unit.  Since the polymerized O-antigen is not attached to 
pilin (33), it seems as if Und-bound repeating units serve as the glycosylation substrate.  If 
this is true, this substance is available for glycosylation at the interior as well as the exterior 
surfaces of the cytoplasmic membrane.   
 Data from our laboratory revealed that expression of plasmid-encoded 1244 pilin in a 
PAK pilD mutant resulted in the production of only non-glycosylated prepilin (239).  When 
plasmid-encoded 1244 pilAO was expressed, only glycosylated prepilin was produced, 
suggesting that glycosylation occurs prior to the removal of the pilin leader sequence.  
Because this and previous steps of pilin synthesis occur at the cytoplasmic membrane, these 
results suggest that pilin glycosylation also occurs at this location.  In addition, unpublished 
data (Roguskie and Castric) indicated that a wzy (O-antigen polymerase) mutant was able to 
produce glycosylated pilin, indicating that pilin glycosylaiton occurs prior to extension of the 
O-antigen. With these data, it is clear that PilO acts at some point between WbpL and Wzy 
(Fig. 1.4).  Recent unpublished observations (Qutyan and Castric) revealed that regions of 
PilO that are critical for pilin glycosylation extend to the periplasm, suggesting that this sub-
cellular compartment is the metabolic environment for pilin glycosylation (Fig. 1.4).  
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 1.8.6.  Glycan specificity.  Experiments described above reveal that cloned O-
antigen biosynthesis gene clusters serve as the pilin glycan source in strain 1244 (60).  These 
data confirm that the metabolic origin of the glycan is part of the O-antigen biosynthetic 
pathway (60).  Furthermore, these results also suggest that PilO has a broad glycan substrate 
specificity, since these repeating units share little structural similarity to each other (60).   
For example, cloned 1244 pilAO was expressed in eight P. aeruginosa strains containing 
heterologous O-antigens.  Prior to transformation, Western blotting revealed that none of the 
strains tested produced pilin that reacted with a 1244 pilin-specific Mab, indicating that this 
strategy provided an unambiguous determination of glycosylation of plasmid-encoded pilin.  
P. aeruginosa PA103 (serotype O11), lacks a pilO gene as determined using Southern blot 
analysis employing 1244 pilO as a probe (60).  Expression of 1244 pilAO in this organism 
resulted in the production of pilin glycosylated with the O11 repeating unit.  As a control, 
1244 pilA expression in this strain resulted in the production of non-glycosylated 1244 pilin.  
These data were reproducible by expressing 1244 pilAO in seven other P. aeruginosa strains 
that produced structurally distinct O-antigens.  In each case, glycosylated 1244 pilin was 
produced only in the presence of the pilO gene.  Along with the above described experiments 
(60) these results demonstrate that PilO is essential for glycosylation, and suggest that PilO is 
the only requirement for 1244 pilin glycosylation that is not an integral part of another cell 
function.  Furthermore, PilO shows low substrate specificity, in regards to the O repeating 
unit.  Further work is required to determine the essential structural aspects of the glycan 
precursor for glycosylation. 
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1.8.7.  Physiological role of the pilin glycan.  Based upon pilin primary 
structure, nucleotide sequence characteristics of regions adjacent to the pilA gene, as well as 
pilus antigenic relatedness, P. aeruginosa pilin can be classified into at least two categories, 
referred to as group I and group II (34).  Strain 1244 pilin belongs to group I, and results 
from our laboratory indicated that group I pilins are all glycosylated, presumably in a manner 
identical to that of strain 1244, whereas group II pilins are not glycosylated.  Interestingly, 
the group I pilin was expressed in significantly more P. aeruginosa clinical isolates from 
cystic fibrosis patients than any other pilin type (136) suggesting that glycosylation may 
provide a selective advantage in this environment.  The function of the 1244 pilin glycan 
molecule has not yet been elucidated, however, since this modification was present in more 
cystic fibrosis clinical isolates, the glycan could be associated with enhanced virulence. 
 
1.8.8.  Immunogenicity of the pilin glycan. It is well known that bacterial 
glycoproteins stimulate the mammalian immune response.  For example, the prokaryotic 
glycoprotein extract, RU 41740, from Klebsiella pneumoniae has been reported to stimulate 
human monocyte cells, and suppress apoptosis (70).  Mice immunized with purified 1244 pili 
produced sera that reacted strongly with both pilin and LPS, as determined by Western 
blotting and ELISA (41).  These observations suggest that the glycan should be considered 
for design of a P. aeruginosa 1244 pilus-based, LPS-targeted vaccine as immunization via 
glycosylated pilin may provide both anti-pilin and anti-O-antigen protection.   
 
1.9.  Role of eubacterial protein glycosylation in pathogenesis.  Increased virulence 
has been associated with glycosylation of surface protein of pathogenic bacteria.  For 
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instance, mutation of, rfbC, a gene necessary for flagellin glycosylation, resulted in virulence 
attenuation of strains PAK and PAO1 in the burned mouse model, suggesting a role in 
virulence for flagellin glycosylation (10). 
 The N-linked glycosylation system of C. jejuni provides virulence by providing 
antigenic phase variation, and increasing host susceptibility to infection (176). Without the 
ability to glycosylate proteins, C. jejuni has a reduced ability to adhere to and colonize 
epithelial cells of mouse intestinal tracts (176).   In addition, it has been hypothesized that C. 
jejuni general protein glycosylation may modulate protein functionality (176).  Unlike 
Campylobacter flagella, whose protein monomers are exposed to the environment, 
Helicobacter possesses flagella that are sheathed from the immune response by a 
membranous jacket.  A possible function for H. pylori flagellin glycosylation is coupled to 
that of protein secretion (118).  Because glycoproteins have been discovered to play 
important roles in pathogenesis, it would be inane to overlook virulence as a role for the 
1244 pilin glycan. 
 
1.10.  P. aeruginosa vaccines. Due to the antibiotic-resistant nature of P. aeruginosa, 
much emphasis on combating this pathogen has been placed on prophylaxis rather than 
treatment of infection.  However, vaccines against P. aeruginosa have shown limited 
success, where few have gone beyond Phase II clinical studies (203).  LPS-based approaches 
toward P. aeruginosa vaccination have been copiously explored (50, 61, 88, 214).  A major 
disadvantage to these vaccines is the toxicity associated with the lipid A portion of LPS.  In 
addition, utilization of multivalent LPS vaccines resulted in antigenic suppression (88), 
which significantly decreased vaccine efficacy.  Other P. aeruginosa cellular components 
 36
explored for their use as a vaccine include flagella, pili, mucoid exopolysaccharide, 
exotoxins, outer membrane proteins, in addition to whole cells (203).  
Attenuation of P. aeruginosa PAO1, accomplished by deletion of aroA, a gene 
involved in the synthesis of amino acid containing aromatic R-groups, yielded a promising 
candidate for a live vaccine strain (178).  When administered to mice intra-nasally, this strain 
elicited significant protection in the acute pneumonia model against 4 out of 5 strains of 
homologous serotypes (177).  However, this mutant did not provide cross-protection strains 
possessing heterologous serotypes, indicating the limits to its potential.  In a similar 
approach, a Salmonella enterica aroA mutant harboring a plasmid containing the PA103, 
serogroup O11 O-antigen biosynthetic gene cluster, was administered orally to mice (61).  
These mice were subjected to an intranasal challenge, consisting of a lethal dose of P. 
aeruginosa 9882-80 (serotype O11) whereby significant protection had been observed (61). 
Perhaps the most well-studied Pseudomonas vaccine is an octavalent O-antigen-
endotoxin A conjugate vaccine, developed by Berna Biotech in Swizerland (50).  Currently, 
this vaccine is in phase III clinical studies in cystic fibrosis patients, and ancillary human 
studies demonstrated a strong cellular immune response associated with vaccine 
administration (255).  Although success has been associated with this vaccine, purification of 
exotoxin A, in addition to isolation of O-antigen, followed by an additional chemical-
conjugation step represent an expensive and time-consuming process.   
 
1.11. Bacterial glycoconjugate vaccines.  A glycoconjugate vaccine is constructed 
by chemically coupling bacterial surface carbohydrates to a carrier protein.  This approach in 
designing anti-bacterial vaccines has proven to be extremely effective (2, 116).  For example, 
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the success of the P. aeruginosa vaccine by the Berna Biotech group was mentioned in the 
previous section.  In addition, several commercial glycoconjugate vaccines are now available 
that protect against H. influenzae, S. pneumoniae, and N. meningitidis among others (116).  
However, there are downsides to the production of glycoconjugate vaccines, such as the 
large amount of time and expense involved in purifying both bacterial carbohydrates, and 
protein.  Moreover, these molecules must be cross-linked resulting in an additional step.  
Stability and integrity of the glycoconjugate is also a major concern.  Because the pilin 
glycosylation machinery of P. aeruginosa 1244 covalently links bacterial saccharide (O-
antigen) to protein (pilin), this system may potentially be exploited to biologically produce 
anti- bacterial glycoconjugate vaccines.  Because the glycan specificity of this system is low, 
there is great potential to exploit this system to conjugate a number of O-antigen repeating 
units from dangerous gram-negative pathogens to pilin.  However, it must first be determined 
if the pilin glycan is capable of directing a protective immune response against the 
corresponding O-antigen. 
 
1.12.  Dissertation goals.  Previous research from our laboratory has revealed that P. 
aeruginosa 1244 glycosylates its pilus monomer, pilin, with an oligosaccharide identical to 
the O-subunit of this strain (33).   Each pilin monomer contains a single glycan with no 
evidence of alternate glycoforms or non-glycosylated subunits (33).  The glycan is O-linked 
to Ser148, the C-terminal residue of pilin.  This glycosylation is mediated by the 
oligosaccharyl-transferase, PilO (32).  Putatively, PilO transfers a single O-subunit from its 
Und-PP carrier to this Ser of pilin on the periplasmic face of the cytoplasmic membrane 
(Qutyan and Castric, unpublished observations).  Work presented here was conducted to 
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determine the pilin structures necessary for glycosylation, and to identify structural aspects 
of the glycan precursor important for glycosylation.  This is the first study, to date, detailing 
the specificity of a prokaryotic protein glycosylation reaction. 
Glycosylation of surface proteins is important for pathogenesis of many gram-
negative bacteria (225).  As P. aeruginosa is an important opportunistic respiratory 
pathogen, the 1244 pilin glycan was examined for its role in enhancing virulence. 
The O-antigen is a major surface polysaccharide of the LPS molecule of most gram-
negative bacteria, and consequently, antibodies directed against this cellular component have 
been shown to protect against infection (45, 76). Because the protein glycosylation 
machinery of P. aeruginosa 1244 covalently links an O-antigen subunit and pilin, studies 
suggested the possibility for exploitation of this system to biologically produce 
glycoconjugate vaccines (41, 102, 103).  The final goal of this dissertation was to determine 
if immunization with P. aeruginosa 1244 pilin provides O-antigen specific protection. 
 
 
The goals of my research, which are detailed in this dissertation, were:  
• To determine the glycosylation specificity of P. aeruginosa 1244 pilin. 
• To determine the structural features of the P. aeruginosa 1244 pilin glycan 
essential for substrate recognition and pilin glycosylation. 
• To determine if the P. aeruginosa 1244 pilin glycan is involved in pathogenicity. 
• To determine if immunization with P. aeruginosa 1244 pilin provides O-antigen 
specific protection. 
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Chapter 2. Glycosylation substrate specificity of Pseudomonas aeruginosa 1244 pilin1 
 
                                                          
1 Work in this chapter was published in the Journal of Biological Chemistry, Vol. 281, No. 2, pp. 1128-1136, 
January 13, 2006 
© 2006 by The American Society for Biochemistry and Molecular Biology, Inc. 
 
2.1 Abstract. The β-carbon of the Pseudomonas aeruginosa 1244 pilin C-terminal 
Ser is a site of glycosylation.  The present study was conducted to determine the pilin 
structures necessary for glycosylation.   It was found that while Thr could be tolerated at the 
pilin C-terminus, the blocking of the Ser carboxyl group with the addition of an Ala 
prevented glycosylation.  Pilin from strain PA103 was not glycosylated by P. aeruginosa 
1244, even when the C-terminal residue was converted to Ser.  Substituting the disulfide loop 
region of strain PA103 pilin with that of strain 1244 allowed glycosylation to take place.  
Neither conversion of 1244 pilin disulfide loop Cys residues to Ala nor the deletion of 
segments of this structure prevented glycosylation.  It was noted that the PA103 pilin 
disulfide loop environment was electronegative, while that of strain 1244 pilin had an overall 
positive charge.  Insertion of a positive charge into the PA103 pilin disulfide loop of a 
mutant containing Ser at the C-terminus allowed glycosylation to take place.  Extending the 
“tail” region of the PA103 mutant pilin containing Ser at its terminus resulted in robust 
glycosylation.  These results suggest that the terminal Ser is the major pilin glycosylation 
recognition feature, and that this residue cannot be substituted at its carboxyl group.   While 
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no other specific recognition features are present, the pilin surface must be compatible with 
the reaction apparatus for glycosylation to occur.  
 
2.2 Introduction. Pseudomonas aeruginosa is a Gram-negative bacterium that 
expresses polar filaments called type IV pili.  These pili are polymers of a primarily 
proteinaceous subunit referred to as pilin.  While all known type IV pilins are modified by 
the cleavage of a leader-sequence followed by the N-methylation of the exposed Phe (156), 
the pilin of P. aeruginosa 1244 is additionally glycosylated.  This glycosylation requires the 
presence of PilO, an enzyme whose coding sequence is in the same operon as pilA, the pilin 
structural gene (32). 
 The first discovered examples of prokaryotic glycoproteins were archaeal S-layer 
proteins (160).  Since this finding, numerous examples of protein glycosylation in eubacteria 
have been identified (18, 195, 213, 225, 235) indicating that this protein modification is 
distributed among all biological kingdoms.  Proteins destined for glycosylation may be 
modified at a single or multiple sites along the peptide chain (213, 225) in which the glycan 
may be one sugar, or an assortment of diverse saccharides.  Oligosaccharide assembly can 
take place either by sequential sugar addition to the target protein or by synthesis prior to 
glycosylation in which the entire pre-formed glycan is transferred as a single unit (213, 225).  
Numerous protein/sugar linkages have been characterized involving many functional groups 
present on peptide chains and most of the commonly encountered monosaccharide moieties 
(213), in addition to exotic prokaryotic sugars such as bacillosamine, pseudaminic acid, and 
derivatives (225).  Carbohydrates in eukaryotes and prokaryotes, alike, are usually bound to 
the peptide chain via the amide nitrogen of an Asn residue (N-linked) or via the functional 
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hydroxyl group of Ser or Thr (O-linked).  Some of the more uncommon glycosylation 
linkages include the mannose linkage to the C-2 of the indole ring of Trp observed in the 
mammalian cytokine, interleukin 12 (213), and Tyr O-glycosylation of a surface protein of 
the prokaryote, Acetogenium kivui (174).  Besides the N-linked glycosylation system in 
Campylobacter jejuni (71, 225, 227, 232, 251), little is known of glycan biosynthesis and 
transferases of prokaryotic glycosylation systems. 
In P. aeruginosa 1244, a single glycan is attached to each pilin monomer in an O-
linked fashion to the C-terminal residue, Ser 148 (41).  This residue is adjacent to the pilin 
disulfide loop (DSL), a structure previously associated with adhesion and immunogenicity 
(34, 142).  An intriguing aspect of P. aeruginosa 1244 pilin glycosylation, is that the 
trisaccharide used to modify pilin is structurally identical to the O-antigen repeating unit (33, 
60).  This suggested that the pilin glycan is a product of the O-antigen biosynthetic pathway.  
DiGiandomenico et al., showed that strain 1244 mutants lacking functional wbpM or wbpL 
genes (both involved in the initial steps of O-antigen biosynthesis) synthesized no O-antigen, 
and produced only non-glycosylated pilin (60).  Expression of gene clusters coding for 
heterologous O-antigens in strain 1244 resulted in the production of pilin glycosylated with 
the heterologous saccharide confirming that the source of the pilin glycan is part of the O-
antigen biosynthetic pathway.  PilO is not essential for O-antigen or pilin biosynthesis and is 
the only glycosylation-specific protein requirement in P. aeruginosa 1244 pilin glycosylation 
(60) suggesting that it is an oligosaccharyltransferase.  
In transferase mediated protein glycosylation, specific interaction is necessary 
between this enzyme, a glycan source, and the target protein, in order to facilitate the 
enzymatic attachment of the saccharide to the designated amino acid functional group (213, 
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225).  A consensus peptide sequence of Ser/Thr-Xaa-Asn, in which Xaa can be any residue, 
except Pro, acts as the environment for N-linked glycosylation as observed in N-glycosylated 
proteins of C. jejuni, Mycobacterium tuberculosis, and Clostridium thermocellum (18, 251).  
A consensus sequence for O-glycosylation, other than the requisite of a Ser/Thr residue, has 
not been identified, indicating distinct substrate specificity for individual transferases that 
mediate O-linked glycosylation.  Gaining an understanding of the pilin structures necessary 
for pilin glycosylation by P. aeruginosa 1244 would provide insight into an important 
biological process in which little is understood, and may usher the comprehension of O-
linked glycosylation specificities of other systems. 
 The present study is the most comprehensive investigation of prokaryotic 
glycosylation substrate specificity to date.  These results suggest that the C-terminal Ser of P. 
aeruginosa 1244 pilin is the major glycosylation recognition structure, and that this residue 
cannot be substituted at its carboxyl group. While no other specific recognition features are 
present, the pilin surface must be compatible with the reaction machinery for glycosylation to 
occur.  Further, evidence is presented that suggests that pilin folding and disulfide bond 
formation occurs prior to glycosylation.  These findings could have future applications in 
vaccine engineering.   
 
2.3 Materials and Methods. 
 
2.3.1 Culture conditions. Bacterial strains and plasmids used in this study are 
listed in Table 2.1.  Intermediate plasmids utilized for mutant construction can be found in 
Table 2.2.  For general culturing, bacteria were grown aerobically at 37°C on LB agar plates 
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or in LB broth, shaken at 250 rpm.  Cultures were grown on CAYE medium [2% agar, 
0.75% casamino acids, 0.15% yeast extract [Silipigni-Fusco, 1987 #205]] for preparation of 
cell extracts.  The concentrations of antibiotics used in selective media were as follows: 
ampicillin at 50 μg/ml for Escherichia coli; carbenicillin at 250 μg/ml for P. aeruginosa; 
kanamycin at 35 μg/ml for E. coli and 100 μg/ml for P. aeruginosa; tetracycline at 100 
μg/ml for P. aeruginosa.  IPTG was supplemented to media to a final concentration of 5 mM 
to induce expression of genes under the control of the tac promoter. 
 
2.3.2. Homology modeling. Homology modeling was performed by 
submission of mature pilin sequences to the online 3D-PSSM program (124).  DS Viewer 
Pro 6.0 was used to visualize tertiary structures and to generate molecular surfaces and 
Gasteiger charges.  Fig. 2.1 shows the primary (35) and predicted tertiary structure of 1244 
pilin derived from homology modeling. 
 
2.3.3. Generation of P. aeruginosa 1244 pilA mutants. The deletion mutant, 
1244.2024, was constructed by first digesting pPAC202 (35), which contained a 7.8 Kb 
insert harboring the pilAO operon, with PstI.  This removed a 3.8 Kb fragment containing the 
operon and left flanking insert pieces of 1.9 and 2.1 Kb attached to the vector.  The fragment 
containing the vector was ligated with a KmR cartridge, generated by digesting pUC-4K 
(Pharmacia) with PstI, producing pPAC2024K.  The cloned region of this plasmid was 
removed by digestion with EcoRI and ligated with pBR322 digested with the same enzyme 
producing pPAC3/6.  This construct was introduced into P. aeruginosa 1244 by triparental 
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mating (189) using tetracycline resistance as a selective marker.  Tested clones were found to 
also be KmR indicating that incorporation of the plasmid by recombination had occurred.  
Colony lifts probed with a strain 1244 pilin-specific monoclonal antibody produced pilin-
negative clones which were TcS, CbS, and KmR indicating loss of vector and the functional 
pilA gene.  Loss of pilin production was confirmed by Western blot, while loss of pilA was 
confirmed by Southern blot using pPAC2024K insert DNA as a probe.   
The initial step for construction of the insertion mutant, strain 1244.47, involved 
ligation of pBR322 digested with BamHI and NheI with the 12 Kb fragment produced by the 
digestion of pPAC202::Tn501-13, a previously described construct (35), with BamHI and 
XbaI.  The plasmid produced by this ligation reaction was confirmed by restriction site 
analysis and introduced into P. aeruginosa 1244 by triparental mating (189) using mercury 
resistance as a selective marker.  Tested clones were found to also be CbR indicating that 
incorporation of the plasmid by recombination had occurred.  Approximately 2 × 105 colony 
forming units (CFUs) of one of these clones were incubated with 2 × 106 plaque forming 
units (PFUs) of pilus-specific bacteriophage PE69 in 200 µl of LB broth for 20 min at room 
temperature.  Aliquots of this material were plated on LB-Hg medium where clones 
produced were found to be HgR and CbS, indicating the loss of vector.  Disruption of the pilA 
gene of one of these clones, referred to as strain 1244.47, was confirmed by Southern blot 
using strain 1244 pilA DNA as a probe.  Loss of gene function was confirmed by Western 
blotting of 1244.47 cell extracts using a pilin-specific monoclonal antibody as a probe 
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Table 2.1. Strains and plasmids used in this study. 
Strains/plasmids Description Source or reference 
Strains   
  P. aeruginosa   
      1244 Wild type, IATS O7 (183) 
      1244N3 rpoN (TcR) (182) 
      1244.47 pilAO (HgR) This study 
      1244.2024 pilAOBCD (KmR) This study 
      PA103 Wild type, IATS O11 (146) 
  E. coli   
      XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac   Stratagene 
      XL10-Gold endA1 supE44 thi-1 recA1 gyrA96 relA1 lacHte  Stratagene 
      DH5α supE44 hsdR17 recA1 endA1 gyrA96 thi-1 relA1 Gibco BRL  
      HB101 supE44 hsdS20 recA13 ara-14 proA2 lacY1 galK2 rpsL20 xyl-5 
mtl-1 
(21) 
Plasmids   
  pUCP26 4.9 Kb pUC18-derived broad host-range cloning vector, TcR (243) 
  pUCP26pilO pUCP26 with 1244 pilO This study 
  pMMB66EH 8.8 Kb broad-host-range expression vector, ApR/CbR (77) 
  pPAC46 pMMB66EH with 1244 pilAO (32) 
  pPAC202::Tn501-13 a cosmid subclone containing a transposon insertion in 1244 pilA (35) 
  p1244 S148T pPAC46 with coding sequence for Ser 148 of pilA mutated to Thr This study 
  p1244 A149 pPAC46 with the addition of an Ala and a stop codon after Ser 148 
of pilA 
This study 
  pSD5 pMMB66EH with PA103 pilA This study 
  p103 P144S pSD5 with the Pro 144 codon of pilA mutated to Ser This study 
  p103 PKS pSD5 with codons for Asn 142, Glu 143, and Pro 144 of pilA 
mutated to Pro, Lys, and Ser respectively 
This study 
  pHYBRID pMMB66EH with the chimeric pilA coding for the first 123 
residues of PA103 pilin, a Gly at residue 124, and the last 31 
residues are those of 1244 pilin.  This plasmid also contains pilO. 
This study 
  pHYB-O pMMB66EH with the chimeric pilA from pHYBRID.  This plasmid 
does not contain pilO. 
This study 
  p1244 C127A pPAC46 with coding sequence for Cys 127 of pilA mutated to Ala This study 
  p1244 C145A pPAC46 with coding sequence for Cys 145 of pilA mutated to Ala This study 
  p1244Δ135-139 pPAC46 with coding sequence for residues 135-139 of pilA 
(AWKPN) deleted. 
This study 
  p1244Δ135-144 pPAC46 with with coding sequence for residues 135-144 of pilA 
(AWKPNYAPAN) deleted. 
This study 
  p1244Δ128-144 pPAC46 with with coding sequence for residues 128-144 of 1244 
pilA (KITKTPTAWKPNYAPAN) deleted. 
This study 
  p103 INS136 pSD5 with coding sequence for residues 135-139 of 1244 pilA 
(AWKPN) inserted at amino acid positions 136-141 of PA103 pilA 
with Pro 144 (now Pro 149) mutated to Ser. 
This study 
  p1244 S147 pPAC46 with mutant pilA that had coding sequence for Lys 147 
mutated to Ser and Ser 148 mutated to a stop codon 
This study 
  p1244 S149 pPAC46 with 1244 pilA that had the Ser 148 codon mutated to Ala 
and the addition of Ser 149 followed by a stop codon. 
This study 
  p1244 S150 pPAC46 with mutant pilA that had coding sequence for Ser 148 
mutated to Ala, an Ala at position 149, a Ser at position 150 
followed by a stop codon 
This study 
  p103 S146 pSD5 with with coding sequence for two Ala inserted into PA103 
pilA at positions 144 and 145 terminating in Ser 146. 
This study 
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Table 2.2. Intermediate plasmids used in this study. 
Strains/plasmids Description Source or reference 
Plasmids   
  pRK2013 KmR, helper plasmid for triparental mating (189) 
  pUC18 2.7 Kb cloning vector; ApR (249) 
  pUC19 2.7 Kb cloning vector; ApR (249) 
  pPAL100 pMal-cRI with 1244 pilO, ApR (170) 
  pUC46 pUC19 with 1244 pilAO (41) 
  pSAD100 pUC18 with PA103 pilA This study 
  pSAD100a pSAD100 with coding sequence for Pro 144 of  pilA mutated to Ser This study 
  pSAD100b pSAD100 with coding sequence for Asn 142, Glu 143, and Pro 144 
of pilA mutated to Pro, Lys, and Ser respectively 
This study 
  pJAS58 pUC18 with PA103 pilA that contains an AgeI and HindIII site at 
the 5′ end of the gene 
This study 
  pJAS75 pUC18 with a chimeric pilA coding for the first 123 residues of 
PA103 pilin, a Gly at residue 124, and the last 31 residues are those 
of 1244 pilin.  This plasmid also contains pilO of PA1244. 
This study 
  pUC HYB-O pUC18 with the chimeric pilA from pHYBRID.  This plasmid does 
not contain pilO. 
This study 
  pUC135-139 pUC46 with coding sequence for residues 135-139 of pilA 
(AWKPN) deleted 
This study 
  pUCRMD pUC46 with coding sequence for residues 135-144 of pilA 
(AWKPNYAPAN) deleted 
This study 
  pUC-loop pUC46 with coding sequence for residues 128-144 of pilA 
(KITKTPTAWKPNYAPAN) deleted 
This study 
  pUC+FIL pSAD100a with coding sequence for residues 135-139 of 1244 pilA 
(AWKPN) inserted at amino acid positions 136-141 of PA103 pilA 
with Pro 144 (now Pro 149) mutated to Ser 
This study 
  pUC S149 pUC46 with mutant pilA that had coding sequence for Ser 148 
mutated to Ala and the addition of Ser 149 followed by a stop 
codon 
This study 
  pUCNEAAS pSAD100 with coding sequence for two Ala inserted into pilA at 
positions 144 and 145 terminating in Ser 146 
This study 
 
 
2.3.4. Plasmid construction. In order to analyze pilin specificity for 
glycosylation, cloned pilA was either subjected to site-directed mutagenesis (QuikChange 
mutagenesis kit), deletion/ insertion mutagenesis (ExSite mutagenesis kit), or a hybrid pilA 
was constructed consisting of portions of strain PA103 and 1244 pilin coding sequence 
(Table 2.1; Fig. 2.2).  
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Figure. 2.1.  Primary and tertiary structure of 1244 pilin.  Strain 1244 pilin 
tertiary structure was derived from homology modeling.  Predicted α-helix, β-
sheets, and DSL are labeled on the model and above the corresponding amino 
acid sequence of mature 1244 pilin. 
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2.3.4.1. Construction of pSD5. The PA103 pilA gene was cloned by 
ligating the BamHI/SalI fragment of PCR-amplified PA103 DNA with pUC18, which had 
been digested with the same enzymes, yielding pSAD100.  The primers employed were 5′ – 
GCGCAGGATCCAGGTTCAGGCGTTAGGCC – 3′ and 5′ – 
GCGCAGTCGACCGACTGAGCTAATCCGGC – 3′.  The cloned PA103 pilin gene was 
moved into the vector pMMB66EH by ligating the EcoRI/HindIII fragment of pSAD100 
containing the PA103 pilA gene with pMMB66EH, which had been digested with the same 
enzymes, placing pilA under the control of a tac promoter. This plasmid was designated 
pSD5.  Plasmid construction was conducted in E. coli HB101, and triparental mating was 
Figure 2.2.  Amino acid sequences of segments of wild type and mutant pilins used in this 
study.  Strains and plasmids producing the pilins are shown on the left.  Residues differing 
from the wild type strain as a result of a mutation are written in white and highlighted in black. 
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used (189) to mobilize this plasmid to strain 1244 where it could be tested for expression and 
glycosylation status. 
 
2.3.4.2. Construction of pHYBRID and pHYB-O. Oligonucleotide 
primers, 5′ – CATGATTACGAATTCGAGCTCGGTACCCGG – 3′ and 5′ – 
GCAGACAGAAGCTTGCAAGGACACCGGTAATTTCCCTGCCCGCATTCTTCGG – 3′ 
were used to amplify pSAD100 between the multicloning site and nucleotide 394 of the 
translated region of PA103 pilA.  The amplified DNA was cut with EcoRI and HindIII and 
the 0.5 Kb fragment produced was ligated with pUC18, which had also been digested with 
EcoRI and HindIII, yielding the plasmid, pJAS58.   
The final 370 translated base pairs of the PA 1244 pilA gene, the entire pilO gene, and 
the tRNAthr gene including the HindIII site in pUC46 were amplified using the primers 5′ – 
GCACGTAGGACCGGTTCGCGTAAAAATGACGGAGTCTGG – 3′ and 5′ – 
CCAGTGCCAAGCTTCCGGCGGATCAACG – 3′.  The amplified DNA was digested with 
AgeI and HindIII, and the gel purified 1.9 Kb fragment was ligated with pJAS58 which had 
been digested with the same enzymes. This yielded the plasmid, pJAS75, which encoded 
residues 1-123 of PA103 pilin fused to the coding sequence of the 31 C-terminal residues of 
1244 pilin.  This protocol resulted in the conversion of Val 124 to Gly.  The fusion junction 
was confirmed by nucleotide sequencing.  The plasmid, pJAS75 was digested with EcoRI 
and HindIII, and the gel purified 2.4 Kb fragment was ligated with pMMB66EH digested 
with these same enzymes, which yielded pHYBRID.  Construction of pHYBRID was 
conducted in E. coli DH5α, and this plasmid was moved into 1244.47 via triparental mating 
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(189) to test for pilin expression and glycosylation status.  Amino acid sequence of the 
relevant portion of pilin produced from the expression of pHYBRID is shown in Fig. 2.2. 
The EcoRI/NheI pHYBRID fragment containing the hybrid pilin gene was ligated 
with pUC18 digested with EcoRI and XbaI.  This yielded the plasmid, pUC HYB-O.  This 
construct was digested with EcoRI and HindIII and the fragment containing the hybrid pilA 
was ligated with pMMB66EH which had been digested with the same enzymes.  This 
yielded the plasmid pHYB-O which contained the chimeric pilA gene, but lacked a 
functional pilO gene.  This plasmid was constructed in E. coli XL10-Gold and was moved to 
1244.47 via triparental mating (189) to test for pilin expression and glycosylation status. 
 
2.3.4.3. Construction of pUCP26pilO. This plasmid was constructed 
in order to present pilO in genetic environments lacking this gene.  The BamHI/HindIII 
fragment from the plasmid pPAL100 was ligated with pUCP26 which had been digested 
with the same enzymes.  pUCP26pilO was constructed in E. coli HB101, and because this 
plasmid lacked tra sites, it was moved into P. aeruginosa 1244.47 via electroporation (211) 
rather than triparental mating.  The pilin glycosylation ability of PilO produced by 
pUCP26pilO was confirmed by Western blot analysis of a cell extract of 1244.47 / pPAC24 / 
pUCP26pilO using an anti-1244 pilin monoclonal antibody, which revealed the presence of 
glycosylated strain 1244 pilin (data not shown). 
 
2.3.5. Mutagenesis of cloned pilA DNA.  Site directed mutagenesis was 
accomplished by using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, 
Calif.) as previously described (41).  Briefly, primers were designed that incorporated a 
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single, double, or triple amino acid change into either 1244 or PA103 pilin.  For primer 
sequences, see Table 2.3.  The templates for these mutagenesis reactions were cloned pilA 
genes from the appropriate strains encoded within plasmids pUC18, pUC19 or pMMB66EH. 
Successful mutations were confirmed by nucleotide sequencing.  When pilA encoded in 
pUC18 or pUC19 was used as a template, the EcoRI/HindIII fragments of the mutated 
plasmid were ligated with broad-host range vector pMMB66EH which had been digested 
with the same enzymes.  Plasmid construction was conducted in E. coli XL1-Blue or XL10-
Gold and triparental mating (189) was used to mobilize plasmids into appropriate P. 
aeruginosa strains for analysis.  Relevant portions of the amino acid sequences of mutated 
pilins are shown in Fig. 2.2. 
The ExSite mutagenesis kit (Stratagene, La Jolla, Calif.) was used to delete portions 
of the coding sequence of the DSL of 1244 pilin.  The mutagenesis reactions were employed 
using appropriate primers, listed in Table 2.3, with pUC46 as a template.  The deletions were 
confirmed by nucleotide sequencing.  The 2.3 Kb gel purified EcoRI/HindIII fragment 
containing the pilA gene was ligated with the broad-host range vector, pMMB66EH, which 
had been digested with the same enzymes. The DSL structure of pilin produced by these 
plasmids (p1244Δ135-139, p1244Δ135-144, and p1244Δ128-144) is presented in Fig. 2.2.  
These plasmids were constructed in E. coli XL1-Blue and moved into P. aeruginosa 1244N3 
by triparental mating (189) to test for expression of the mutant pilA gene and pilin 
glycosylation status.  
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Table 2.3. Primers and templates used in ExSite and QuikChange mutagenesis. 
Pilin type Mutation Primer Seta Template 
PA103 P 144 to S 
 
5′ – CCAATCAACAAAAACAGCTATTAAGACTCATTACAA 
CCC– 3′and its complement 
pSAD100 
 N, E, P 142-
144 to P, K, S 
5′ – CCAATCAACAAAAACAGCTATTAAGACTTCGGACAA 
CCCTTAGG – 3′ and its complement 
pSAD100a 
1244 C 127 to A 
 
5′ – GACGGAGTCTGGAACGCCAAAATCACCAAAACTCC – 3′ 
and its complement 
pPAC46 
 C 145 to A 
 
5′ – CTACGCTCCGGCTAATGCGCCGAAATCCTAATCGG – 3′ 
and its complement 
pPAC46 
 Deletion of K 
147 
5′ – GCTCCGGCTAATTGCCCGTCCTAATAATCGGTTTTTT 
GAGTTG – 3′ and its complement 
pPAC46 
 Insertion of A 
at position 
148 (before 
S148) 
5′ – CGGCTAATTGCCCGAAAGCCTCCTAAGTTTTTTGAGT 
TGTTTTGAGTGTG – 3′ and its complement 
pPAC46 
 Insertion of A, 
A at positions 
148 & 149 
(before S148) 
5′ – CGCTCCGGCTAATTGCCCGAAAGCCGCCTCCTAATC 
GGTTTTTTGAG – 3′ and its complement 
p1244 S149 
 S 148 to T 
 
5′ – CCGGCTAATTGCCCGAAAACCTAATCGGTTTTTTGAG – 
3′ and its complement 
pPAC46 
 Insertion of A 
at position 
149 (beyond 
S148) 
5′ – CGGCTAATTGCCCGAAATCCGCCTAAGTTTTTTGAGT 
TGTTTTGAGTGTG – 3′ and its complement 
p1244 S149 
 Deletion of 
residues 135-
139 
5′ –  Phos TACGCTCCGGCTAATTGCCCGAAA – 3′ and 5′ – 
TGTAGGAGTTTTGGTGATTTTGCA – 3′ 
pUC46 
 Deletion of 
residues 135-
144 
5′ – Phos TGCCCGAAATCCTAATCGGTTTTTTGAGTTGTTT 
TG – 3′ and 5′ –  TGTAGGAGTTTTGGTGATTTTGCA – 3′ 
pUC46 
 Deletion of 
residues 128-
144 
5′ – Phos TGCCCGAAATCCTAATCGGTTTTTTGAGTTGTTT 
TG – 3′ and 5′ – GCAGTTCCAGACTCCGTCATTTTTACG – 3′ 
pUC46 
PA103 
(P144S) 
 
 
 
 
Insertion of 
1244 pilin 
residues 135-
139 to 
positions 136-
141 
5′ – GCCTGGAAGCCCAACTTTATTCCTAAGGGTTGTAATG 
AGTC – 3′ and 5′ – Phos CATCTCTTCCTGAGTAGAGGTGCA 
AGT – 3′ 
pSAD100a 
 Insertion of A, 
A at positions 
144 and 145 
(before S144) 
5′ – CTCAGGAAGAGATGTTTATTCCTAAGGGTTGTAATGAG 
GCGGCGTCTTAATAGCTGTTTTTGTTGATTGGTGTCGATCG
GTATTG – 3′ and its complement 
pSAD100a 
aPhos, 5′ phosphorylated 
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The ExSite mutagenesis kit was used to insert the coding sequence for residues 135-
139 of 1244 pilin (AWKPN) between the coding sequence of Met 135 and Phe 136 of PA103 
pilin utilizing primers listed in Table 2.3, with pSAD100a as a template.  The template gene 
was a mutant that coded for Ser at the 3′ codon.  Proper insertion was confirmed by 
nucleotide sequencing.  The 2.3 Kb EcoRI/HindIII fragment of this plasmid was ligated with 
the broad-host range vector, pMMB66EH, which was digested with the same enzymes, 
resulting in the plasmid, p103 INS136 (Fig. 2.2). This plasmid was constructed in E. coli 
XL1-Blue and moved into P. aeruginosa 1244.47 by triparental mating (189) to test for 
expression of the mutant pilA gene and pilin glycosylation status. 
 
2.3.6. Western blot analysis. Western blotting using cell extracts was 
performed as previously described (35).  Extracts of 1244N3 / pPAC46 and 1244N3 / 
pPAC24 (32) were used as the source of 1244 glycosylated pilin standards, and 1244 non-
glycosylated pilin standards, respectively.  When mutant pilin was not easily detectable from 
cell extracts in Western blot analyses, the membrane fraction was extracted as a means to 
concentrate pilin for analysis.  Here, the membrane fraction was harvested from 200 ml LB 
overnight broth cultures.  The A650 of the culture was recorded followed by centrifugation at 
5,000 rpm in a GSA rotor for 20 min at 4°C.  The pellet was washed twice with 200 ml 
phosphate buffered saline and was resuspended in 10 ml of lysis buffer (10 mM K2HPO4, 30 
mM NaCl, 0.25% Tween-20, 10 mM β-mercaptoethanol, 10 mM EDTA, 10 mM EGTA).  
This material was sonicated (three 15 sec bursts, on ice) and centrifuged at 6,000 rpm in an 
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SS-34 rotor for 10 min at 4°C to remove unbroken cells and debris.  The supernatant fluid 
was subjected to ultracentrifugation (SW60Ti rotor) at 30,000 rpm for 1 h after which the 
membrane material was located in the pellet.  The membrane fraction was resuspended in 
400 μl deionized H2O.  Initial A650 values taken for cell culture density were used to 
normalize samples for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE).   
Cell extracts and membrane fraction samples were separated by SDS-PAGE using 
16% T, tris-glycine or 16% T, tricine gels (192).  Tricine-PAGE was used when PA103 pilin 
was being analyzed as this pilin resolved into sharper bands under these conditions.  
Separated molecules were electroblotted to nitrocellulose paper and blocked as previously 
described (35).  Either anti-1244 pilin mouse monoclonal antibody, 5.44 (206), anti-PA103 
pilin mouse monoclonal antibody, 2.97 (191), or anti-pilin polyclonal serum was used as the 
primary probe to detect the proteinaceous portion of pilin.  In order to determine whether or 
not the pilin was glycosylated, anti-1244 pilin glycan monoclonal antibody, 11.14 (33), or 
anti-1244 pilin glycan polyclonal serum was used as the primary probe.  To obtain the anti-
1244 pilin glycan polyclonal antibodies, rabbit serum from an animal that was immunized 
with pure P. aeruginosa 1244 glycosylated pili was adsorbed with pure 1244 pili containing 
a heterologous glycan.  This yielded a glycan-specific serum devoid of a pilin protein 
response.  The monoclonal antibodies were used as a probe when epitope disruption did not 
result from mutagenesis of pilin genes (34, 191).  Alternatively, polyclonal serum was 
employed.  A fluorescein isothiocyanate-- or alkaline phosphatase-conjugated secondary 
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antibody (36) was used and fluorescence was detected using a FluorImager595 (Molecular 
Dynamics) employing the 530 DF30 filter. 
 
2.4. Results. 
 
2.4.1. Structural requirements of the pilin glycosylation residue. Previous 
evidence indicated that the C-terminal residue, Ser 148 (Fig. 2.2), is the glycosylation site of 
P. aeruginosa 1244 pilin (41).  To determine whether a Thr could be tolerated at this 
position, the Ser 148 codon of pPAC46 was changed to a Thr codon, yielding p1244 S148T 
(Fig. 2.2).  When extracts of strain 1244N3, a pilAO negative mutant (182), expressing this 
construct were subjected to Western blot analysis (Fig. 2.3), it was seen that pilin containing 
Thr in the 148 position was capable of being glycosylated.  This was determined by position 
of pilin migration (Fig. 2.3A) on SDS-PAGE and by reaction with a glycan-specific antibody 
(Fig. 2.3B).  These results indicate that recognition of the hydroxyl group at the 
glycosylation site was not hindered by the presence of the Thr methyl group. 
Since the strain 1244 pilin glycosylation site is at the carboxy-terminus, this amino 
acid, in addition to lacking a C-linked residue, contains a carboxyl group.  In order to see if 
this arrangement was necessary for glycosylation, p1244 A149, a construct in which an Ala 
codon was inserted after Ser 148, was generated and expressed in 1244N3. Western blot 
analysis of cell extracts of 1244N3 / p1244 A149 revealed that pilin produced was non-
glycosylated as determined by apparent molecular weight (Fig. 2.3A) and by lack of reaction 
with a glycan-specific antibody (Fig. 2.3B).   These results suggest that pilin glycosylation 
by strain 1244 requires that the residue being modified be at the carboxy-terminus.  Such a 
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situation would explain why none of the other Ser or Thr of this protein, even though likely 
at the protein surface, were glycosylated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.2. Minimal pilin structures necessary for glycosylation. In order to 
determine structures important in glycosylation of strain 1244 pilin, residues of PA103 pilin 
(Fig. 2.2), a normally non-glycosylated pilin were replaced with those of 1244 pilin, and 
assayed for glycosylation.  When plasmid pSD5, which contained the pilA gene from PA103 
behind a tac promoter, was expressed in strain 1244, PA103 pilin produced had the same 
apparent molecular weight as that of wild type (Fig. 2.4A) as determined by Western blot 
using a PA103 pilin-specific monoclonal antibody as a probe.  This is not surprising since 
strain 1244 pilin glycosylation requires a C-terminal Ser (41), while PA103 pilin terminates 
Figure 2.3.  Western blot analysis of P. aeruginosa 1244 mutant pilins.   Western 
blot of 1244 pilin produced by P. aeruginosa 1244N3 / p1244 S148T and 1244N3 / 
p1244 A149 of cell extracts using anti-1244 pilin monoclonal antibody 5.44 (A) or 
anti-1244 pilin glycan monoclonal antibody 11.14 (B) as a probe.  G is glycosylated 
1244 pilin and NG is non-glycosylated 1244 pilin.  Pilin terminating in Thr rather 
than Ser was glycosylated (1244N3 / p1244 S148T) whereas pilin terminating in Ala, 
where Ser 148 was the penultimate residue, was non-glycosylated. 
 57
in a Pro (Fig. 2.2).  Site directed mutagenesis was used to convert the C-terminal pilin 
residue encoded in pSD5 to Ser thereby producing p103 P144S (Fig. 2.2).  When this 
plasmid was expressed in P. aeruginosa 1244 and pilin was assayed by Western blot for 
modification by PilO, it was revealed that the PA103 pilin produced showed no difference in 
apparent molecular weight when compared to wild-type PA103 pilin, indicating the absence 
of glycosylation (Fig. 2.4A).  The pilin glycosylation ability of the host strain was confirmed 
by Western blot analysis using an anti-1244 pilin monoclonal antibody, which revealed the 
presence of glycosylated strain 1244 pilin (data not shown).  These results indicate that other 
structures besides the carboxy-terminal Ser/Thr are important for pilin glycosylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4.  Western blot analysis of P. aeruginosa PA103 mutant pilins.  Western blot of 
pilin produced by P. aeruginosa 1244 / pSD5, 1244 / p103 P144S, and 1244 / p103 PKS 
using anti-PA103 pilin monoclonal antibody 2.97 as a probe (A).  G and NG are glycosylated 
and non-glycosylated pilin standards, respectively, on a separate blot which was probed with 
anti-1244 pilin monoclonal antibody, 5.44.  Wild type PA103 pilin (pSD5), PA103 pilin with 
residue Pro 144 (p103 P144S) mutated to Ser, as well as PA103 pilin with residues Asn 142, 
Glu 143, and Pro 144 mutated to that of 1244 pilin, Pro, Lys, and Ser respectively (p103 PKS) 
were all non glycosylated in the presence of PilO.  The amino acid sequences of the DSL and 
tail regions of strains 1244 and PA103 pilin were aligned for comparison (B).  Experiment 
originally carried out by Jason Comer and Peter Castric.  This experiment was repeated by the 
author for construction of the figure. 
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 Both 1244 and PA103 pilins contain a ‘tail’ region that consists of three residues 
beyond the C-proximal DSL Cys (Fig. 2.4B).  p103 PKS (Fig. 2.2) was generated to 
determine if either of the remaining residues in the tail served as a recognition site for pilin 
glycosylation.  When this plasmid was expressed in strain 1244 and extracts of these cells 
were subjected to Western blot analysis, it could be seen that the only PA103 pilin produced 
was non-glycosylated (Fig. 2.4A).  This result suggests that structures other than the 1244 
pilin tail region are needed for glycosylation. 
In order to determine the role of the DSL in glycosylation, the loop structure of strain 
PA103 pilin was substituted with the analogous region of strain 1244.  The plasmid 
constructed to test this, pHYBRID, codes for a hybrid protein consisting of the first 123 
residues of PA103 pilin, the C-terminal 31 residues of 1244 pilin (which includes the entire 
1244 DSL), and PilO, all behind a tac promoter (Fig. 2.2).  This construct was expressed in 
1244.47, a pilAO negative mutant, where membrane fractions were subjected to Western blot 
analysis (Fig. 2.5).  The blot, when probed with a pilin-specific antibody, revealed the 
presence of a band with an apparent molecular weight similar to that of glycosylated pilin 
(Fig. 2.5A).  When pilO was absent, this band was replaced with one corresponding with 
non-glycosylated pilin (Fig. 2.5A).  In addition, in the presence of PilO, pilin produced 
reacted with an antibody specific for the pilin glycan, whereas there was no reaction to the 
hybrid pilin expressed in the absence of PilO (Fig. 2.5B), indicating that the higher apparent 
molecular weight of the hybrid pilin was a result of the presence of the glycan (Fig. 
2.5A&B).  These results indicate that the presence of the 1244 pilin DSL was able to 
facilitate glycosylation of PA103 pilin.  
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2.4.3. Mutational analysis of the P. aeruginosa 1244 pilin DSL. The finding 
that replacement of the DSL of PA103 pilin with that from strain 1244 supported 
glycosylation, while the PA103 pilin (even with the replacement of the tail region) did not, 
suggests that either the DSL of 1244 pilin contains specific structures important in the 
glycosylation reaction, or that components of the PA103 pilin loop somehow prevent 
glycosylation.   
To examine the role of strain 1244 pilin DSL structures, we first looked at the 
disulfide bond to see if its formation was essential for glycosylation.  Plasmids p1244 C127A 
and p1244 C145A (Fig. 2.2), constructs which encoded mutant pilins incapable of forming 
the disulfide bond of the DSL, were generated and expressed in strain 1244N3. Western blot 
Figure 2.5.  Western blot analysis of P. aeruginosa hybrid pilin.  Western blot of pilin 
produced by P. aeruginosa 1244.47 / pHYBRID and 1244.47 / pHYB-O using anti-pilin 
polyclonal serum as a probe (A) or anti-1244 pilin glycan monoclonal antibody 11.14 (B) 
as a probe.  G is glycosylated 1244 pilin and NG is non-glycosylated 1244 pilin.  Hybrid 
pilin was glycosylated in the presence of PilO (pHYBRID) whereas removal of PilO 
abrogated glycosylation (pHYB-O).  The presence of a pilin band was found only in the 
presence of IPTG (A), and empty vector controls did not produce a band (pMMB66EH). 
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analysis of extracts of these cells showed that mutant pilin produced by either p1244 C127A 
or p1244 C145A was primarily glycosylated, although low levels of non-glycosylated pilin 
was produced from p1244 C127A (Fig. 2.6A).  These results suggest that an intact DSL is 
not essential for glycosylation to occur.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6.  Western blot analysis of P. aeruginosa 1244 mutant pilins with Cys mutation 
or DSL deletion.  Western blot of pilin produced by P. aeruginosa 1244N3 / p1244 C127A 
and 1244N3 / p1244 C145A using anti-1244 pilin monoclonal antibody 5.44 as a probe (A).  
Western blot analysis of pilin produced by P. aeruginosa 1244N3 / p1244Δ135-139, 1244N3 
/ p1244Δ135-144, 1244 / p1244Δ128-144 using anti-1244 pilin monoclonal antibody 5.44 as a 
probe (B) or anti-1244 pilin glycan monoclonal antibody 11.14 (C) as a probe. G is 
glycosylated 1244 pilin and NG is non-glycosylated 1244 pilin.  All mutants produced some 
glycosylated pilin, however, p1244 C127A (A), p1244Δ135-144, and p1244Δ128-144 (B) 
produced some non-glycosylated pilin. 
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 Although the disulfide bond, itself, was not necessary for glycosylation, there 
remained the possibility that specific regions of the DSL were involved in recognition of 
pilin by PilO.  With this in mind, mutagenesis was carried out to delete roughly one-third, 
two-thirds, and the entire DSL (p1244Δ135-139, p1244Δ135-144, and p1244Δ128-144 
respectively [Fig. 2.2]) from the loop region in order to assess the importance of specific 
regions of the DSL in glycosylation.  These constructs were expressed in 1244N3 and 
Western blot analysis of cell extracts revealed that these mutants produced pilins of 
progressively lower apparent molecular weights (Fig. 2.6B), presumably due to the deletions.  
All three of these mutants produced pilin that reacted with the glycan-specific antibody, and 
were therefore glycosylated (Fig. 2.6C).  In addition, some non-glycosylated pilin was 
produced, especially by p1244Δ128-144, suggesting that glycosylation of the pilin lacking a 
DSL is less efficient than glycosylation of wild type pilin (Fig. 2.6B).  The presence of 
glycosylated pilin in these mutants indicates that the specific groups or regions of the DSL 
are not essential in the glycosylation reaction. 
 
2.4.4. Influence of DSL charge on pilin glycosylation. Because deletion of 
the 1244 pilin DSL did not abrogate glycosylation, it is likely that the 1244 pilin DSL does 
not contain specific structures necessary for this reaction.  Since PA103 pilin containing a 
1244 pilin DSL was glycosylated, while PA103 pilin containing a C-terminal Ser was 
incapable of being glycosylated by PilO, physical properties of the PA103 pilin DSL may be 
responsible for preventing glycosylation in this mutant background.   
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Comparison of the 1244 and PA103 pilin DSLs revealed several differences, 
including a low degree of sequence identity (Fig. 2.2).  Interestingly, the isoelectric point of 
the 1244 pilin DSL is basic (pH 9.31) whereas the pI of the PA103 pilin DSL is acidic (pH 
4.53) indicating a significant difference in charge between these two DSLs.  Homology 
modeling suggests that residues Glu 133, Glu 134, and Glu 143 of the PA103 pilin DSL and 
tail region project outward from the pilin molecule, providing a negative surface, whereas the 
1244 pilin is predicted to have a positive surface (Fig. 2.7).  In order to determine if DSL 
charge influences pilin glycosylation, DNA sequence coding for a piece of the 1244 pilin 
DSL previously deleted, AWKPN, was inserted into the center of the p103 P144S DSL 
generating the plasmid p103 INS136 (Fig. 2.2).  This construct was expressed in 1244.47 and 
membrane fractions were subjected to Western blot analysis (Fig. 2.8).  The pilin encoded by 
p103 INS136 was glycosylated in the presence of pilO (Fig. 2.8A) as determined by the 
apparent molecular weight of the band that reacted with pilin-specific polyclonal rabbit 
serum and by the reaction with glycan-specific polyclonal rabbit antiserum (Fig. 2.8B).  In 
the absence of pilO, the apparent molecular weight of pilin encoded by p103 INS136 was 
similar to that of non-glycosylated pilin, and the mutant pilin did not react with glycan-
specific antiserum.  However, Fig. 2.8A also shows the presence of non-glycosylated pilin 
being produced by the mutant expressing p103 INS136 in the presence of PilO, indicating 
that in this mutant, pilin glycosylation is not as efficient as in the wild type strain.   
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Glycosylation of pilin produced by p103 INS136, coupled to the fact that the DSL is 
not essential for glycosylation of 1244 pilin, indicates the possibility that the charge provided 
by this sequence yielded a somewhat permissive environment for pilin glycosylation.  If the 
PA103 pilin DSL environment interferes with glycosylation, extension of the tail region 
could possibly position the glycosylation site far enough away from the pilus surface to allow 
glycan attachment.  However, before testing this with PA103 pilin, it was necessary to 
determine whether tail length influenced glycosylation of strain 1244 pilin.  The 1244 pilin 
tail region was extended by adding coding sequence for one or two alanines, resulting in 
mutant pilins terminating in CPKAS or CPKAAS, respectively (p1244 S149 and p1244 
S150; Fig. 2.2).  Constructs were expressed in strain 1244N3 and pilin glycosylation status 
was determined by subjecting cell extracts to Western blot analysis (Fig. 2.9A&B).  The 
Figure 2.7.  Predicted surface properties of the strain 1244 and PA103 pilin DSLs.  
Tertiary structures of 1244 pilin and PA103 (P144S) pilin generated by homology modeling.  
The residues of the DSL and tail are pink and the C-terminal residue is yellow.  Molecular 
surface of the DSL was generated and displayed in terms of Gasteiger charges where blue is 
positive and red is negative. 
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glycosylated form was present in cells expressing either of these pilins as determined by the 
presence of a band with an apparent molecular weight similar to the glycosylated pilin 
standard (Fig. 2.9A) and reaction with the glycan-specific antibody (Fig. 2.9B).  The 
presence of some non-glycosylated pilin in the mutant expressing p1244 S150 was also 
detected (Fig. 2.9A).  These results provide evidence that extension of the DSL tail does not 
interfere with pilin glycosylation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Since glycosylation of these 1244 pilins occur, the extension of the tail region of 
PA103 pilin terminating in Ser may position the terminal Ser far enough away from the DSL 
to permit glycosylation.  To test this, the tail region of p103 P144S was extended by the 
insertion of two Ala codons between the penultimate Glu and the carboxy-terminal Ser 
Figure 2.8.  Western blot analysis of PA103 mutant pilin with insertion.  Western blot of 
pilin produced by P. aeruginosa 1244.47 / p103 INS136 in the presence of PilO 
(pUCP26pilO) or without PilO (pUCP26) using anti-pilin polyclonal serum as a probe (A) or 
anti-1244 pilin glycan polyclonal serum (B) as a probe.  G is glycosylated 1244 pilin and NG 
is non-glycosylated 1244 pilin.  Pilin encoded by p103 INS136 was glycosylated in the 
presence of PilO whereas removal of PilO abolished glycosylation.  The presence of a pilin 
band was consistent with the presence of IPTG (A), and empty vector controls did not 
produce a band (pMMB66EH). 
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producing p103 S146 (Fig. 2.2).  This plasmid was moved into strain 1244.2024 where cell 
extracts were subjected to Western blot analysis (Fig. 2.9C&D).  When pilA from p103 S146 
was coexpressed with pilO, the pilin produced had a higher apparent molecular weight than 
when in the absence of pilO, indicating pilin glycosylation (Fig. 2.9C).  Pilin expressed in the 
presence of pilO reacted with glycan-specific serum, indicating glycosylation, while no 
reaction was seen in the absence of pilO (Fig. 2.9D).  It is also obvious that p103 S146 pilin, 
in the absence of pilO, had a higher apparent molecular weight when compared to wild type 
PA103 pilin (Fig. 2.9C).  This is due in part to the extra Ala residues, but also to the 
production of only prepilin in this pilD strain.  Overall, these results show that extension of 
the C-terminal Ser puts the glycosylation site in a permissive environment. 
In order to determine the influence of shortening tail length on glycosylation of strain 
1244 pilin, I generated p1244 S147 (Fig. 2.2).  This construct was expressed in strain 
1244N3 and pilin glycosylation status was determined by subjecting cell extracts to Western 
blot analysis (Fig. 2.9A&B).  Non-glycosylated pilin was exclusively expressed by this 
mutant as determined by apparent molecular weight and by lack of reaction with a glycan 
specific antibody (Fig. 2.9A&B).  These results suggest that a minimum tail length is 
required to allow the interaction of enzyme and substrates.   
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Figure. 2.9.  Western blot anaysis of mutant pilins with altered tail lengths.  Western blot 
of pilin produced by P. aeruginosa 1244N3 / p1244 S147, 1244N3 / p1244 S149, and 1244N3 
/ p1244 S150 using anti-1244 pilin monoclonal antibody 5.44 as a probe (A) or anti-1244 
pilin glycan monoclonal antibody 11.14 (B) as a probe. G is glycosylated 1244 pilin and NG 
is non-glycosylated 1244 pilin.  Pilin with longer tails were glycosylated (S149 and S150) 
whereas pilin with a shortened tail region was not glycosylated (S147).  Western blot of pilin 
produced by P. aeruginosa 1244.2024 / p103 S146 in the presence of PilO (pUCP26pilO) or 
without PilO (pUCP26) using anti-PA103 pilin monoclonal antibody 2.97 as a probe (C) or 
anti-1244 pilin glycan polyclonal serum (D) as a probe.  Pilin encoded by p103 S146 was 
glycosylated in the presence of PilO whereas removal of PilO eliminated glycosylation.  The 
presence of a pilin band was consistent with the presence of IPTG (A), and empty vector 
controls did not produce a band (pMMB66EH).  Pilin produced by 1244.2024 / p103 S146 / 
pUCP26 was non-glycosylated, however it has a higher molecular weight than wild type 
PA103 pilin because the leader sequence was not cleaved and this mutant pilin had two 
additional alanines in the tail region. 
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2.5. Discussion. The pilin glycan of P. aeruginosa 1244 is identical to the O-antigen 
repeating unit of this organism and exists in a ratio of one glycan per pilin subunit (33).  This 
structure is attached by ether linkage to the β-carbon of Ser 148, the pilin C-terminal residue 
(41).  Modification of the C-terminus is unusual when compared with O-glycosylation of 
other prokaryotic proteins.  For example, the single Neisseria gonorrhoeae pilin glycan is 
attached at Ser 63 (171, 218), a residue in the central portion of the domain between the N-
terminal α-helix and β-sheet region, referred to as the αβ-loop (47).  In the C. jejuni O-
linked flagellin glycosylation system, 19 separate Ser/Thr residues are modified by the 
addition of a pseudaminic acid moiety, none of which are located at the C-terminus (232).  In 
the present chapter, results show that glycosylation of this residue is abrogated by the 
addition of Ala at position 149, making Ser 148 the penultimate residue meaning that the C-
terminal position is required.  This suggests that either the exposed carboxyl group of this 
residue is recognized by PilO, or the bulk of an additional residue prevents enzyme contact.  
This, in either case, would be a good mechanism for insuring glycosylation of only the 
terminal Ser.  The value of the 1244 glycan at the pilin C-terminus may be related to its 
proximity to the DSL, a structure that facilitates adhesion to host tissue by attachment to 
surface glycolipids (205).  This structure, while exposed at the pilus tip is at least partially 
buried between the subunits of the fiber shaft (141).  Previous data has shown that the glycan 
is located on the fiber surface where it attenuates the natural hydrophobicity of the pilus 
(210).  It is possible that the surface location of the glycan also stabilizes the DSL and 
protects it against antibody recognition or proteolysis, thus maintaining pilus integrity and 
promoting virulence. 
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Neither the replacement of the PA103 pilin C-terminal residue with Ser nor 
exchanging the pilin tail region of this protein with that of 1244 resulted in glycosylation.  
However, a substitution using the complete 1244 pilin DSL region allowed glycosylation, 
suggesting that either the 1244 structure contained recognition elements, or the PA103 pilin 
DSL was incompatible with glycosylation.  Deletions of portions of the 1244 pilin DSL 
indicated that these residues were not required for glycosylation, while altering the charge 
arrangement of the PA103 pilin DSL allowed partial glycosylation to occur.  These results 
suggest that the glycosylation apparatus is not compatible with the electronegative 
environment of the PA103 pilin DSL.  This may be due to an influence on PilO or to 
repulsion from the negative charges of the undecaprenol carrier lipid or the pseudaminic acid 
of the O-antigen repeating unit.  This interpretation is strengthened by the finding that 
extending the tail of the PA103 pilin (in which the terminal Pro had been replaced with Ser) 
resulted in a strong glycosylation response.  This mutation likely positioned the glycosylation 
site far enough away from the negative charges of the DSL to place the terminal Ser in a 
permissive environment.  Shortening the tail of 1244 pilin prevented glycosylation, 
suggesting that a minimal distance is required in this segment in the wild type strain as well, 
possibly due to a steric effect or to an influence on Ser flexibility.  The importance of a 
specific environment provided by residues near the glycosylation site has been observed in 
several O-linked glycosylation systems.  For example, in C. jejuni flagellin glycosylation, 
most of the modified residues were located in a hydrophobic patch of this protein, and Ser 
and Thr that were adjacent to charged residues were not typically glycosylated (232).  In the 
eukaryotic mucin-type O-glycosylation system (237) as well as in glycosylated cellulases of 
the prokaryotes, Clostridium thermocellum and Bacteroides cellulosolvens (78), glycosylated 
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Ser/Thr were located among regions rich in Ser/Thr/Pro, suggesting that properties of these 
residues provided a preferential environment for glycosylation.  Altogether, these results 
indicate that pilin glycosylation requires only a C-terminal Ser and a compatible protein 
surface.  In addition, an incompatible surface will allow activity if the glycosylation site is 
extended sufficiently.  These results suggest that the tail region may function to present the 
glycosylation target at the minimally optimal distance from the pilin subunit.  Extension of 
the tail region of pilin did not prevent glycosylation, indicating that molecular flexibility is 
well tolerated in the pilin glycosylation reaction.  Further work will be required to establish 
whether this minimal motif can function as a glycosylation site for other proteins, or if there 
are pilin-specific factors, possibly related to the membrane location of both pilin and PilO. 
Western blot analyses revealed that a pilD mutant, deficient in prepilin leader 
cleavage, is capable of pilin glycosylation (unpublished observations; Fig. 2.9C&D) 
suggesting that glycosylation occurs early in pilus biogenesis.  Since 1244 pilins with 
mutated cysteines, as well as pilins that lacked large segments of the pilin C-proximal region, 
could serve as a glycosylation substrate, it was clear that an intact DSL was not required for 
this modification.  However, shortening 1244 pilin by one residue while maintaining a C-
terminal Ser prevented glycosylation.  Altogether, these results suggest that, under normal 
conditions, pilin is folded and the DSL is formed prior to glycosylation.  Previous work has 
shown that proteins destined for glycosylation commonly fold into their native state prior to 
this modification (232, 237).  This is consistent with the finding that Ser/Thr residues of 
flagellin, predicted to be surface exposed, were found to be glycosylated in C. jejuni, 
whereas buried residues were unmodified (232).  Similarly, the eukaryotic mucin-type O-
glycosylation system utilizes only Ser/Thr residues exposed after protein folding (10).  
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The exploitation of this glycosylation system for vaccine engineering should be 
explored.  Previous results have demonstrated that pure pili from strain 1244 induced the 
production of antibodies in mice against not only the proteinaceous portion of the pilin and 
the glycan, but also against the O-antigen of this organism (41).  In addition, evidence has 
been presented that PilO is capable of transferring an O-repeat from a number of different P. 
aeruginosa serotypes to 1244 pilin (60).  These results suggest the potential for designing a 
broadly protective pilus-based vaccine specific for both the O-antigen and pilin protein.  Pilin 
from strain PA103 is not glycosylated and belongs to a structurally distinct subgrouping 
referred to as group II (34).  I have shown that PA103 pilin can easily be engineered to act as 
a glycosylation substrate.  Because addition of the glycosylation substrate to PA103 pilin 
requires only minor alteration, one would expect a minimal effect on the immunogenicity of 
this protein.  Group I and II pilins are the most common types found among clinical isolates 
(136, 210).  Combining these molecules with common O-antigen repeating units would 
target an immune response to the pilin protein and pilin glycan (inhibiting twitching motility 
(33)) as well as the O-antigen of lipopolysaccharide (facilitating phagocytosis).  The breadth 
of the vaccine would be generated by increasing targets rather than by component 
redundancy.  This means that, since this vaccine strategy involves the utilization of a small 
number of pilin and O-antigen types, the likelihood of antigenic suppression observed with 
the administration of multivalent pilus (104, 168) or O-antigen vaccines (88) would be 
reduced.  Finally, it may be possible to engineer non-pilin proteins to act as glycosylation 
substrates, a strategy that would greatly widen the types of conjugate vaccines developed. 
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Chapter 3. Pseudomonas aeruginosa 1244 pilin glycosylation: glycan substrate 
recognition.2  
 
3.1. Abstract. The pilin of Pseudomonas aeruginosa 1244 is glycosylated with an 
oligosaccharide that is structurally identical to the O-antigen repeating unit of this organism.  
Concordantly, the metabolic source of the pilin glycan is the O-antigen biosynthetic pathway.  
The present study was conducted to investigate glycan substrate recognition in the 1244 pilin 
glycosylation reaction.  Comparative structural analysis of O-subunits that had been 
previously shown to be compatible with the 1244 glycosylation machinery revealed 
similarities among sugars at the presumed reducing termini of these oligosaccharides.  
Therefore, the glycosylation substrate was hypothesized to be within the sugar at the 
reducing end of the glycan precursor.  Since much is known of PA103 O-antigen genetics, 
and because the sugar at the reducing termini of the O7 (strain 1244) and O11 (strain PA103) 
are identical (β-N-acetyl fucosamine), PA103 and strains that express lipopolysaccharide 
(LPS) with a truncated O-antigen subunit were used to test this hypothesis.  LPS from a 
strain mutated in the wbjE gene produced an incomplete O-subunit, consisting only of the 
monosaccharide at the reducing end (β-D-N-acetyl fucosamine), indicating that this moiety 
contained substrate recognition elements for WaaL. Expression of pilAO1244 in PA103 
wbjE::aacC1 followed by Western blotting of extracts of these cells indicated that pilin 
produced has been modified by the addition of material consistent with a single N-acetyl 
fucosamine.  This was confirmed by analyzing endopeptidase-treated pilin by mass 
                                                          
2 Work in this chapter was published in the Journal of Bacteriology, Vol. 188, No. 12, June, 2006 
© 2006 by The American Society for Microbiology 
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spectrometry.  These data suggest the pilin glycosylation substrate recognition features lie 
within the reducing-end moiety of the O-repeat, and structures of the remaining sugars are 
irrelevant.   
 
3.2. Introduction. Pseudomonas aeruginosa is a Gram-negative, opportunistic 
pathogen that expresses type IV pili (156), fibrous surface appendages that protrude from the 
poles of the cell (75).  Pili contribute to bacterial pathogenicity by initiating colonization of 
host tissue through adhesion, and mediating motility across surfaces (156).  A single pilus 
fiber is a polymer of a proteinaceous subunit, referred to as pilin (156).  Pilin of P. 
aeruginosa 1244 is modified by glycosylation, a process that requires the presence of the 
enzyme PilO (32). 
Since the discovery of archaeal S-layer glycoproteins (160) numerous accounts of  
protein glycosylation in prokaryotes have been recorded, especially among surface proteins 
of pathogens (195, 225).  Examples of Gram-positive bacteria in which this post-translational 
modification has been documented include, Streptococcus mutans (36), S. parasanguis (216), 
Mycobacterium tuberculosis (62), and Bacillus anthracis (224).  Among the Gram-negative 
bacteria, much of the research attention has focused on the two glycosylation systems of 
Campylobacter jejuni (86, 226, 227), in addition to flagellin glycosylation of P. aeruginosa 
(25) and Helicobacter pylori (194), and pilin glycosylation of Neisseria spp. (113, 171, 218) 
and P. aeruginosa 1244 (32, 33, 210).   
P. aeruginosa 1244 pilin contains a single covalently bound glycan (33) that is O-
linked to the β-carbon of Ser148 (41), the carboxy-terminal residue (35).  The pilin glycan is a 
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trisaccharide, structurally identical to the O-antigen repeating unit of the serotype O7 
lipopolysaccharide (LPS) of strain 1244 (33), which suggested that the glycan might 
originate in the same metabolic pathway as O-antigen biosynthesis.  Evidence supporting this 
was provided by the finding that mutation of genes involved in initial steps of O-antigen 
biosynthesis (either wbpM or wbpL) abolished pilin glycosylation (60).  In addition, 
expression of heterologous O-antigen gene clusters in P. aeruginosa 1244 allowed for pilin 
to be decorated with the heterologous saccharide, confirming that pilin glycosylation and O-
antigen biosynthesis shared a common metabolic origin (60).  Furthermore, the putative 
oligosaccharyltransferase, PilO, is the only protein required for glycosylation that is not 
involved in O-antigen or pilin synthesis (60).  
P. aeruginosa O-antigen biosynthesis proceeds by the “Wzy-dependent” mechanism 
(59, 72) during which, individual O-antigen repeating units are constructed on the 
cytoplasmic side of the cell membrane by sequential addition of nucleotide-activated sugars 
to the carrier lipid, undecaprenyl phosphate (Und-P) (72, 180).   In P. aeruginosa PA103, 
WbpL catalyzes the transfer of β-D-FucNAc to Und-P (59), followed by the addition of α-L-
FucNAc by a previously uncharacterized transferase.  Finally, the glucosyltransferase, WbjA, 
adds β-D-Glc to complete the O11 subunit (58).  The putative flippase, Wzx, translocates the 
undecaprenyl pyrophosphate (Und-PP) -linked O-repeat to the periplasmic face (152, 159, 
162) of the cell membrane, where O-antigen polymerization (159) is mediated by Wzy (59, 
180).  O-antigen chain length is regulated by Wzz (187), and the O-ligase, WaaL, transfers 
the entire O-antigen  to the core polysaccharide (1, 162).  A Wzy mutant cannot synthesize 
polymerized O-antigen, however, these cells are capable of producing a core that contains a 
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single O-antigen repeating unit, a phenotype referred to as core + 1 (59).  Interestingly, 
mutation of wbjA yielded cells that produced a core containing an incomplete O-subunit, and 
possessed a core + 2/3 phenotype (58).  These phenotypes suggest that O-antigen 
polymerization and complete assembly of the individual O-subunit are not necessary for 
core-O-antigen ligation (58).  A similar phenomenon was observed in a mutant of E. coli K-
12 that could only synthesize the first sugar of its O-subunit (72). 
Results from a previous study that investigated pilin specificity in the P. aeruginosa 
1244 glycosylation reaction suggested that the positioning of Ser at the pilin C-terminus is 
critical for recognition by the glycosylation machinery (102).  Although no other specific 
recognition features are present, the pilin surface charge must be compatible with the 
glycosylation apparatus (102). Glycosylation requires an enzyme with specificity for both the 
target protein and the glycan source (213, 225).  Little is known of glycan features important 
for recognition in prokaryotic oligosaccharyltransferase-mediated protein glycosylation 
systems.  In the O-linked glycosylation system of P. aeruginosa 1244 pilin, completely 
assembled individual O-antigen subunits bound to Und-PP (60), are transferred en bloc to 
pilin (33, 60).  A similar model is proposed for C. jejuni N-linked glycosylation (71, 225).  
As a variety of structurally distinct O-subunits can be used as the P. aeruginosa 1244 pilin 
glycan (60), the apparent saccharide recognition features for catalysis by this system are 
unclear.  However, the 1244 pilin glycosylation machinery does exhibit specificity for the O-
antigen subunit, as other Und-PP-linked saccharides, such as peptidoglycan components, are 
not linked to pilin (33).  Elucidating essential structural aspects of the 1244 pilin glycan 
precursor for glycosylation would contribute to the understanding of an important post-
translational modification.   
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Results presented here indicate that WbjE catalyzes the addition of the second sugar, 
α-L-N-acetyl fucosamine, to the O11 subunit of P. aeruginosa PA103.  In addition, the 
current study provides a detailed description of the glycan substrate recognition features of 
the P. aeruginosa 1244 pilin glycosylation system.  These results suggest that the sugar at the 
reducing end of the O-antigen repeating unit contains the major glycosylation recognition 
information, and that structural aspects of the remaining sugars are unimportant. Evidence 
presented here suggests that the carbohydrate moiety at the reducing end of the O-repeat also 
possesses the recognition information necessary for catalysis by WaaL, the O-antigen ligase 
as was previously observed in E. coli K-12 (72).  By examining endopeptidase-treated 1244 
pilin produced in trans by O-antigen mutants, I demonstrate a novel approach for analysis of 
O-subunits.  The findings of this study could have implications for utilization of the 1244 
pilin glycosylation system in vaccine engineering. 
 
3.3. Materials and Methods. 
 
3.3.1. Bacterial strains and media.  P. aeruginosa strains and plasmids used 
in this study are listed in Table 3.1.  Escherichia coli DH5α (Invitrogen), SM10 (208), and 
HB101 (21) were used for genetic manipulations.  Luria (L) broth or agar was used for 
routine growth of bacteria.  Cetrimide agar base (Difco) was used for the isolation of P. 
aeruginosa after triparental matings.  For analysis of pilin, overnight-cultures were used to 
inoculate petri plates containing CAYE solid medium, which consisted of 0.75% casamino 
acids, 0.15% yeast extract, and 2% agar (207).  The media contained gentamicin (250 µg/ml 
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for P. aeruginosa and 15 µg/ml for E. coli), kanamycin (30 μg/ml for E. coli), carbenicillin 
(250 µg/ml for P. aeruginosa), ampicillin (50 µg/ml for E. coli), and/or tetracycline (50 
μg/ml for P. aeruginosa), as required.  When necessary, media was supplemented with 5% 
sucrose or 5 mM IPTG. 
 
3.3.2. DNA manipulations.  Plasmid DNA was isolated with Qiaprep Spin 
Miniprep Kit (Qiagen Sciences, Valencia, CA) or Wizard Plus Minipreps (Promega Corp., 
Madison, WI).  Restriction endonucleases and modification enzymes (New England Biolabs, 
Beverly, MA; Boerhinger Mannheim Corp., Indianapolis, IN) were used as specified by the 
manufacturer.   
 
Table 3.1. P. aeruginosa strains and plasmids used in this study. 
Strains/plasmids Description Source or reference 
Strains   
  P. aeruginosa   
      PA103 Wild type, IATS O11 (146) 
      1244N3 rpoN (TcR), IATS O7 (182) 
      PA103 wzy::aacC1 wzy (GmR) (59) 
      PA103 wbjA::aacC1 wbjA (GmR) (58) 
      PA103 wbjE::aacC1 wbjE (GmR) This study 
   
Plasmids   
  pRK2013 KmR, helper plasmid for triparental mating (189) 
  pLPS2 broad host range cosmid containing the P. aeruginosa PA103 O11 
gene cluster 
(82) 
  pEX100T 5.8-kb gene replacement vector, oriT, sacB+, ApR (200) 
  pUCGm contains a GmR cassette (aacC1), ApR, GmR (199) 
  pEX100T-wbjE::aacC1 pEX100T with insertion of the GmR cassette (aacC1) in wbjE This study 
  pUCP18 pUC18-derived broad host-range shuttle vector, ApR / CbR (202) 
  pCD207 pUCP18 with P. aeruginosa PA103 wbjE This study 
  pMMB66EH 8.8-kb broad host range expression vector, ApR/ CbR (77) 
  pPAC46 pMMB66EH with P. aeruginosa 1244 pilAO (32) 
  pPAC24 pMMB66EH with P. aeruginosa 1244 pilA (32) 
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The wbjE sequence was obtained from a PCR fragment amplified from the pLPS2 
plasmid.  Primers for the amplification of the wbjE gene were 83-30 (5′ – 
gctgaaacccctcggctttaagg – 3′) and 6-95-E (5′– gcatcgcgattcaccttccg – 3′) and were purchased 
from Ransom Hill (Ramona, CA).  PCR was performed with the EasyStart PCR Mix-in-a-
Tube (Molecular Bio-Products, Inc., San Diego, CA) or with Vent-PCR as described by 
manufacturer (New England BioLabs, Beverly, MA) and either an Applied Biosystems 
GeneAmp PCR System 9700 thermocycler or a Perkin-Elmer GeneAmp PCR System 2400 
thermocycler.  PCR products were purified by agarose gel electrophoresis as previously 
described (46).  Following agarose gel electrophoresis, DNA fragments were isolated with 
the Qiaquick Gel Extraction Kit (Qiagen) as specified by the manufacturer.  Nucleotide 
sequence determination of both strands of the cloned DNA was carried out by the 
Biomolecular Research Facility (University of Virginia).  Nucleotide sequence fragments 
were assembled and analyzed with the Gene Construction Kit (SciQuest, Research Triangle, 
NC) computer program.  
 
3.3.3. In vitro mutagenesis and gene replacement.  A wbjE mutation was 
made in the chromosome of P. aeruginosa PA103 as follows.  A blunt-ended wbjE PCR 
product, as described above, was cloned into the SmaI site in the pEX100T vector.  A non-
polar mutation of wbjE was constructed in vitro by insertion of a gentamicin resistance gene 
(aacC1), recovered as an 854 bp SalI fragment from pUCGm, into the SalI site in wbjE on 
pEX100T.  This construct (pEX100T-wbjE::aacC1) was introduced into the mobilizing E. 
coli strain SM10, and SM10 / pEX100T-wbjE::aacC1 was conjugated with P. aeruginosa 
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PA103 by pelleting approximately equal numbers of donor (grown overnight at 37°C) and 
recipient (grown overnight without shaking at 42˚C) strains in microcentrifuge tubes and 
spotting them onto the center of an L agar plate.  After incubation for 12 to 18 hours at 37˚C, 
the cells were resuspended in 1 ml of L broth and plated on gentamicin-containing cetrimide 
plates.  Colonies arising after 48 h were purified on the same medium and the swabbed onto 
L agar plates containing both gentamicin and sucrose.  Since pEX100T contains the sacB 
gene, which renders Gram-negative bacteria sensitive to sucrose, colonies arising on sucrose- 
and gentamicin-containing plates carried wbjE::aacC1 on the chromosome and had lost the 
vector-associated sacB gene.  These colonies were tested for sensitivity to carbenicillin to 
confirm the loss of vector DNA.  Gene replacement was confirmed by PCR amplification of 
chromosomal DNA with primers flanking the aacC1 insertion site in wbjE.  
 
3.3.4. Complementing plasmid.  The same Vent-PCR product that was used 
for the gene replacement, as described above, was cloned in SmaI-digested plasmid pUCP18.  
Restriction analysis indicated that the fragment was inserted in the orientation opposite that 
of the lacZ gene on the plasmid.  The recombinant plasmid, referred to as pCD207, was 
transformed into P. aeruginosa PA103 wbjE::aacC1 by the electroporation protocol of 
Enderle and Farwell (68).  For pilin analysis, triparental mating was used to mobilize 
pMMB66EH-derived plasmids into P. aeruginosa strains (189).    
 
3.3.5. Isolation of LPS.  P.  aeruginosa LPS was isolated by the proteinase K 
digestion method of Hitchcock and Brown (98), followed by hot-phenol extraction with 
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slight modifications.  Cells grown overnight in L broth with appropriate antibiotics were 
equilibrated to an optical density of 0.5 at a wavelength of 600 nm. This volume of bacterial 
suspension was then transferred to a microcentrifuge tube and centrifuged at 13,100 × g for 5 
min.  The supernatant was removed and the pellet was resuspended in 200 μl of lysis buffer 
(2% sodium dodecyl sulfate [SDS], 4% β-mercaptoethanol, 10% glycerol, and 0.002% 
bromphenol blue in 1M Tris [pH 6.8]), and boiled for 15 min.  The lysed cells were treated 
with RNase and DNase for 30 min at 37˚C.  The cells were then digested for 3 h at 59˚C with 
120 µg of proteinase K.  The digested lysates were then extracted with an equal volume of 
90% phenol for 15 min at 65˚C with periodic vortexing.  After centrifugation in a 
microcentrifuge at maximum speed for 10 min, both the aqueous and phenol layers were 
transferred to new tubes and extracted with 1 ml of diethyl ether.  The aqueous layers from 
these extractions were removed, pooled, and again extracted with hot phenol.  The aqueous 
layer (blue) was again extracted with 1 ml of ether and centrifuged, and the LPS-containing 
aqueous layer was diluted 1:3 with fresh lysis buffer and used for SDS-polyacrylamide gel 
electrophoresis (PAGE) analysis. 
 
3.3.6. SDS-PAGE and Western immunoblotting.  LPS samples were 
separated by SDS-PAGE as previously described (46), on 12% or 13% acrylamide running 
gels.  LPS was visualized by silver staining with a protocol derived from Tsai and Frasch 
(234).  For pilin analysis, cell extracts were separated by SDS-PAGE using 16% Tris-glycine 
(1244 pilin) or 16% Tricine gels (PA103 pilin) prior to Western blotting (102). 
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Western immunoblot analyses were performed as previously described (35, 46).  The 
antibody used was anti-1244 pilin Mab 6.45, which does not recognize PA103 pilin (206).  
The blot was developed at room temperature with a fluorescein isothiocyanate-conjugated 
secondary antibody.  Fluorescence was detected using a FluorImager595 (Molecular 
Dynamics) employing the 530 DF30 filter. 
 
3.3.7. Isolation and purification of pili.  Pili from PA103 wbjA::aacC1 / 
pPAC46, PA103 wbjE::aacC1 / pPAC46, 1244N3 / pPAC46, and 1244N3 / pPAC24 were 
harvested as previously described (207).  Briefly, cell cultures were grown in aluminum foil-
covered 68- by 28- by 3-cm metal pans that contained 500 ml of CAYE medium, appropriate 
antibiotics, and 5 mM IPTG, at 37°C for 14 h (1244 N3 / pPAC46 and 1244 N3 / pPAC24) 
or 18 h (PA103 wbjA::aacC1 / pPAC46 and PA103 wbjE::aacC1 / pPAC46).  Cells from 
each pan were suspended in 50 ml of sodium phosphate buffer (207).  Cell suspensions were 
stirred vigorously for 30 min at room temperature.  The pili were isolated from the 
supernatant after centrifugation at 16,000 x g for 30 min at 4°C.  Pili were purified by 
repeated precipitation in the presence of 3% polyethylene glycol 8000 and 0.5 M NaCl (207, 
210).  
 
3.3.8. Analytical methods.  GluC (V8 protease, Roche Applied Science) 
specifically hydrolyzes peptide and ester bonds at the carboxylic side of glutamate residues.  
GluC endopeptidase digestions of pilin samples were performed as previously described 
(41).  Digested pilin was initially analyzed by SDS-PAGE (17% tris-glycine gel) followed by 
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Coomassie brilliant blue staining to detect the presence of the ~5-6 kDa fragment (data not 
shown).  The digestion mixture was subjected to two overnight dialyses against 6 liters of 
deionized water (0.025% sodium azide) at 4°C.  Dialyzed samples were analyzed via matrix-
assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry by Dr. 
Mark Bier of the Mellon Institute Center for Molecular Analysis, Carnegie Mellon 
University, using a PerSeptive Biosystems Voyager STR with DE and a high m/z detector.  
O-antigen repeating unit structures (127, 173) were drawn using ChemDraw 9.0 for 
comparative analysis. 
 
3.4. Results 
 
3.4.1. Structural comparison of O-antigen repeating units.  In a previous 
study that investigated the glycan specificity of PilO, results indicated that nine P. 
aeruginosa serotypes (seven having known O-antigen structures) and E. coli O157, all 
possessed an O-subunit that could serve as the 1244 pilin glycan (Fig. 3.1) (60).   This 
suggested that common structures among these O-subunits could be important for 
recognition by the 1244 glycosylation machinery.  Comparative structural analysis of these 
sugars revealed drastic differences in charge, size, configuration, linkage, and number of 
sugars (Fig. 3.1).  However, it is evident that the Und-PP/ pilin- linked moieties (reducing 
end) share structural similarities (Fig. 3.1).  Such similarities include a C-1 linkage to the 
Und-PP carrier, D configuration, C-3 linkage to the adjacent sugar, and the presence of a 2-
N-acetyl group (Fig. 3.1).  Much of the variance between these O-repeats lies within the 
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remaining carbohydrate moieties (Fig. 3.1).  For instance, the serotype O7 repeat of strain 
1244 is a trisaccharide in which the sugar in the third position, (counting the Und-PP/ pilin- 
linked moiety at the reducing end as the first position), pseudaminic acid, is a 14-carbon 
sugar in the α configuration.  This pseudaminic acid is linked (1Æ4) to the second sugar, 
xylose, a β-5-carbon sugar.  In contrast, the O6 repeating unit is a tetrasaccharide, in which 
the second and third moieties are β-sugars (linked 1Æ3), consisting of seven and nine 
carbons respectively, whereas the fourth moiety is in the α configuration and consists of 6 
carbons.  The structural comparison of the O-repeats from Fig. 3.1 suggests that the moiety at 
the reducing terminus may possess the glycan recognition features necessary for catalysis by 
the pilin glycosylation machinery, and structural aspects of other saccharides are 
nonessential. 
 
3.4.2. Characterization of PA103 wbjE::aacC1.  To experimentally 
determine if the structural elements of the glycan necessary for glycosylation are within the 
reducing-end moiety of the O-antigen repeating unit, a mutant that incapable of complete O-
subunit assembly beyond the first sugar, β-N-acetyl fucosamine, was required (Fig. 3.1).  
Because little is known of the O-antigen genetics of strain 1244 (serotype O7), I utilized a 
strain more commonly studied in O-antigen biosynthesis, PA103 (serotype O11), as a genetic 
background (58, 59).  Notably, the first sugar moiety the O7 serotype O-subunit is identical 
to that of the serotype O11 subunit (β-D-FucNAc; Fig. 3.1).  Because wbjE encodes the only 
remaining hypothetical glycosyltransferase in the O11 biosynthetic gene cluster (58, 59), I 
hypothesized that WbjE mediated the attachment of α-L-FucNAc to undecaprenyl 
 83
pyrophosphate-linked β-D-FucNAc during assembly of the O11 O-antigen repeating unit.  If 
this was true, its inactivation would result in an incomplete O-antigen subunit consisting only 
of β-D-FucNAc.  A mutation of wbjE was constructed in vitro by insertion of a gentamicin 
resistance gene (aacC1).  LPS was isolated from PA103, PA103 wzy::aacC1 (59), PA103 
wbjA::aacC1 (58), PA103 wbjE::aacC1, and PA103 wbjE::aacC1 / pCD207 (Table 3.1).  
This LPS was subjected to SDS-PAGE followed by silver staining which revealed that 
PA103 makes long side-chain O-antigen (Fig. 3.2) that was not detectable in the LPS 
mutants.  O-antigen was noted in the PA103 wbjE::aacC1 mutant containing the 
complementing clone pCD207 indicating that the wbjE mutation was non-polar (Fig. 3.2).    
The size of the LPS core was compared in these strains (Fig. 3.2).  LPS from all 
strains contained a band corresponding to a complete core (Fig. 3.2).  As anticipated, LPS 
from PA103 and O-antigen polymerase mutant, PA103 wzy::aacC1, contained core + 1 (59) 
and PA103 wbjA::aacC1 makes a core and a core + 2/3 (Fig. 3.2) (58).  A small amount of 
LPS that migrated faster than the core + 2/3 was observed with PA103 wbjE::aacC (Fig. 
3.2).  Complementation with the plasmid pCD207 resulted in the expression of a complete 
core + 1 (Fig. 3.2).  These data suggest a core + 1/3 phenotype for PA103 wbjE::aacC1 
indicating that WbjE adds the α-L-FucNAc to undecaprenyl pyrophosphate-bound β-D-
FucNAc (Fig. 3.3), and as in PA103 wbjA::aacC1, an incomplete O-subunit can be 
transferred to the core (58). 
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Figure 3.1.  Comparative structural 
analysis of O-antigen subunits 
previously shown to be compatible 
for use in pilin glycosylation (60).  
Chair conformations of O-repeats were 
drawn using ChemDraw 9.0 based on 
structures presented by Knirel (127) 
and/ or Perry and MacLean (173).  
Presumably, the sugar at the reducing 
end (highlighted in gray) is bound to 
Und-PP prior to pilin glycosylation, O-
antigen polymerization, and ligation to 
the core-lipid A.  PilO from strain 1244 
(serotype O7) was found to mediate the 
O-linkage between carbon-1 of the 
moiety at the reducing terminus (β-D-
FucNAc) to Ser148 of pilin (33, 41).  All 
O-repeats tested for use as the glycan 
were likely bound to pilin in this 
fashion. 
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3.4.3. Pilin glycan substrate recognition.  To determine if the solitary 
reducing-end sugar in the O-antigen repeat could be transferred to P. aeruginosa 1244 pilin, 
pPAC46 (which contains pilAO1244) was expressed in PA103 wbjE::aacC1.  To further 
examine the effect of incomplete synthesis of the O-subunit on glycosylation, pPAC46 was 
also expressed in PA103 wbjA::aacC1.  Subsequently, plasmid-encoded pilin was assayed 
for glycosylation by subjecting extracts of these cells to Western blot analysis using a 1244 
pilin-specific Mab as a probe (Fig. 3.4).  Pilin produced by 1244N3 / pPAC46 and 1244N3 / 
Figure 3.2.  Analysis of LPS isolated from P. aeruginosa PA103 and 
derivatives. P. aeruginosa lipopolysaccharide was isolated by the 
proteinase K digestion method of Hitchcock and Brown (98), followed by 
hot-phenol extraction with slight modifications. Samples were separated by 
SDS-PAGE (46), followed silver-staining.  This experiment was carried out 
by Charles R. Dean and Joanna B. Goldberg. 
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pPAC24 were used as glycosylated and non-glycosylated standards (32) respectively.   This 
blot revealed that pilin produced by PA103 wbjE::aacC1 / pPAC46 had a slightly higher 
apparent molecular weight than the non-glycosylated pilin standard (Fig. 3.4).  PA103 
wbjA::aacC1 / pPAC46 synthesized pilin that had a slightly lower apparent molecular weight 
than both the glycosylated pilin standard, and heterologously glycosylated pilin of PA103 / 
pPAC46 (Fig. 3.4) (60).  However, the apparent molecular weight of PA103wbjA::aacC1 / 
pPAC46 was higher than pilin produced by PA103 wbjE::aacC1 / pPAC46 (Fig. 3.4).  This 
blot suggests that the incomplete O-subunits synthesized by the wbjE and wbjA mutants are 
being utilized for glycosylation, as the difference in the apparent molecular weight of the 
pilin produced is consistent with the size differences observed in the LPS (Fig. 3.2 & 3.4).  It 
is therefore likely that in PA103 wbjE::aacC1 / pPAC46, the pilin glycan is a single β-
FucNAc, and a disaccharide in PA103 wbjA::aacC1 / pPAC46, while as previously shown, 
PA103 pPAC46 produces pilin glycosylated with the entire O11 subunit (60) (Fig. 3.1). 
To conclusively determine the glycosylation status of pilin produced by PA103 
wbjA::aacC1 / pPAC46 and PA103 wbjE::aacC1 / pPAC46, purified pilus preparations were 
treated with the endopeptidase, GluC (41), followed by MALDI-TOF analysis (Fig. 3.5A, B, 
& C).  The largest pilin fragment produced by GluC digestion (Fig. 3.5A) consists of the C-
terminal 51 residues, which contains the glycosylation site, with a molecular weight 
predicted from the amino acid sequence to be 5,331 (41).  GluC treated pilin produced by 
1244N3 / pPAC46 and 1244N3 / pPAC24 were used as glycosylated and non-glycosylated 
controls (32), respectively (spectra not shown; Fig. 3.5C).  The largest fragment mass from 
the GluC-treated glycosylated pilin control contained covalently bound material with a 
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molecular weight of 670 (Fig. 3.5C) which is consistent with the value determined for the 
strain 1244 glycan structure as previously determined (33). The non-glycosylated pilin 
produced a GluC fragment within the range of the value predicted by the amino acid 
sequence (Fig. 3.5C).  GluC treated pilin from PA103 wbjA::aacC1 / pPAC46 produced a 
fragment with a molecular weight of 5,705 (±20) with no signal seen at the mass predicted 
by the pilin gene, indicating the addition of material with the molecular weight of ~374 had 
been covalently linked to the protein (Fig. 3.5B & C).  Endopeptidase treatment of pilin 
produced by PA103 wbjE::aacC1 / pPAC46 produced a fragment with a mass of 5,519 Da 
(±20) revealing the presence of additional covalently bound material with a molecular weight 
of ~188 (Fig. 3.5B & C).    These data support the description of the LPS phenotypes (Fig. 
3.2) and the pilin Western blot analysis (Fig. 3.4) in reference to the size of the incomplete 
O-antigen subunits.  The additional value of ~374 for GluC treated PA103 wbjA::aacC1 / 
pPAC46 pilin is consistent with the molecular weight predicted for the first two carbohydrate 
moieties of the O11 subunit (58).  This suggested that the pilin glycan produced here consists 
of the disaccharide, α-L-FucNAc-(1Æ3)-β-D-FucNAc-(1Æ Ser148).  Pilin produced by 
PA103 wbjE::aacC1 / pPAC46 contained a modification with a molecular weight of 188, a 
value consistent with the first carbohydrate moiety of the O11 subunit, suggesting that this 
pilin glycan likely consists of β-D-FucNAc-(1ÆSer148).  The unlabeled peak detected in both 
spectra (Fig. 3.5B) was likely generated due to the presence of one of the peptide fragments 
of the GluC-digested 1244 pilin that did not contain the glycan, or a contaminant of the pilus 
preparation.  These results confirm that WbjE adds the second sugar, α-L-N-acetyl 
fucosamine to the O11 O-antigen subunit (Fig. 3.6A).  Furthermore, the first sugar of this 
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subunit, β-D-N-acetyl fucosamine, can be transferred to the core oligosaccharide, as well as 
pilin, indicating that this sugar contains the substrate recognition features necessary for 
catalysis by both WaaL and PilO.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Und-P
Und-PP-FucNAc
Und-PP-FucNAc-FucNAc
Und-PP-FucNAc-FucNAc-Glc
Lipid A-core-[FucNAc-FucNAc-Glc]n
Und-PP- [FucNAc-FucNAc-Glc]n
WbpL
WbjE
WbjA
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Wzx, Wzy, and Wzz PilO
Pilin-FucNAc-FucNAc-Glc
Figure 3.3.  Proposed pathway for the assembly of P. aeruginosa serogroup O11 
O-antigen and pilin glycosylation.  WbpL initiates O-antigen synthesis by the 
addition of nucleotide-activated N-acetyl fucosamine onto Und-P (187).  Data 
presented in this chapter suggests that WbjE adds the second N-acetyl fucosamine, 
while WbjA adds the terminal glucose to complete the O11 subunit (58).  Subsequent 
O-antigen biosynthesis steps involve the transportation to the periplasm (Wzx), 
polymerization of O-antigen units (Wzy), chain length determination (Wzz), and 
linkage of the O-antigen to the LPS core (WaaL) (59, 187).  Previous work suggests 
that LPS from PA103 wbjA::aacC1 contains a core + 2/3 indicating that the O-antigen 
subunit need not be complete prior to transfer to the lipid A-core (58).  In pilin 
glycosylation, PilO mediates the transfer of a single, complete O-subunit from Und-PP 
to pilin (60). 
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Figure 3.4.  Western blot analysis of plasmid-encoded P. aeruginosa 1244 pilin.  Cell 
extracts were prepared from overnight plate cultures in which induction of pilAO1244 
(pPAC46) or pilA1244 (pPAC24) was accomplished by the addition of 5 mM IPTG to the 
media, unless indicated otherwise.  The blot was probed with 1244 pilin-specific Mab, 6.45.  
G is glycosylated 1244 pilin, and NG is non-glycosylated 1244 pilin.  The dotted line was 
drawn from the centers of the NG pilin and the PA103 / pPAC24 pilin bands (also non-
glycosylated) to better illustrate the difference in molecular weight between the pilins shown 
on this blot. 
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Figure 3.5. GluC digestion of 1244 pilin.  Panel A: Amino acid sequence of 1244 pilin in 
which vertical arrows indicate GluC cleavage sites.  The largest GluC fragment (underlined), 
consists of residues 98-148, and is predicted to have a molecular mass of 5331 Da.  This 
fragment contains the 1244 pilin glycosylation site, Ser148 (41).  Panel B: MALDI-TOF spectra 
for GluC-treated pilin produced by PA103 wbjA::aacC1 / pPAC46 and PA103 wbjE::aacC1 / 
pPAC46 are shown.  Panel C: The deduced glycan mass is listed for each of the pilins subjected 
to GluC digestion and MALDI-TOF. 
 91
3.5. Discussion. The results of this study indicated that WbjE catalyzed the addition 
of the second sugar, α-L-N-acetyl fucosamine, to the O11 subunit (Fig. 3.3).  Because the 
first sugar of the O11 subunit is identical to the reducing-end moiety of the O7 subunit of 
strain 1244, and therefore the 1244 pilin glycan (33), pilAO1244 was expressed in the wbjE 
mutant and pilin was tested for glycosylation to analyze glycan substrate recognition.  Pilin 
produced contained a modification that had a molecular weight consistent with a single β-D-
FucNAc.  This suggested that the reducing-end moiety of the O-antigen subunit possesses the 
necessary structures for glycosylation, and the remaining sugars of the glycan precursor are 
nonessential. 
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Figure 3.6.  Saccharide structures.  Panel A: The P. aeruginosa serotype O11 repeating 
unit where brackets above the O-subunit indicate saccharide(s) produced by the designated 
strains.  Panel B: Reducing-end moieties from O-subunits of Francisella tularensis strain 15 
and Shigella sonnei phase I (129). 
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Previous studies have shown that incomplete O-subunits can be ligated to the core 
oligosaccharide (58, 72, 126, 252).  Data presented in the current study indicated that a single 
β-D-FucNAc was transferred to the core oligosaccharide in the wbjE mutant.  It is therefore 
likely that the structural information recognized by WaaL of P. aeruginosa PA103 was also 
in the reducing sugar of the O-repeat.  This interpretation is strengthened by previous data 
indicating that WaaL is capable of ligating a number of different polysaccharides to the core 
(74), as all of the O-repeats tested possessed similar reducing sugars.  In addition, gene 
replacement of glf in an E. coli K-12 O-antigen mutant strain produced an LPS phenotype 
like that of the PA103 wbjE::aacC1, indicating a similarity between WaaL specificity of both 
systems (72).  These results are consistent with an earlier study showing that Wzx from 
several different O-antigen systems seemed to have specificity for the sugar at the reducing 
terminus of Und-PP-linked O-subunit (153). Collectively, these data suggest that among 
related groups of Gram-negative bacteria, the reducing sugar of the O-repeat acts as a 
universal foundation, in which enzymes involved in construction of surface antigens are 
compatible.  Therefore, a variety of sugars can be added to this foundation sugar, which is 
recognized by machinery critical for surface display, such as PilO and WaaL.  If this is true, 
it appears as if evolution has provided an efficient means to ensure maximum surface 
diversity by providing congruity between products of horizontally transferred genes.  For 
example, if a heterologous O-antigen biosynthetic operon was passed from one bacterium to 
another, the saccharide produced would likely be compatible with endogenous PilO and/ or 
WaaL, and therefore surface-expressed, due to the similarities in O-subunit reducing-end 
sugars.  Because waaL and pilO are not located in the same operon as O-antigen biosynthetic 
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genes (32, 187), there is little likelihood of co-horizontal transfer, underlying the necessity 
for cohesion with heterologous O-antigens.  Notably, WaaL mediates the addition of 
polymerized O-antigen, and also has specificity for the common antigen, as this enzyme 
mediates ligation of both polysaccharides to the core-Lipid A (1).  However, PilO does not 
transfer polymerized O-antigen, or common antigen subunits onto pilin, as each pilin 
monomer contains a single glycan, identical to the O-antigen repeating unit with no evidence 
of alternate glycoforms (33).  Because PilO does not transfer polymerized O-antigen to pilin, 
this suggests that structural attributes of the long side chain O-antigen-Und-PP contribute to 
loss of affinity for the pilin glycosylation machinery.  This may be due to the size of the 
polymerized O-antigen, or an increase of affinity for WaaL.  Additional work will be needed 
for clarification. 
To discern structural components of the reducing-end sugar of the O-repeat important 
for glycan substrate recognition, cloned heterologous O-antigen biosynthetic operons 
producing structurally distinct reducing end-sugars (129) could be expressed in P. 
aeruginosa 1244 where pilin produced may be assayed for presence of the heterologous 
glycan.  For example, the O-subunit of Burkholderia cepacia serotype B (β-D-Gal-(1Æ3)-α-
D-Fuc) or those of various P. syringae strains (repeats of L- and/or D-Rha in various 
arrangements) contain sugars at their reducing termini dissimilar from those discussed here 
(129).  Results of such studies may serve to define the glycan specificity of the 1244 pilin 
glycosylation reaction.  Until these experiments are conducted, one cannot dismiss the 
possibility that the Und-PP carrier alone, or a minimal component of the bound carbohydrate, 
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such as the C-1, or the ether oxygen, contains the substrate recognition properties for the 
1244 pilin glycosylation machinery.  
A plasmid encoding pilAO1244 was expressed in the wbjE and wbjA mutants, and 
subsequently, pili produced were extracted and subjected to GluC digestion in which 
fragments were analyzed by MALDI-TOF.  Due to the intrinsic properties of pili, such as 
extracellular location, fibrous morphology, and solubility in water, pili can be easily purified 
from cell cultures.  In addition, GluC digestion separates pilin into pieces readily detectable 
in MALDI-TOF, in which the fragment containing the glycan is the largest (41).  This 
methodology not only represents an efficient means of analysis of the pilin glycan molecular 
weight, but also an expedient technique for analysis an organism’s O-antigen repeating unit.  
In this novel approach, pilin is used as an O-subunit ‘trap’.  Therefore, one may analyze the 
repeating unit apart from the core and lipid A, a previously unattainable endeavor.  The 
sugars of the glycan could be sequenced and further analyzed by employing procedures 
previously described (33).  Alternative means to analyze O-antigen include acidic and 
alkaline degradation of extracted LPS, processes that do not disrupt the core-O-
polysaccharide bond, and could potentially chemically modify the O-antigen (127).  
Previously, LPS biosynthesis and eukaryotic protein glycosylation have been 
hypothesized to have a common evolutionary origin (27, 28) based on similarities between 
the eukaryotic dolichol and prokaryotic Und-P carrier lipids, the metabolic assembly of 
oligosaccharides, in addition to sequence similarity between eukaryotic and prokaryotic 
glycosyltransferases.  Feldman et al., suggested that the N-linked glycosylation systems of C. 
jejuni and eukaryotes are homologous processes (71).  Similarly to the 1244 pilin 
glycosylation system, the C. jejuni N-linked glycosylation system has shown the capability to 
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utilize O-antigen for protein glycosylation in an engineered E. coli strain.  When pglB from 
C. jejuni was co-expressed with different LPS biosynthesis gene clusters in an E. coli LPS 
mutant (waaL and the rhamnosyl transferase wbbL), production of recombinant AcrA 
containing covalently bound, full-length O-antigen was produced (71).  If the eukaryotic N-
linked glycosylation system had evolved from a similar system to that of C. jejuni, it is 
plausible that 1244 pilin glycosylation represents an ancestral form.  This conclusion is based 
on the intrinsic utilization of the O-subunit as the 1244 pilin glycan, and the above 
mentioned similarities between the glycosylation systems of C. jejuni and P. aeruginosa 
1244. 
Because O-antigen can be covalently linked to protein by both the N-linked 
glycosylation system of C. jejuni, and the P. aeruginosa 1244 pilin glycosylation machinery, 
these systems could potentially be utilized to produce anti-LPS O-antigen vaccines (41, 71).  
Previous data have indicated that pure pili from P. aeruginosa 1244 stimulated the 
production of antibodies in mice against the proteinaceous portion of pilin and the glycan, as 
well as antibodies against the O-antigen of this organism (41).  The 1244 glycosylation 
system may be best applied for vaccine engineering by taking an approach to vaccinate 
against organisms with few serotypes such as Shigella sonnei, Francisella tularensis, and E. 
coli serotype O157 (129).  As previously mentioned, the E. coli serotype O157 subunit can 
be utilized as the 1244 pilin glycan, while S. sonnei and F. tularensis appear to produce O-
subunits with reducing-end moieties that are structurally compatible for glycosylation (Fig. 
3.6B).  Other than generating a vaccine using pilin as the glycosylated protein, the breadth of 
protection may be increased by mutation of non-pilin proteins, such as toxoids, to possess the 
1244 pilin glycosylation substrate (102).  For example, combining expression of the S. 
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sonnei O-antigen gene cluster and mutagenized shiga toxin allowing compatibility with the 
1244 glycosylation machinery, may yield a biologically produced, bivalent anti-toxin, anti-
LPS vaccine. 
 
 97
Chapter 4. Influence of pilin glycosylation on Pseudomonas aeruginosa 1244 pilus 
function.3 
 
4.1. Abstract. The opportunistic pathogen Pseudomonas aeruginosa is a leading 
cause of nosocomial pneumonia.  Among its virulence factors, the type IV pili of P. 
aeruginosa strain 1244 contain a covalently linked, three-sugar glycan of previously 
unknown significance.  The work described in this chapter was carried out to determine the 
influence of the P. aeruginosa 1244 pilin glycan on pilus function, as well as a possible role 
in pathogenesis.  To accomplish this, a deletion was introduced into the pilO gene of this 
organism. The isogenic knockout strain produced, 1244G7, was unable to glycosylate pilin, 
but could produce pili normal in appearance and quantity.  In addition, this strain had 
somewhat reduced twitching motility, was sensitive to pilus-specific bacteriophages, and 
could form a normal biofilm.  Analysis of whole cells and isolated pili from wild type P. 
aeruginosa strain 1244 by transmission electron microscopy with a glycan-specific 
immunogold label showed that this saccharide was distributed evenly over the fiber surface.  
The presence of the pilin glycan reduced the hydrophobicity of purified pili, as well as whole 
cells.  With regard to pathogenicity, P. aeruginosa strains producing glycosylated pili were 
commonly found among clinical isolates, and particularly among those strains isolated from 
sputum.  Competition index analysis using a mouse respiratory model comparing strain 1244 
and 1244G7 indicated that the presence of the pilin glycan allowed for significantly greater 
                                                          
3 Work in this chapter was published in Infection and Immunity, Vol. 73, No. 12, pp. 7922-7931, December, 2005 
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survival in the lung environment.  These results collectively suggest that the pilin glycan is a 
significant virulence factor and may aid in the establishment of infection. 
 
4.2. Introduction. Pseudomonas aeruginosa is a gram-negative pathogen capable of 
causing severe infections in individuals with compromised defense mechanisms (20).  This 
organism elaborates multiple virulence factors including type IV pili, protein fibers 
extending from the cell’s pole (221).  These pili contribute to the disease process by 
promoting colonization through adhesion and by mediating a method of surface translocation 
called twitching (156).  They are composed primarily of a monomeric subunit called pilin, a 
protein derived from a precursor by cleavage of its six amino-terminal residues and the N-
methylation of the newly revealed phenylalanine at this terminus (222).  Pilin of P. 
aeruginosa 1244 is further modified by glycosylation (32). 
Until recently, common knowledge held that prokaryotes did not glycosylate proteins.  
This was thought to be so even though copious evidence existed that glycans were found 
covalently attached to archeal and eubacterial S-layer proteins (139, 140, 160, 246).  More 
recent work has led to the appreciation that prokaryotic protein glycosylation is widespread, 
with a large number being associated with the cell surface of pathogens.  Among the gram-
positive bacteria, several examples of Streptococcus species important in periodontal disease 
have been shown to produce glycosylated proteins (16).  In addition, Mycobacterium 
tuberculosis envelope proteins along with a potential adhesin of this organism have been 
proven to be glycosylated (62, 95), and a major component of the exosporium layer of the 
Bacillus anthracis endospore is a glycoprotein (224).  Numerous examples of surface protein 
glycosylation among the gram-negatives also exist, including adhesins of Escherichia coli 
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(17, 144), Chlamydia trachomatis (135), and Haemophilus influenzae (85).  Protein 
glycosylation in Campylobacter species has been well studied where two glycosylation 
systems have been demonstrated, one targeting secreted proteins, with the other limited to 
flagellin glycosylation (227).  Glycosylation of flagellin subunits has been examined also in 
Pseudomonas aeruginosa (193) and in Helicobacter pylori (194).  Pilin glycosylation also 
occurs in Neisseria meningitidis (218). 
   Structural analysis of the P. aeruginosa 1244 pilin glycan indicates that this moiety is 
a trisaccharide identical with the lipopolysaccharide O-antigen repeating unit of this strain 
(33).  Each pilin monomer possesses a single glycan, with no evidence of either 
nonglycosylated subunits or other alternate glycoforms (33).  Analysis of a purified 
aminoglycan produced by total proteolysis of pure glycosylated pilin showed the presence of 
a serine, indicating that the glycan is covalently bound via the β-carbon of this residue (33).  
Site-directed mutagenesis of the gene coding for pilin (pilA) and sequence analysis of pilin 
endopeptidase fragments revealed that the serine to which the glycan is attached is the 
carboxy-terminal residue of this protein (41).  The structure of the strain 1244 pilin glycan 
suggests that it is a product of the O-antigen biosynthetic pathway.  In support of this idea, it 
has been shown that 1244 mutant strains defective in specific steps in O-antigen biosynthesis 
are unable to make glycosylated pili (60).  Confirmation of this suggestion came with the 
finding that cloned O-antigen biosynthesis gene clusters coding for heterologous antigen 
could be expressed in P. aeruginosa 1244 producing pilin glycosylated with the heterologous 
saccharide (60).   
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pilO, a gene required for pilin glycosylation (32), is predicted to code for a 
hydrophobic and basic protein with a molecular weight of 50,682, and exists as part of an 
operon which includes pilA, the gene encoding pilin.  PilO is the presumed 
glycosyltransferase responsible for attachment of the O-antigen repeating unit to pilin.  
Expression of cloned 1244 pilAO operon in a heterologous P. aeruginosa strain, which 
normally produced nonglycosylated pilin, results in the production of glycosylated pilin (60).  
Furthermore, only 1244 pilin lacking glycan is made when the strain 1244 pilA gene alone 
was expressed in this genetic background.  These results suggest that PilO is the only 
glycosylation factor required that is not part of either the pilin or the O-antigen pathways. 
The inner core of the type IV pilus fiber is composed of the pilin hydrophobic α-
helical tail, while the globular head region of this stickpin-shaped protein makes up the fiber 
surface structure (47).  The residue to which the strain 1244 glycan is covalently attached is 
immediately adjacent to the type IV pilin-specific disulfide loop (DSL) region, a structure 
important in host glycolipid-specific binding (205).  Lee, et al., (141) showed that the DSL is 
at least partially buried in the outer protein layer of the pilus shaft and is only surface 
exposed at the fiber tip.  These results suggest that the pilin glycan might also not be present 
at the fiber surface, or be surface-expressed only at the pilus tip.  Occurrence of this 
negatively charged and hydrophilic structure at the pilus surface would be expected to have a 
significant influence on the interaction of the fiber with its environment, a situation that 
would likely influence pilus function.  Work presented in this paper employing immunogold 
labeling has shown that the glycan, unlike the DSL, is surface-located over the entire pilus.  
Experiments employing a P. aeruginosa 1244 isogenic knockout mutant unable to 
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glycosylate pilin suggest that the presence of the glycan strongly modulates pilus surface 
hydrophobicity.  Evidence is presented indicating that P. aeruginosa strains producing 
glycosylated pili are commonly found among clinical isolates.  In addition, data shows that 
pilin glycosylation increases colonization as determined by the mouse acute pneumonia 
model.   
 
4.3. Materials and Methods. 
 
4.3.1. Organisms and growth conditions.  The bacterial strains, viruses, and 
plasmids used are listed in Table 4.1.  All bacterial strains were routinely grown aerobically 
at 37°C. Broth cultures were grown on a rotatory shaker at 275 rpm.  LB plates or broth were 
used for routine culture growth.  The following selective agents were employed in media at 
the indicated concentrations:  ampicillin at 100 µg/ml for Escherichia coli; carbenicillin at 
250 µg/ml for Pseudomonas aeruginosa 1244; gentamicin at 15 µg/ml for E. coli and 100 
µg/ml for P. aeruginosa; tetracycline at 15 µg/ml for E. coli and 50 µg/ml for P. aeruginosa.  
IPTG was employed at a concentration of 5 mM. 
 
4.3.2 Generation of a strain 1244 PilO null mutant by allelic replacement.  
The Bam HI/Eco RI fragment of pPAC202 was ligated with pNOT322 cut with these same 
enzymes producing pGIL100.  An Xho I site of this construct was removed by digestion with 
Eco RI and Xba I followed by Klenow polishing and religation producing pGIL101.  A DNA 
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fragment containing the gentamicin resistance gene of pPC110 was amplified using the 
following oligonucleotide primers:  1)  NILIP15 (5′- GCGCGCCTCGAGCAGCTATGACC 
ATGATTACGAATTCCCC-3′), which contained an Xho I site, and 2) NILIP 16 (5′-
GCCCCCGCTAGCCGTTGTAAAACGACGGCCAGTGAATTCCCC-3′) which contained 
a Nhe I site.  The DNA produced was digested with Nhe I and Xho I and ligated with 
pGIL101 digested with the same enzymes.  This produced a construct, pGIL200 that 
contained a 1268 base pair deletion in the pilO gene.  The Nhe I/Xho I fragment of pGIL200 
containing the gentamicin resistance gene was ligated with pPAC124, a plasmid containing 
the pilAO operon, cut with the same enzymes producing pPUC46Gm.  The Pst I/Hin dIII 
fragment of this construct, which contained the mutated pilO gene, was ligated with 
pEX18Tc cut with these same enzymes, producing pGIL300.  pGIL300, was moved into P. 
aeruginosa 1244 by triparental mating.  Tetracycline and gentamicin resistant clones 
provided evidence that the plasmid had integrated into the bacterial chromosome.  Continued 
subcultureing of these clones on selective media containing gentamicin and 5% sucrose gave 
rise to colonies that were tetracycline sensitive, suggesting the loss of the functional pilO 
gene.  This was confirmed by Southern blot analysis using strain 1244 pilA DNA as a probe.  
This mutant was referred to as strain 1244G7 
 
4.3.3. Construction of pMBT100.  The Xba I/Nhe I fragment of pPAC124, 
which contained the P. aeruginosa 1244 pilA gene, was removed and the vector religated.  
The Bam HI/Hind III fragment of this plasmid was ligated with pT7-7 (228) cut with the 
same enzymes.  This construct was digested with Eco RI and Bam HI, the overhangs filled in 
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using DNA polymerase, and the blunt ends religated.  The Xba I/Hind III fragment from this 
plasmid containing the pilO gene was ligated with pUC18 digested with the same enzymes.   
The Eco RI/Hind III fragment from this construct was ligated with pMMB66EH (77) 
digested with the same enzymes.  This construct was referred to as pMBT100 and contained 
the strain 1244 pilO gene under control of a tac promoter. 
 
4.3.4. Isolation and purification of pili.  Glycosylated strain 1244 pili were 
harvested as previously described (32).  Nonglycosylated strain 1244 pili were produced 
from strain 1244G7 using a procedure described by Silipigni-Fusco (207).  Here, CAYE 
solid medium, which was composed of 0.75% Casamino Acids, 0.15% Yeast Extract, and 
2% agar, was used for cell growth.  Cultures were grown in foil covered 68 × 28 × 3 cm 
metal pans containing 500 ml of CAYE medium for 14 hr at 37ºC.  Cells from each pan were 
resuspended with 50 ml of 4.0 mM sodium potassium phosphate, pH 7.0, and stirred 
vigorously for 30 min at room temperature.  Cells were removed by centrifugation at 
16,000xg for 30 min at 4ºC, leaving the pili suspended in the supernatant fluid.  Both 
glycosylated and nonglycosylated pili were purified by repeated precipitation in the presence 
of 3% polyethylene glycol and 0.5M NaCl (207).    
In order to remove polyethylene glycol, which interfered with mass analysis using 
MALDI-TOF, 2-5 mg of pili were first dialyzed against 6 L of deionized water containing 
0.025% sodium azide and then bound to a Mono-Q column equilibrated with 0.02 M 
Tris/HCl, pH 7.3.  Pili were eluted with 1% solution of SDS and dialyzed as described above.  
This material was lyophilized, and resuspended with 0.5 ml of 67% ethanol.  After overnight 
incubation at 4ºC, the material was centrifuged and the pellet was lyophilized. 
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Table 4.1.  Strains, plasmids, and bacteriophages used in this study. 
 
4.3.5. Transmission immuno-electron microscopy.  Cells grown for 14 hrs 
at 37ºC on CAYE agar were gently suspended in phosphate buffered saline (PBS) and 
applied to a formvar-coated copper grid.  This material was fixed at room temperature for 5 
min with 2% paraformaldehyde and 0.01% glutaraldehyde in PBS.  The grid was then 
Strain/plasmid/virus Description Source or reference 
Bacteria:   
  P. aeruginosa    
    1244 Wildtype strain, Group I pili (183) 
    1244G7 PilO-negative mutant This study 
    1244wbpL O-antigen negative mutant (60) 
    1244N3 rpoN (182) 
    9D2 Wildtype strain, Group I pili (34) 
    577B Wildtype strain, Group I pili (34) 
    653A Wildtype strain, Group I pili C.C. Brinton, University of Pittsburgh 
    134VA Wildtype strain, Group I pili C.C. Brinton, University of Pittsburgh 
    PA103 Wildtype strain, Group II pili (34) 
    PAK Wildtype strain, Group II pili (34) 
    T2A Wildtype strain, Group II pili (34) 
    Isolate collection Clinical isolates S.D. Kominos, Mercy Hospital, 
Pittsburgh 
   
Plasmids:   
  pC110 Apr, Gmr, pUC7 derivative (233) 
  pEX18Tc Tcr, , oriT, SacB, allelic replacement vector (200) 
  pGIL100 Apr, pNOT322 containing pilAO operon. This study 
  pGIL101 Apr, pGIL100, Eco RI/Xba I fragment removed This study 
  pGIL200 Apr, Gmr, 1.3 kb replacement of pilO DNA This study 
  pGIL300 Tcr, sacB, Pst I/Hin dIII frag from pPAC124GM This study 
  pMBT100 Apr, 1.2 kb insert containing 1244 pilO under tac promoter in 
pMMB66EH  
This study 
  pMMB66EH Apr, broad host range vector (77) 
  pNOT332 Apr, Tcr, cloning vector (201) 
  pPAC24 Apr, 0.8 kb insert containing strain 1244 pilA under tac promoter 
in pMMB66EH 
(32) 
  pPAC46 Apr, 2.3 kb insert containing strain 1244 pilAO under tac 
promoter in pMMB66EH  
(32) 
  pPAC124 Apr, 2.3 kb insert containing strain 1244 pilAO under tac 
promoter in pUC18 
(32) 
  pPAC202 Tcr, subclone containing strain 1244 pilAO operon (35) 
  pUC46GM Apr, Gmr, pPAC124 with 1.3 kb replacement of pilO DNA This study 
  pUCP19exoUspcU Apr, pUC19-based plasmid carrying the exoU and  spcU (5) 
  pT7-7 Apr, Cloning vector containing T7 RNAP promoter. (228) 
   
Viruses:   
  PE69, PO4, M6,  P. aeruginosa pilus-specific RNA  bacteriophages (24) 
  F116 P. aeruginosa pilus-specific RNA  bacteriophages (132) 
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subjected at room temperature to three 5 min PBS washes, three 5 min treatments with a 
0.5% bovine serum albumin (BSA) in PBS solution, and a 30 min incubation in 5% normal 
goat serum in the BSA solution, followed by three more 5 min washes in the BSA solution.  
The primary antibody employed, monoclonal 11.14, recognizes both the O-antigen and the 
pilus glycan of P. aeruginosa 1244 (33).  The treated grid was incubated for 60 min at room 
temperature with this antibody diluted 10-3 in PBS, followed by three 5 min washes with the 
BSA solution.  The sample was then incubated with secondary antibody, goat anti-mouse 
IgG labeled with 5nm gold particles (Amersham Biosciences, Piscataway), for 60 min at 
room temperature.  The grid was washed with the BSA solution three times for 5 min each 
and PBS three times for 5 min each, after which the entire grid was fixed in 2.5% 
glutaraldehyde  for 5 min.  After three min 5 min PBS and a 1 min distilled water wash, 2% 
phosphotungstic acid, pH 6, was briefly applied to the grid and excess solution wicked away 
with filter paper, after which it was allowed to dry.  Images were taken using a JEM 1210 
Computer Controlled High Contrast 120kV transmission electron microscope.   
 
4.3.6. Hydrophobicity assays.  To measure pilus hydrophobicity, 
approximately 2 mg of purified pili from strains 1244, 1244G7, and PA103 were 
resuspended in 0.5 ml of 10 mM Tris/HCl, pH 8.0 in a microcentrifuge tube.  Enzyme grade 
ammonium sulfate was added to the desired percent saturation after which the sample was 
incubated at room temperature with shaking for 30 min after the salt had gone into solution.  
The tubes were centrifuged at 14,000xg for 10 min and supernatant fluid was transferred to a 
fresh tube.  This procedure was repeated to produce the desired fractionation range.  
Precipitates were resuspended in deionized water and tested for protein concentration using 
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the BCA assay (Pierce).  To test cell hydrophobicity, strains were grown on CAYE agar 
plates for 14 hr at 37°C.  Growth formed on individual plates was gently resuspended with 5 
ml of CAYE broth.  Growth was estimated by determining optical density at 650 nm and 
cultures were normalized to give 2 ×1010 cells per ml.  15 μl of suspended cells were mixed 
on a microscope slide with and equal volume of 0.5, 1.0, or 2.0 M ammonium sulfate and 
incubated for 25 min at room temperature.  The samples were examined at timed intervals for 
agglutination using a dissection microscope. 
  
4.3.7. SDS-PAGE, isoelectric focusing, and immunoblot analysis.  Pilin 
samples were analyzed electrophoretically using 15.0% T, Tris-glycine SDS-PAGE gels.  
Pili samples to be subject to isoelectric focusing were treated with 2% β-octylglucoside for 
15 min at room temperature.  This material was separated in a pH gradient from 3.5 to 9.0 
using a Pharmacia PhastSystem apparatus in which the gels had been equilibrated with 1.0% 
β-octylglucoside.  Pilin separated by SDS-PAGE was transferred to nitrocellulose membrane 
by electroblotting, whereas diffusion blotting was used for transfer of pilin separated by 
isoelectric focusing.  For immunoblot analysis, blocking was carried out as previously 
described (35) and either monoclonal antibody 11.14 (33), 6.45 (206), 5.44 (206), or 2.97 
(191)  was used as probe.  Screening clinical isolates by Western blot employed an anti-1244 
pilin polyclonal preparation (41).  Reaction for these assays was determined using an alkaline 
phosphatase-labeled secondary antibody as has been described previously (35).  For pilin 
quantitation using Western blots, a FITC-labeled secondary antibody was employed.   
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4.3.8. Analytical methods.  Dr. Mark Bier of the Mellon Institute Center for 
Molecular Analysis, Carnegie Mellon University, carried out pilin mass determinations by 
MALDI-TOF using a PerSeptive Biosystems Voyager STR with DE and a high m/z detector.  
Detection and quantitation of Western blots using FITC-labeled secondary antibody was 
carried out using a Molecular Dynamics Model 595 Fluorimager equipped with ImageQuant 
software.   
 
4.3.9. Pilus functionality assays.  Twitching motility was determined using 
the protocol described previously (33).  The protocol of O’Toole and Kolter (169) was 
employed to determine biofilm formation.  Bacteriophage sensitivity was tested using the 
cross-streak method described previously (35). 
 
4.3.10. Clinical isolate screening.  P. aeruginosa strains tested for pilus type 
were obtained from Dr. Spyros Kominos, Mercy Hospital, Pittsburgh, PA.  These isolates 
were grown overnight at 37°C on LB agar plates.  Whole cell extracts were separated by 
PAGE and analyzed by Western blot using polyclonal antibodies raised by immunization of 
mice with pure strain 1244 pili. 
 
4.3.11. Strain competition assay.  The acute pneumonia model was carried 
out using 6-8 week old female Balb/c mice (Hilltop Lab Animals, Scottdale, PA).   Animal 
experiments complied with institutional and federal guidelines regarding the use of animals 
in research.  Prior to challenge, mice were anesthetized with intraperitoneal injections of 0.25 
ml of freshly prepared and filter sterilized ketamine (6.7 mg/ml) and xylazine (1.3 mg/ml) in 
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0.9% saline.  Challenge cells were grown for approximately 14 hr at 37°C on TSA agar 
plates.  These cells were gently resuspended with sterile saline and diluted to the 
approximate desired inoculum level (also with sterile saline) by absorbance at 650 nm.  10 μl 
of the cell suspension diluted with sterile saline was applied to each nostril (20 μl per 
mouse), after which the animals were monitored (for a period of four days) for morbidity and 
mortality.  Actual CFUs of the inocula were determined by plating on TSA plates.  Using this 
procedure, the 50% lethal dose of strain 1244 had previously been determined to be 6.3 × 106 
CFU (results not shown).  It was deemed desirable to reduce this value in order to minimize 
any nonspecific inflammation effect caused by the challenge dose.  Previous work has shown 
that the presence of exoU can be correlated with increased pathogenicity in the respiratory 
model (5).  By employing PCR, using primers specific for the ExoU-positive strain P. 
aeruginosa PA103, it was determined that strain 1244 lacks exoU  (results not shown).  The 
constitutive expression of exoU from pUC19exoUspcU in strain 1244 resulted in ExoU 
expression as determined by PCR, using the above mentioned primers, and reduced the LD50 
of strain 1244 to 1.8 × 105.  The acute pneumonia model was employed for the competition 
assay, using the procedure for anesthetization and challenge described above.  Here a 
suspension containing known amounts of P. aeruginosa strains 1244 and 1244G7 (totaling 
one strain 1244 LD50) was administered to each of six mice.  These animals were sacrificed 
after twelve hr and lung, liver, and speen removed, weighed and homogenized in 1 ml sterile 
saline.  In order to determine the total cell count and to differentiate between strains 1244 
and 1244G7, the homogenate was diluted in sterile saline and plated on TSA-Cb250, and 
TSA-CB250Gm100.   
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4.4. Results. 
 
4.4.1. Mutant isolation and characterization.  A P. aeruginosa 1244 mutant 
deficient in the ability to glycosylate pilin was produced in order to study the influence of the 
pilin glycan on pilus structure and function.  This strain, 1244G7, had a 1,268 bp segment of 
pilO, a gene which had previously been shown to be required for pilin glycosylation (32), 
replaced with a gentamicin-resistance cartridge. A Western blot using a 1244 pilin-specific 
monoclonal antibody as probe showed that pilin produced by strain 1244G7 had a lower 
apparent molecular weight as compared to that produced by the wild type strain (Fig. 4.1A).  
MALDI-TOF analysis (Table 4.2) of purified mutant pilin indicated that this protein had a 
mass of 15,650 (± 30), which agrees with the value predicted by gene structure (32).  Wild 
type 1244 pilin, as described previously (33), has a mass of 16,307 (± 25).  The difference in 
between the mutant and wild type pilins is approximately the value determined for the strain 
1244 glycan structure (33).   
For confirmation of these results, pili produced by strain 1244G7 were depolymerized 
by detergent treatment and the subunits produced subjected to isoelectric focusing, blotted to 
nitrocellulose paper, and probed with pilin or glycan-specific monoclonal antibodies.  The 
results (Fig. 4.1B) showed that while, as described previously (32) pilin produced by the 
parent strain focused at pH 4.75, pilin produced by 1244G7 focused at approximately 6.25, a 
value consistent with a nonglycosylated subunit.  Further, while glycosylated 1244 pilin was 
recognized by a glycan-specific monoclonal antibody, pilin from the mutant did not react.  
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To see if the introduction of a functional pilO gene complemented this defect, pMBT100, a 
plasmid that contained a functional copy of the pilO gene under control of an inducible 
promoter, was introduced into strain 1244G7.  While a vector control produced 
nonglycosylated pilin, the inclusion of pilO restored the ability to produce glycosylated pilin 
(Fig. 4.1A).  Overall, these results show that 1244G7 is able to produce only nonglycosylated 
pilin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.  Immunoblots of pilin from P. aeruginosa 1244 and 1244G7.  (A) Western 
blot of cell extracts prepared from overnight plate cultures using the pilin protein specific 
monoclonal 6.45.  P. aeruginosa 1244G7/pMMB66EH and P. aeruginosa 
1244G7/pMBT100 were grown in the presence of Cb and IPTG.  Arrows indicate the 
position of molecular weight standards.  (B)  Electrofocusing immunoblot of purified pilin. 
Arrows indicate the focusing gel pH gradient.  This experiment was carried out by James 
G. Smedley, III. 
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Table 4.2.  Mass determination of P. aeruginosa pilins. 
Pilin Source Predicted mass (Da)a) Measured mass (Da) 
   1244 15,648 16,307 (± 25)b) 
   1244G7 15,648 15,650 (± 30) 
   PA103 15,169   15,192 (± 30) 
   PAK 15,018 15,020 (± 30) 
   T2A 14,727 14,760 (± 30) 
a) Value predicted by gene structure, and corrected for N-methylation and loss of cysteine 
protons. 
b) As determined previously (33). 
 
In order to determine whether the absence of the glycan resulted in a reduction of 
piliation, strains 1244 and 1244G7 plate-grown cells were subjected to a shearing treatment 
that was followed by isolation of the pili produced.  Sheared pili were analyzed by Western 
blot using a pilin protein-specific primary antibody and a secondary antibody labeled with a 
fluorescent dye.  Quantitation of fluorescence showed that the mutant produced 
approximately 95% the amount of extracellular pilin made by the wild type strain.  These 
results indicate that the presence of the pilin glycan had little influence on the degree of 
piliation.  A standard twitching assay indicated that 1244G7 cells produced twitch zones that 
had an approximately 33% smaller diameter as compared wild-type cells (results not shown).   
A quantitative assay showed that both strains produced approximately the same amount of 
biofilm.  Finally, using a cross-streak assay, it was determined that strain 1244 was sensitive 
to pilus phages PE69 and PO4, but not F116 or M6.  A mutant strain, 1244.47, which was 
unable to produce pilin, was shown to be resistant to PE69 and PO4, confirming that these 
viruses were pilus-specific (results not shown).  Strain 1244G7 was found to also be sensitive 
to these phages indicating that the absence of pilin glycan did not interfere with phage 
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attachment to the pilus.  These results suggest that pilin glycosylation does not strongly 
influence basic pilus function.  In addition, growth curves of strains 1244 and 1244G7 are 
identical (results not shown) indicating that neither the loss of the pilO gene nor the presence 
of the Gm cartridge makes the mutant less physiologically fit. 
 
4.4.2. Pilus glycan location and distribution.  In order to assess the potential 
influence of the pilin glycan on the interaction between the pilus and its immediate 
environment, it was first necessary to show that the glycan occupies a position for such 
contact.  Previous results indicated that the pilin glycan is covalently attached to the carboxy-
terminal residue of this protein (41).  This places it immediately adjacent to the type IV pilin-
specific DSL region.  Previous studies have determined that the pilin DSL of P. aeruginosa 
PAK is only surface-located at the pilus tip, and that it is in at least a partially buried form on 
the fiber shaft (205).  With this in mind it was necessary to determine if the glycan was 
present at the fiber surface, and, if so, whether it was distributed evenly over the surface or 
limited to a particular portion of the pilus.   
To do this, cell-associated pili and purified pili of strain 1244 were examined using 
transmission electron microscopy.  Samples, fixed on a coated copper grid, were treated with 
a monoclonal antibody that, while specific for 1244 O-antigen, also recognized the pilin 
glycan (33).  A gold-labeled secondary antibody allowed visualization of the site of 
monoclonal recognition.  Fig. 4.2A shows label associated with the pilus indicating that the 
glycan is present at the fiber surface.  Further, the absence of reaction with the flagellum 
indicates that the pilus-associated reaction was not due to LPS contamination.  The presence 
of label on the cell surface suggested that the probe recognized lipopolysaccharide-bound O-
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antigen or glycosylated pilin subunits associated with the outer membrane.  Examination of 
1244G7 cells using this same protocol revealed that this organism produced pili that were 
indistinguishable in length, number and structure from those seen on strain 1244.  When the 
immunogold procedure described above was applied to 1244G7 (Fig. 4.2B), no reaction was 
seen associated with the pili, however label was again seen associated with the O-antigen of 
the cell surface.   
To confirm these results, and to show that the strain 1244 response was not due to 
LPS coating of the fibers, strain 1244 pili were purified to levels in which only minor LPS 
contamination occurred (41).  When these pili were examined by transmission electron 
microscopy using the immunogold protocol, it could be seen that a strong reaction still 
occurred, and that the response was distributed evenly over the entire pilus surface (Fig 
4.2C).  Reaction is seen only associated with the pilus.  By contrast, pili purified from strain 
1244G7 produced no significant immunogold reaction (Fig 4.2D), although a scattered 
response is seen associated with minor pilus-associated debris.  Outer membrane fragments 
contaminating these pilus preparations is the likely cause this response.  Altogether, these 
results indicate that the pilin glycan is 1) present at the fiber surface and 2) is not localized to 
any particular region of the pilus. 
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4.4.3. Influence of pilin glycosylation on the pilus surface.  The presence of 
the hydrophilic and negatively charged glycan on the surface of the pilus would be expected 
to have a significant influence on physical properties of this fiber.  To test this, the relative 
hydrophobicity of pili from strain 1244 and the mutant 1244G7 was determined.  For further 
Figure 4.2. Transmission electron micrographs of cell associated and purified pili of P. 
aeruginosa 1244 and P. aeruginosa 1244G7.  (A) Strain 1244 cells probed with monoclonal 
11.14 and gold-labeled secondary antibody.  The arrow indicates pili while the arrowhead 
marks the flagellum.  (B) Strain 1244G7 cells probed with monoclonal 11.14 and gold-labeled 
secondary antibody.  The arrow indicates pili while the arrowhead marks the cell.  (C) Strain 
1244 pili probed with monoclonal 11.14 and gold-labeled secondary antibody.  (D) Strain 
1244G7 pili probed with monoclonal 11.14 and gold-labeled secondary antibody.  The bar 
indicates 100nm.  Original experimentation carried out by Erica Jewell and Donna Beer Stolz. 
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comparison, pili from a strain that did not produce glycosylated pili were also examined.  
The apparent molecular weight of pilin from P. aeruginosa PA103, as determined by 
Western blot using a pilin-specific serum as probe, approximated that of nonglycosylated 
1244 pilin (Fig. 4.3), suggesting that it was not glycosylated.  This was supported by 
MALDI-TOF analysis of pili purified from this organism (Table 4.2), which indicated the 
pilin mass to be 15,192 (± 30), which agrees with the value predicted by the pilin structural 
gene structure (115), minus the leader sequence.  In addition, purified pilin from this 
organism did not react with a serum specific for strain PA103 O-antigen (60), further 
suggesting that this protein is not glycosylated.  
 
 
 
 
 
 
 
 
 
  
To test the relative hydrophobicity of the pili of strains 1244, 1244G7, and PA103, 
these fibers were purified and subjected to ammonium sulfate precipitation.  Figure 4.4 
shows that while the pili of strain 1244 did not come out of solution until an ammonium 
Figure 4.3.  Western blot of P. aeruginosa pilins.  Cell extracts were 
prepared from overnight plate cultures.  Blot was separated and the 
PA103 lane probed with pilin protein specific monoclonal 2.97, while 
the remaining blot was probed with pilin protein specific MAb 5.44. 
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sulfate saturation of 45% was reached, only 15% saturation was required for precipitation of 
the pili from strain 1244G7.  These results indicate that the presence of the glycan on the 
strain 1244 pilus surface resulted in a dramatic reduction of hydrophobicity.  Interestingly, 
the pili of strain PA103, which normally are not glycosylated, was also found to be strongly 
hydrophobic.  Purified pili from P. aeruginosa PAK and T2A, strains which, like PA103, 
produce nonmodified pili (Table 4.2), also came out of solution at 15% saturated ammonium 
sulfate (results not shown), indicating that they also presented hydrophobic surfaces. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.3 shows the ability of ammonium sulfate to agglutinate P. aeruginosa cells, 
an assay that determines relative surface hydrophobicity.  Here it can be seen that piliated 
Figure 4.4.  Ammonium sulfate fractionation of purified P. 
aeruginosa pili.  The solid bar indicates strain 1244G7 pili.  The 
transparent bar is for pili from strain PA103.  The cross-hatched 
bars are for strain 1244 pili.  This experiment was carried out by 
Peter Castric.  
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1244 cells produced no agglutination in the presence of 15 or 25% saturated ammonium 
sulfate during the twenty five min test period.   By contrast, strain 1244G7 cells produced an 
agglutination response by eighteen min in the presence of 15% ammonium sulfate and by six 
min in the presence of this salt at 25% saturation.  Both strains were agglutinated in less than 
one min in 45% saturated ammonium sulfate.  These results suggest that the glycosylation 
state of the pilus has an influence on the overall hydrophobicity of these cells.  For 
comparison, 1244wbpL, a mutant that is unable to construct O-antigen (60), produces an 
agglutination response in 0.5M ammonium sulfate within one min, which demonstrates the 
importance of this saccharide layer in modulating cell hydrophobicity.  To see if the 
agglutination response of strain 1244G7 was due to a defect in lipopolysaccharide 
biosynthesis, this glycolipid was extracted from both 1244 and 1244G7 and analyzed by 
Western blot using an O-antigen specific antibody.  The material extracted from strain 
1244G7 appeared identical to that of wild type in amount and size distribution (results not 
shown) suggesting that the difference in hydrophobicity seen was not due to a variation in O-
antigen composition between these strains.  Altogether, these results show that the presence 
of the pilus glycan has a strong influence on the pilus, which, in turn, influences the physical 
properties of the whole cell. 
Table 4.3.  Ammonium sulfate induced agglutination of P. aeruginosa cells.  This experiment 
was carried out by Peter Castric. 
  
 
 Agglutination (min)  
Ammonium Sulfate 
(% saturation) Strain 1244 Strain 1244G7 Strain 1244wbpL 
15 NDa) 18 1 
25 ND 6 1 
45 1 1 1 
a) ND, not detectable 
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4.4.4. Influence of pilin glycosylation on pathogenicity.  The results 
described in the previous section indicated that the presence of the glycan had a significant 
effect on the pilus surface, however not all P. aeruginosa pilins are glycosylated.  These 
results suggest that there may be relative advantages to either arrangement, and that a strain 
producing a particular pilus type might be more successful in occupying a specific 
environmental niche, including ones involved in pathogenicity.  With this in mind 
experiments were carried out to see if pilin glycosylation had an effect on P. aeruginosa 
1244 virulence. 
The pilins of P. aeruginosa can be placed into at least two major groups based on 
primary structure and antigenicity (34).  The Western blot presented in Fig. 4.3 indicates that 
four pilins, previously shown by sequence to belong to Group I (34), all react with antibodies 
prepared against pure strain 1244 pilin.  This suggests that this serum can be used to screen 
isolates for the presence of Group I pilins.  In addition, the apparent molecular weights of 
these pilins are significantly higher than that seen for nonglycosylated 1244 pilin even 
though the predicted molecular weights are similar, indicating that these proteins are all 
postranslationally modified. Further, testing these pilins by immunoblot with O-specific 
antisera indicates that they all carry the O-antigen (results not shown).  The slight variation in 
apparent molecular weight is likely due to differences in glycan size. 
Western blot screening of whole cell extracts of fifty clinical isolates using an anti-
1244 pilin polyclonal serum showed that twenty-three belonged to Group I (Table 4.4).  
These results were consistent with an earlier study which showed that pilin from 58 of 95 P. 
aeruginosa clinical isolates tested reacted with this antiserum as determined by Western blot 
(Blanch and Castric, unpublished observations).  The data presented in Table 4.4 is 
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particularly interesting because they suggest that the group I pilins were found predominantly 
in strains isolated from sputum samples, suggesting the possibility that pilin glycosylation 
allows for enhanced pathogenicity in the respiratory tract environment.   
 
Table 4.4.  Frequency of Group I pilins among clinical P. aeruginosa isolates.  This experiment 
was conducted by Andrew Syboldt. 
 
Source 
 
 
Frequency of positives 
 
Sputum 12/18 
Urine 2/6 
Ear 2/6 
Wound 2/7 
Unknown 5/13 
Total 23/50 
 
 
In order to accurately test the relative virulence of strains 1244 and 1244G7, a 
competition assay based on the mouse acute pneumonia model was employed.  Here, six 
mice were challenged each with a mixture of strain 1244 and 1244G7 in a ratio, as 
determined by growth on selective media, of 1.39:1.  The challenge dose was approximately 
equivalent to the LD50 of strain 1244.  These animals were sacrificed at 12 hr after challenge 
and the numbers of wild type and mutant bacteria present in lung tissue were determined on 
the basis of growth on selective media.  A competition index (42) was determined by first 
calculating the ratio of 1244 to 1244G7 in the lung samples (Table 4.5).  After correcting for 
the ratio of these strains in the inoculum (column four of Table 4.5), it can be seen that strain 
1244 clearly survives in the lung environment far better than does strain 1244G7.  Chi –
squared analysis indicated that significantly more of strain 1244 than strain 1244G7 was 
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present in the mouse lung at 12 hr following challenge (χ2 = 42.61; d.f. = 5, P < 0.0001).  
These results showed that, on average, strain 1244 was more successful in this environment 
by a factor of 3.12.   
 
Table 4.5.  Relative colonization by P. aeruginosa strains 1244 and 1244G7 using the mouse 
respiratory model. 
 
Cell Counts (CFU/gram) Animal 1244 1244G7 Ratio Adjusted Ratio
a) 
1 4.41 x 106 1.10 x 106 4.01 2.88 
2 3.20 x 107 9.90 x 106 3.23 2.32 
3 1.24 x 107 2.06 x 106 6.02 4.33 
4 4.24 x 107 1.23 x 107 3.45 2.48 
5 5.72 x 106 1.01 x 106 5.66 4.07 
6 5.83 x 106 1.60 x 106 3.64 2.62 
a) Value adjusted for ratio of strain 1244 to 1244G7 in the challenge dose. 
 
Since a nonspecific response to the high challenge dose used in these experiments 
could call into question the significance of these results, this procedure was repeated using 
strains 1244 and 1244G7 expressing exoU, a situation that substantially lowered the LD50 of 
both challenge strains.  The challenge dose employed was equivalent to one LD50 for strain 
1244 expressing the cytotoxin gene, and an initial ratio of 2.49:1 was used.  The treatment of 
six animals produced an average competition index of 3.44 indicating that these results were 
consistent with the above data.  Chi-squared analysis (χ 2=87.9, d.f.=5, P<0.0001) indicated 
that the results were significant. 
Analysis of spleen and liver tissue produced low and non-significant values for either 
strain, indicating that dissemination had not occurred at this dosage and time point.  Testing 
an animal at 0 time showed a proportion of mutant to wild type that was identical with that 
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seen in the challenge dose.  Altogether these results indicate that the presence of the pilus 
glycan promotes lung colonization by P. aeruginosa strain 1244. 
 
4.5. Discussion. Evidence presented in this chapter indicates that the pilin glycan is 
present at the pilus surface.  Further, it is not localized, but is distributed uniformly over the 
fiber exterior.  Previous work has shown that the pilin subunit and the glycan exist in a 1:1 
ratio (33).  This, along with the relatively small molecular size of the glycan in comparison to 
the surface of the pilin subunit, suggests that this saccharide does not form a continuous layer 
over the pilus surface.  The covalent attachment of the glycan to the carboxy-terminal pilin 
residue (41) places it at the edge of the subunit facet (47).  This means that this structure is to 
be found at the seam between adjacent pilins.  Altogether, these results suggest that, given 
the predicted subunit arrangement within the type IV pilus (48), evenly spaced glycosylation 
sites occur as helically arranged ascending rows of glycan on the fiber surface.   
The pilus glycan organization proposed would provide ample space for interaction 
between the pilus protein surface and its environment.  This is likely the reason why pilus-
specific bacteriophages PO4 and PE69 are able to recognize glycosylated as well as 
nonglycosylated strain 1244 pili.  Accordingly, these viruses are also able to infect P. 
aeruginosa strain 9-D2, which produces nearly identical pilin (34), but which has a 
distinctively different pilin glycan (unpublished observations).  These results, as well as the 
ability of the glycan-negative mutant to carry out twitching motility, suggest that the 
presence of this saccharide has a minimal effect on the ability of the pilus to extend and 
retract.  Further, the finding that the absence of the pilin glycan in strain 1244G7 does not 
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alter the extent of piliation suggests that the glycan does not interact with components of the 
pilus polymerization/depolymerization cycle.  
While the pilus glycan isn’t present as a continuous layer, it is capable, owing to its 
negative charge (33) and strong hydrophilicity, of having a significant influence on the 
interaction between the surface of the pilus fiber and its environment.  Thus, as shown in the 
present work, removal of the glycan from the P. aeruginosa 1244 pilus greatly increases the 
hydrophobicity of these fibers.  The evidence that pilins from strains PA103, PAK, and T2A 
are normally nonglycosylated and have a highly hydrophobic surface suggests that this pilus 
surface arrangement is not uncommon.  The presence of pili with such different surface 
properties could facilitate the abiity of particular P. aeruginosa strains to successfully occupy 
specific microenvironments.  This could mean that this characteristic has a potentially 
important role in pathogenicity.  For example, cells normally producing nonglycosylated, 
hydrophobic pili might more easily colonize hydrophobic environmental surfaces, such as 
catheters or prosthetic devices, due to increased nonspecific adherence.  Here these 
organisms could form biofilms and subsequently disseminate to other host sites. 
Strains producing glycosylated pili could interact in a different manner.  The present 
study has provided evidence that P. aeruginosa Group I pili are glycosylated, and that strains 
producing them are frequently found among clinical isolates. The latter point agrees with 
previous studies using strain 1244 pilin-specific monoclonal antibodies (34).  More 
importantly, Group I pili producing strains were found to be common among isolates from 
respiratory sources.  This is consistent with Kus, et al., (136) who found a high frequency of 
Group I strains among cystic fibrosis isolates.  In order to see if there is a relationship 
between pilin glycosylation and respiratory pathogenicity, strain 1244 and the mutant 
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producing nonglycosylated pili were subjected to a competition assay using the mouse acute 
pneumonia model.  This test is based on colonization of the lung and is a sensitive indicator 
of pathogenicity.  Here the ratio of bacteria producing glycosylated pili to those making 
nonglycosylated pili increased by a factor of between three and four during the initial twelve 
hr period of challenge.  These results strongly suggest that the presence of the pilin glycan 
makes P. aeruginosa 1244 a more effective respiratory pathogen as compared to its glycan-
deficient isogenic mutant.  To confirm these results, competetion experiments should be 
carried out in which the inoculum contains a higher proportion of 1244G7 than the wildtype 
strain 1244.  The mechanism by which pilin glycosylation might influence P. aeruginosa 
1244 virulence in the respiratory tract is not clear, however it is possible that this effect is 
due to an enhanced resistance to the nonspecific host defenses in the presence of the pilin 
glycan.  For example, it has been shown that pili are sites of nonopsonic phagocytosis and 
that an increase in cell hydrophobicity was associated with killing by nonopsonic 
phagocytosis (212).  If pilus hydrophobicity enhances this response, it is possible that the 
presence of the glycan on the fiber surface alters an important recognition feature thereby 
preventing initial phagocyte contact.  In a similar manner, the masking of portions of the 
pilus surface by the glycan might prevent nonopsonic complement fixation.   
It is possible that the reduced lung colonization seen with strain 1244G7 was due to 
the modest decrease in twitching motility seen with this mutant.  This seems unlikely as 
previous work (12) has shown that while twitch-defective P. aeruginosa strains demonstrated 
impaired dissemination in the mouse respiratory model, there was no reduction in lung 
colonization.   
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The suggestion that pilin glycosylation in P. aeruginosa enhances virulence is 
consistent with findings that glycosylation of surface proteins of other pathogen surface 
proteins facilitate pathogenicity.  A mannose polymer isolated from a Chlamydia trachomatis 
reduced adherence by this organism suggesting that the glycoprotein is involved in adhesion 
(135).  Campylobacter jejuni mutants unable to modify proteins by means of its general 
gIycosylation system showed reduced adherence to human and chicken cells (121).  The 
presence of flagellin glycosylation in P. aeruginosa greatly increases pathogenicity as 
measured by the burned mouse model (9). 
In addition to potentially interacting with nonspecific host defense, the glycan might 
influence receptor recognition, a process that is carried out by pilin subunits located at the 
fiber tip (142).  The 1244 pilin glycan is in close proximity to the pilin DSL ligand site (41).  
The saccharide may stabilize the attachment of the pilus to the host cell surface through weak 
bond interaction with host membrane surface components.  Alternately, the glycan might 
function to protect the host receptor-binding site.  This could be mediated by the flexibility of 
the oligosaccharide and by an interaction between this glycan and components of the pilin 
DSL.  Such a situation could serve to protect the host glycolipid-binding site from 
proteolysis or antibody neutralization of this sensitive epitope.  Studies on the structure of 
pilus tip subunits and on the conformation of the pilin glycan of these structures are required 
to clarify this point. 
The location and distribution of the pilin glycan on the fiber surface makes this 
structure a tempting target for vaccine studies.  Not only do antibodies against the glycan 
recognize the O-antigen (41), but an anti-glycan antibody is capable of inhibiting twitching 
motility (33), a process which has been shown to be important in pathogenicity (42, 253).  
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This latter response is probably due to cross-linking of the pilus fibers.  It is also possible that 
a glycan-specific antibody acting at the pilus tip might interfere with pathogen adhesion to 
the host cell.  Further studies should be directed towards determining if the pilin glycan 
represents a protective epitope and if it can be used in vaccine construction with the intended 
use for the protection or treatment of P. aeruginosa infections. 
In summary, data has been presented indicating that the pilus glycan is not buried, but 
is present at the pilus surface.  In addition, this saccharide is not localized but is uniformly 
distributed.  Evidence presented here suggests that the pilus glycan strongly alters the pilus 
surface environment.  While the presence of this pilin modification does not greatly influence 
basic pilus function, it would be expected to alter the way the pilus, and thus the whole cell, 
interacts with its environment, a situation that could have significance in pathogenicity.  To 
this end, data shown here indicates that P. aeruginosa strains producing glycosylated pili are 
commonly found among clinical isolates, especially those from the respiratory tract.  
Evidence was presented that the presence of the glycan enhances virulence in a mouse acute 
pneumonia model, suggesting that this modification predisposes strains that produce 
glycosylated pili to be more effective respiratory pathogens.  Further experiments are 
required to more completely test this hypothesis. 
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Chapter 5. Immunization with Pseudomonas aeruginosa 1244 pilin provides O-antigen 
specific protection. 
 
 5.1. Abstract.  The O-antigen is both a major structural outer-membrane component 
and the dominant epitope of most gram-negative bacteria.  Pseudomonas aeruginosa 1244 
covalently attaches an O-antigen repeating unit to each pilin monomer.  This chapter shows 
that immunization of mice with pure pilin from strain 1244, using either the mouse 
respiratory or the thermal injury model, resulted in protection from challenge with a pilus-
deficient O-antigen-producing 1244 mutant.  These results provide evidence that the pilin 
glycan stimulates a protective response that targets the O-antigen, suggesting that this system 
could be utilized as a means to develop numerous protective anti-gram-negative bioconjugate 
vaccines.   
 
5.2 Introduction. With the widespread occurrence of antibiotic resistance among 
many bacterial pathogens (250), it is increasingly necessary to turn to vaccination to combat 
these disease-causing organisms.  An important strategy in vaccine design is the use of 
glycoconjugates produced by chemically cross-linking bacterial surface polysaccharides to 
carrier proteins (116).  Saccharides linked to proteins invoke T-cell-dependent immunity 
(11), which involves a memory response, avidity maturation, and immunoglobulin class 
switching (248).  Conversely, bacterial polysaccharides alone are usually associated with a 
T-cell-independent response, which does not involve induction of immunological memory 
(161).  However promising, expansion of glycoconjugate vaccine technology has been 
hampered by the expense of purifying and characterizing surface polysaccharides of bacterial 
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pathogens, selection of an effective carrier protein, and maintaining the quality and stability 
of cross-linked products (116).  
Several anti-bacterial glycoconjugate vaccines are currently commercially available 
(116).  Haemophilus influenzae type b glycoconjugate vaccines (197), in which the surface 
oligosaccharide of this bacterium was conjugated to either diphtheria toxoid (7), tetanus 
toxoid (112), or a meningococcal outer membrane protein (64), were the first to be licensed 
(116). In addition to H. influenzae type b, anti-bacterial glycoconjugate vaccines are also 
commercially available against Streptococcus pneumoniae and Neisseria meningitidis group 
C (116).  Currently, numerous investigations are underway to test and develop 
polysaccharide-protein conjugate vaccines against bacterial pathogens, including Francisella 
tularensis (44), Escherichia coli O157 (130), Shigella sonnei (186), and the opportunistic 
pathogen, Pseudomonas aeruginosa (51).  
 The O-antigen is the dominant surface polysaccharide of the lipopolysaccharide 
(LPS) molecule of most gram-negative bacteria, and consequently, antibodies directed 
against this cellular component have been shown to protect against infection (45, 76).  
Interestingly, P. aeruginosa 1244 covalently attaches a single serotype O7 O-antigen 
repeating unit to Ser148 of pilin (41), with no alternate glycoforms nor evidence of non-
glycosylated forms of this protein (33).  Pilin (encoded by the pilA gene) is the monomeric 
subunit of the type IV pilus, an immunogenic bacterial surface appendage utilized for 
adhesion and surface motility (156).  P. aeruginosa 1244 pilin glycosylation is mediated by 
the oligosaccharyltransferase, PilO (32, 60).  Because this protein glycosylation machinery 
covalently links an O-antigen subunit and pilin, studies have suggested the possibility for 
exploitation of this system to biologically produce glycoconjugate vaccines (41, 102, 103).   
 128
Metabolically, the pilin glycan originates in the O-antigen biosynthetic pathway (60).  
In accordance, expression of heterologous O-antigen gene clusters in P. aeruginosa 1244 
allowed for pilin to be glycosylated with the heterologously expressed O-antigen repeating 
unit (60).  In addition, expression of plasmid-encoded pilAO1244 in non-serotype O7 P. 
aeruginosa strains resulted in pilin glycosylation in which the glycan consisted of the host's 
O-subunit (60).  These experiments indicated that all nine P. aeruginosa O-subunits tested, 
and the E. coli O157 O-subunit could serve as the 1244 pilin glycan (60).  As a variety of O-
subunits could be conjugated to pilin, this indicated that the PilO glycan specificity was low, 
an extremely promising phenomenon in terms of exploiting the 1244 glycosylation 
machinery for generation of glycoconjugate vaccines.  Moreover, recent studies defined the 
substrate specificity of the 1244 glycosylation reaction (102, 103).  These studies indicated 
that PilO recognizes the sugar at the reducing end of the O-antigen repeating unit precursor 
(103), and that successful transfer of this carbohydrate is contingent upon the positioning of 
Ser at the pilin C-terminus, as this configuration is essential for recognition by the 
glycosylation machinery (102).  While no other specific pilin recognition features were 
present, the charge of the pilin surface must be compatible with the glycosylation apparatus 
(102).  Application of these data may allow for the use of diverse gram-negative O-subunits 
to be covalently linked to a variety of engineered proteins, including toxoids, likely 
expanding the potential breadth of protection.  However, it is first necessary to test if P. 
aeruginosa 1244 glycosylated pilin can provide O-antigen-specific protection. 
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5.3. Materials and Methods 
 
5.3.1. Animals.  Mice and rabbit strains used in this study are listed in Table 
5.1.  Immunizations involving NZW female rabbits were conducted by Covance Research 
(Denver, PA).  All animal experiments complied with federal and institutional specifications 
regarding the utilization of animals in research.  All animals were subjected to a 12 hour 
day/night rhythm and were housed in microisolator cages with access to standard food and 
water ad libitum. 
 
Table 5.1. Animal strains, bacterial strains and plasmid used in this study. 
Organism/plasmid Description Source or reference 
Animals   
   Mice   
     ICR 9-16 weeks old Charles River Laboratories, Wilmington, MA 
     C3H/HeJ 9-16 weeks old Jackson Laboratories, Bar Harbor, ME 
     Balb/c female, 6-8 weeks old Hilltop labs, Scottdale, PA 
     CF-1 female, 22 to 25 g Carworth Farms, New York, NY 
   Rabbits   
     NZW female, adult Covance Research, Denver, PA 
 
Bacterial Strains   
  P. aeruginosa   
      1244 Wild type, IATS O7, Group I pilin (183) 
      1244N3 1244rpoN (TcR) (182) 
      1244.47 1244pilA (Hg R)  (102) 
      PAK Wild type, IATS O6, Group II pilin (34) 
  K. pneumoniae B5055 Serotype O1:K2 (92) 
   
Plasmid   
  pPAC46 pMMB66EH with P. aeruginosa 1244 pilAO, ApR/ CbR (32) 
 
 
5.3.2. Bacterial strains and media.  Bacterial strains and plasmid used in this 
study are listed in Table 5.1.  LB broth or agar (1.5%) was used for routine growth of 
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bacteria.  The media contained gentamicin (50 µg/ml), carbenicillin (250 µg/ml), and/or 
tetracycline (50 μg/ml) as needed.  When necessary, media was supplemented with 5 mM 
IPTG. 
 
5.3.3. Isolation and purification of pili.  Glycosylated 1244 pili utilized for 
vaccination were produced from P. aeruginosa 1244N3 / pPAC46 and harvested as 
previously described (207). Briefly, cell cultures were grown in LB broth supplemented with 
appropriate antibiotics, and 5 mM IPTG, at 37°C, shaking at 250 rpm for 14 h.  The pili were 
isolated from the supernatant after centrifugation at 16,000 x g for 30 min at 4°C.  Pili were 
purified by repeated precipitation in the presence of 0.5 M NaCl and 3% polyethylene glycol 
8000 (207, 210).  When required, traces of LPS were removed by treating purified pili in 1-
1.5% β-octyl glucoside (βOG) which caused pilus depolymerization into pilun subunits.   
The βOG treated pilin was subjected to gel filtration and chromatofocusing as previously 
detailed (41).  Following this purification step, LPS was below the limits of detection, which 
was 0.5 ng of LPS / μg of pilin (41).  LPS-free pilin was subjected to overnight dialysis 
against 6 L H2O at 4°C in which the subunits re-aggregated into pilus-like, non-native fibers 
(241).  This material was lyophilized, resuspended in sterile phosphate buffered saline (PBS) 
and filter sterilized.  The BCA protein assay (Pierce) was utilized to determine the protein 
concentration according to the manufacturer's protocol.  
Heterologously glycosylated pili were extracted from PAK / pPAC46 similarly as 
described above.  Cell cultures were grown in aluminum foil-covered 68- by 28- by 3-cm 
metal pans that contained 500 ml of CAYE medium, carbenicillin, and 5 mM IPTG, at 37°C 
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for 14 h.  Cells were suspended in 50 ml of sodium phosphate buffer per pan (207) followed 
by vigorous stirring for 30 min at room temperature.  Pili were isolated from the supernatant 
using the procedure described above (207, 210).  
 
5.3.4. Immunogenicity studies. Two NZW rabbits were injected 
intradermally (i.d.) in the back at multiple sites with a total of 250 μg of LPS-free 1244 pilin 
with Freund's Complete Adjuvant (FCA) on day 1.  On day 21, rabbits received 
subcutaneous (s.c.) and intramuscular (i.m.) boosts containing 125 μg of LPS-free 1244 pilin 
with Freund's Incomplete Adjuvant (FIA).  Rabbits received s.c. boosts containing 125 μg of 
pilin administered in the rear flanks on day 42.  On day 63, rabbits were injected s.c. with 
125 μg pilin with FIA.  Rabbits received s.c. dorsal injections on day 84 containing 100 μg 
pilin and FIA.  The final boost consisted of a s.c. injection in the neck region containing 100 
μg pilin with FIA.  On days 31, 52, 73, 94, and 115, sera were collected and analyzed for 
antibody production (data not shown).  On day 118, approximately 50 ml of sera were 
collected in the terminal bleed, and utilized for subsequent assays. 
In order to evaluate the induction of murine antibodies corresponding with acute 
pneumonia protection studies, the following immunization schedules were used (first/ second 
dose): i.n. (intranasally) /i.n., or i.n./s.c.  At each immunization, a total dose of 5 μg of native 
1244 pili diluted to the appropriate volume in sterile physiologic saline was administered to 
ICR mice.  The time interval between the doses was 7 days.  For i.n. immuniztion, mice were 
anesthetized intraperitoneally (i.p.) with ketamine HCl (80 mg/kg, Aveco Co., Fort Dodge, 
IO) and xylazine HCl (8 mg/kg, Mobay Corporation, Shawnee, KA) prior to the instillation 
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of the pili.  Pili were delivered i.n. in a final volume of 25 μl using individual sterile aerosol-
resistant pipette tips for each mouse to prevent contamination.  The final volume s.c. 
injection was 100 μl.  Control mice received sterile physiologic saline only at exactly the 
same volume and route. At 3, 7, 10, and 14 days after the second dose of vaccine, mice were 
sacrificed by CO2 inhalation to obtain both serum samples via cardiac puncture as well as 
BAL samples.  For BAL samples, lungs were washed once with 1 ml of sterile physiologic 
saline via a 25 G hypodermic needle inserted into the trachea.  At least 0.8 ml of the fluid 
was routinely recovered.   
 
5.3.5. Preparation of challenge. Overnight broth cultures of P. aeruginosa 
1244, Klebsiella pneumoniae B5055, or the 1244 isogenic pilA mutant, P. aeruginosa 
1244.47, were used to lawn-streak Trypticase soy agar plates that were incubated at 37°C for 
12-18 h.  Cells were suspended in sterile PBS and A650 or a Klett colorimeter was used to 
estimate cell density.  Cells were serially diluted and plated as viable cell counts were used to 
more accurately determine the inoculum cell density.   
 
5.3.6. Rabbit serum adsorption. Serum recovered from a female NZW rabbit 
that had been immunized with pure LPS-free pilin was incubated overnight with a 
nitrocellulose lift colony that had been coated with a preparation of strain 1244 pili 
glycosylated with a heterologous, serotype O6 glycan (1244O6 pili; these pili were purified 
from strain PAK / pPAC46).  This adsorption was repeated five times. 
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5.3.7. ELISA. Antibody titers in serum and BAL were determined by means 
of an ELISA using 96-well plates coated with pili from either P. aeruginosa 1244 or strain 
PAK / pPAC46 at concentrations of 2 μg/ml (50 μl/well, incubated overnight at 4°C), or P. 
aeruginosa 1244 LPS at a concentration of 1 μg/ml (100 μl/well, incubated overnight at 
4°C).  After treating wells with blocking buffer and washing, samples were serially diluted 
(2-fold) in blocking buffer and incubated o/n in duplicate at 4°C.  Bound antibodies were 
detected using goat-anti-mouse-IgG/alkaline phosphatase-labeled, goat-anti-mouse-
IgM/alkaline phosphatase-labeled, goat-anti-mouse-IgA, or goat-anti-rabbit/alkaline 
phosphatase-labeled secondary antibodies (Kierkegaard & Perry, Gaithersburg, MD) diluted 
appropriately in blocking buffer and plates were developed with p-nitrophenylphosphate 
(Sigma, St. Louis, MO) in diethanolamine buffer (ph = 9.8).  The reaction was stopped by 
adding 50 μl of 3 M NaOH to each well after 30 min.  ELISA titers were defined as log10 of 
the dilution which gave a change in absorbance at 405 nm (A405) of 0.200 at room 
temperature.  Background A405 in all control wells was always below 0.050. 
 
5.3.8. Acute pneumonia model.  For initial acute pneumonia protection 
studies, ICR mice received either i.n./i.n. or i.n./s.c. administration of pure 1244 pili.  Seven 
days after the second vaccination, anesthesia was administered as described above, and mice 
received an i.n. challenge of approximately 2 × LD50 (4.3 × 106 colony forming units [CFU]) 
of P. aeruginosa 1244 in a final volume of 50 μl (25 μl per nare).  All LD50 values were 
determined according to the method of Reed and Muench (data not shown) (185).  
Morbidity/mortality and body weight were monitored daily for 8 days.  Control mice were 
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vaccinated with sterile physiologic saline as described above.  To ensure the specificity of 
the vaccine, mice that were immunized i.n./i.n. with 1244 pili were challenged with 1.4 × 104 
CFU of K. pneumoniae B5055.  Alternatively, mice were immunized i.n./i.n. with 5 
μg/mouse/dose of E. coli strain PCF pili (kindly provided by Dr. F. Cassels, Walter Reed 
Army Institute of Research, Washington, D.C.) and challenged i.n. with P. aeruginosa 1244 
as described above.  In separate experiments, 1244 pilus-immunized and P. aeruginosa 
1244-challenged mice were sacrificed at 4, 24, and 48 h after bacterial challenge, and BAL 
fluid was obtained under sterile conditions as described above.  In addition, lungs, liver, and 
spleen were excised aseptically, weighed and homogenized.  CFU counts in BAL and organ 
homogenates were determined utilizing methods previously described (92).  
In subsequent acute pneumonia protection studies, Balb/c mice were used, and the 
vaccine consisted of LPS-free 1244 pilin. LPS-free glycosylated pilin (9 μg in 20 μl PBS; 10 
μl per nare) was administered i.n./i.n. as described above.  As a control, mice received 20 μl 
PBS administered i.n./i.n.  Seven days following the second vaccination, mice were 
anesthetized and were challenged with 3.7 x LD50 (4.9 x 107 CFU) of strain 1244.47 which 
was administered i.n. in 20 μl PBS (10 μl per nare).  Following the challenge, mice were 
closely monitored for 96 hours, during which, morbidity/ mortality was recorded.   
 
5.3.9. Burned mouse model.  The burned mouse model was conducted as 
previously described (163).  On day 0, pure LPS-free glycosylated strain 1244 pilin was 
diluted to a concentration of 40 μg/100μl with saline and mixed 1:1 with FIA resulting in a 
solution with a pilus concentration of 20 μg/100μl.  A total of 27 mice were immunized with 
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100 μl of this material via the subcutaneous route (back).  A control group (containing the 
same number of animals) was treated in the same manner with the same solution, except that 
the pili were absent.  This treatment was repeated on day 7.  On day 14, the mice were 
subjected to a nonlethal thermal injury of 15% of the body surface which caused host 
immunosuppression, and were challenged with a subeschar injection of approximately 5 x 
107 CFU of P. aeruginosa 1244.47.  Additionally, eight untreated mice were challenged in 
the same manner.  Following the challenge, mice were observed for five days, during which, 
morbidity and mortality were recorded. 
 
5.3.10. Statistics.  Differences in survival between the groups were analyzed 
with the log rank test.  For all other comparisons, the two-tailed Mann-Whitney U test was 
used.  The statistical analyses were done with either Statistica, version 4.5 for Windows, 
StatSoft, or GraphPad Prism 4.02. 
 
5.4. Results and Discussion. Previously, mice were immunized with pure P. 
aeruginosa 1244 pili, which indicated that these fibers induced a strong B-cell response 
against native pili, the proteinaceous portion of the pilin subunit, the glycan, and the O7 
subunit of the LPS from this strain (41).  Because of this phenomenon, I wanted to determine 
if strain 1244 pilin was efficacious in generating a protective anti-O-antigen response.  It was 
first necessary to test if immunization with these pili could provide protection against a P. 
aeruginosa 1244 infection.  As P. aeruginosa is a leading cause of nosocomial pneumonia 
(167), the murine acute pneumonia model was used to determine the protective efficacy of a 
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vaccine composed of strain 1244 pili.  The following immunization schedules were utilized 
(first/ second dose): intranasally (i.n.) /i.n., or i.n./subcutaneously (s.c.) with seven days 
between doses.  At each immunization, mice received 5 μg of native 1244 pili, diluted in 
sterile physiologic saline.  Serum from both i.n./i.n.- and i.n./s.c.-immunized mice contained 
high titers of LPS-specific antibodies (IgG and IgM; Table 5.2).  These results indicated that 
a specific immune response was well established at one week following the second 
vaccination as evidenced by high serum IgG titer with specificity the serotype O7 O-antigen 
(Table 5.2).  If this response could sufficiently mediate clearance of infection, then strain 
1244 glycosylated pili may provide O-antigen specific immunity (41).  
Because a specific immune response was established one week following the second 
pilus-immunization (Table 5.2), mice were challenged with a lethal dose of wild-type P. 
aeruginosa 1244 at this time-point.  Mice receiving the pilus vaccine i.n./i.n. exhibited 
significant survival compared to mice receiving saline following an intranasal challenge of a 
lethal dose of strain 1244 (P<0.0001; Fig. 5.1A).  Although mice receiving the pilus vaccine 
i.n./s.c. showed reduced survival compared to the i.n/i.n.-immunized mice, these mice still 
exhibited significantly increased survival compared to saline-vaccinated mice (P=0.0030; 
Fig 5.1A).  Compared to the saline-immunized controls, mice immunized with either 
regimen had significantly fewer bacteria in their BAL at 4 h after infection (Fig. 5.1B).  
These data indicated that immunization with strain 1244 pili either prevented adherence of 
bacteria to epithelial surfaces, or promoted clearance of bacteria from the airways.  P. 
aeruginosa 1244 consistently spread throughout the body as evidenced by the culture of 
bacteria from homogenates of peripheral organs, but only mice immunized twice i.n. were 
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capable of lowering numbers of bacterial colony forming units (CFU) in the lungs as well as 
keeping bacterial multiplication or accumulation in the liver and spleen at steady levels 
between 4 and 24 h after challenge (Fig. 5.1C).  In addition, a significant decrease in the 
bacterial CFU from the BAL over time (4 h versus 24 h after bacterial challenge) was 
observed only when the animals were immunized i.n./i.n. (Fig. 5.1B).  Mice immunized 
i.n./s.c. and saline-immunized control mice showed increasing CFU counts in the lungs, 
liver, and spleen at 24 h after infection (Fig. 5.1C).  At 48 h after infection, all saline-
immunized mice were deceased, however the surviving mice immunized either i.n./i.n. or 
i.n/s.c. showed low CFU counts in all three organs investigated (Fig. 5.1C) indicating 
vaccine-induced clearance.  Thus, survival correlated with decreasing bacterial counts both 
locally and systemically over the initial 48 h of infection. 
 
Table 5.2.  Systemic antibody response from mice specific for P. aeruginosa O7 LPS after 
immunization with strain 1244 pili.  ELISA was carried out by Peter Castric. 
 
Routea Ig class 3b 7b 10b 14b 
i.n./i.n. IgG 2.05 c 1.90 1.77 2.37 
 IgM 2.68  2.43 1.96 1.97 
 IgA 0.50 0.50 0.50 0.50 
i.n./s.c. IgG 2.22 2.43 2.13 2.09 
 IgM 2.79 2.90 2.83 2.69 
 IgA 0.50 0.50 0.50 0.50 
      
ai.n., intranasally; s.c., subcutaneously.  The routes denoted are for the first/second immunization in which the time 
between each immunization was 7 days. 
 
bDay after second immunization. 
 
cMean log10 ELISA antibody titer (dilution) which gave a change of A405 of 0.200 after 30 min.  Each value shown 
in the mean of individual titers from three mice. 
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Figure 5.1.  Initial acute pneumonia model protection study.  Panel A: Survival of mice after a lethal i.n. 
challenge of P. aeruginosa 1244.  Mice exhibit significantly increased survival when immunized i.n./i.n. or 
i.n./s.c. with strain 1244 pili compared to mice immunized with saline (control) following a lethal dose of P. 
aeruginosa 1244 administered i.n.  Results are shown as Kaplan-Meier survival curves, and differences in 
survival were calculated by the log-rank analysis; i.n./i.n vs. control, P < 0.0001,***; i.n./s.c. vs. control, P = 
0.0030,**; i.n./i.n. vs. i.n./s.c., P = 0.1449.  Panels B & C: Bacterial growth in the BAL (panel B) or in the 
lungs, liver, and spleen (panel C) of strain 1244 pilus-immunized and saline-immunized mice.  Graphed values 
are medians and error bars represent quartiles.  Data are from 2 independent experiments (n = 4 mice per group 
per experiment). Panel B: *, P = 0.0062 (mice immunized i.n./i.n.) and P = 0.0015 (mice immunized i.n./s.c.), 
respectively, as compared to the corresponding time points of saline-immunized (control) animals (Mann-
Whitney U test).  This experiment was carried out by Tom Held and Alan Cross. 
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It was necessary to investigate if the immune response elicited by immunization with 
P. aeruginosa 1244 pili conferred specific protection, or if the protection was due to a 
generalized inflammatory response caused by administration of pili.  Therefore, utilizing the 
respiratory model, mice that were immunized twice i.n. with strain 1244 pili were 
subsequently challenged with a heterologous bacterium (K. pneumoniae B5055) that did not 
produce pili, and was serologically distinct from strain 1244.  Neither immunized nor control 
mice survived a lethal challenge with K. pneumoniae indicating that vaccination with P. 
aeruginosa 1244 pili protects only against a homologous challenge (Table 5.3).  
Alternatively, mice were immunized i.n./i.n. with Type I pili from E. coli and subsequently 
received a lethal dose of P. aeruginosa 1244.  If non-specific immune factors mediated 
protection, then heterologous pili might be comparably protective as strain 1244 pili.  Results 
indicated that only 30% of mice receiving an i.n. vaccine composed of heterologous pili 
survived the P. aeruginosa 1244 challenge (Table 5.3).  These data verified that the 
protection depicted in Fig. 5.1A was a result of a specific immune response, and was not due 
to inflammation from the pilus vaccine. 
Results presented above (Fig. 5.1) indicated that P. aeruginosa 1244 pili elicited 
significant protection against a lethal challenge of the wild-type strain 1244 in the acute 
pneumonia model likely due to both an anti-pilus and anti-O-antigen response.  Since pili 
administered above were in the native form, these pili were contaminated with trace amounts 
of LPS.  These trace amounts of LPS were not likely responsible for the anti-O-antigen 
stimulation in results presented here (Table 5.2).  Previously, mice were immunized with 
pure strain 1244 LPS in amounts equal to 200%, 100%, and 50% respectively, of the LPS 
contamination levels present in the pili doses from the current study (41).  Serum extracted 
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from these mice did not produce a detectable reaction against pure LPS, as determined by 
Western blotting and ELISA, suggesting that the anti-O-antigen response seen in the current 
study (Table 5.2) was due to stimulation by the pilin glycan, and not due to LPS 
contamination (41). 
 
Table 5.3. Protection studies indicating the specificity of the protective immune response elicited 
by strain 1244 pili.  This experiment was carried out by Tom Held and Alan Cross. 
Immunizationa Challenge Strain 
 P. aeruginosa 1244 K. pneumoniae 
P. aeruginosa 1244 pili 4/4b 0/8 
E. coli pili 3/10 n.d.c 
Saline 0/6 0/6 
 
aMice were immunized i.n./i.n. 
bNumber of surviving mice / number of total mice in each group. 
cn.d., not done 
 
 
To ascertain the protective potential of the anti-O-antigen response stimulated by 
these glycosylated pili, it was necessary to remove traces of LPS contamination. 
Administering a vaccine consisting of pilin devoid of detectable LPS contamination, rather 
than LPS-based vaccines or crude pilus extracts, ensures the absence of the lipid A portion of 
the LPS molecule, resulting in the lack of toxicity, which is particularly important for human 
application.  
Removal of detectable levels of LPS from pilus preparations was accomplished with 
detergent-treated pili as previously described (41, 242).  Detergent was removed upon 
dialysis of the purified pilin, which allowed reaggregation of the pilin subunits into nonnative 
pilus-like fibers (241) (this substance will now be referred to as LPS-free 1244 pilin).  Before 
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testing the protective efficacy of LPS-free 1244 pilin, it was necessary to determine if the 
pilin glycan was a dominant epitope while in the re-aggregated pilus arrangement.  Therefore 
rabbits were immunized with LPS-free 1244 pilin.  Sera from these rabbits were adsorbed 
with 1244 pili, heterologously glycosylated with the serotype O6 O-antigen subunit (1244O6 
pili) to remove pilin protein-specific antibodies.  Adsorbed serum was unresponsive to 
1244O6 pili, while untreated sera had high titers of antibodies specific for these pili, 
suggesting that the adsorption had successfully removed pilin protein-specific antibodies 
(Fig. 5.2A).  The serum adsorbed with 1244O6 pili had slightly lower titers of antibodies 
specific for normal, glycosylated 1244 pili containing the O7 subunit (1244O7) than did the 
untreated serum (Fig. 5.2B).  This difference was probably due to the absence of a pilin 
protein-specific response.  Recognition of glycosylated pili by a serum that lacked a pilin 
protein-specific response suggested that the anti-pilus reaction was directed to the pilin 
glycan.  Both the adsorbed, and un-treated sera exhibited an equal response to serotype O7 
LPS and showed animals immunized with LPS-free 1244 pilin produced a strong anti-LPS 
response (Fig. 5.2C).  Notably, the dominant antibody type produced by these rabbits was 
IgG, as determined by ELISA, which indicated a 4-log difference between IgG and IgM 
titers (data not shown) suggesting the involvement of T-cells.  These results confirm that 
LPS-free 1244 pilin is capable of stimulating a specific B-cell response against both the pilin 
glycan, and the structurally similar O-antigen repeating unit of LPS (41), and suggest that the 
pilin glycan is a major pilin epitope. 
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To determine the capacity of O-antigen specific protection generated by a vaccine 
composed of LPS-free 1244 pilin, the acute pneumonia murine model was once again 
employed, now utilizing a pilA-negative strain (P. aeruginosa 1244.47) as a challenge.  This 
bacterial strain is an isogenic mutant of strain P. aeruginosa 1244 that does not produce pilin 
(102).  However, strain 1244.47 made identical LPS to that of wild-type strain 1244 as 
determined by Western blot analysis utilizing a serotype O7-specific monoclonal antibody as 
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a probe (data not shown).  Mice receiving an i.n./i.n. administration of 9 μg LPS-free 1244 
pilin exhibited significant survival compared to phosphate buffered saline (PBS) -immunized 
mice (P=0.0375; Fig. 5.3A) following an i.n. challenge of a lethal dose of strain 1244.47, 
suggesting that this vaccine provides O-antigen specific mucosal protection.  Notably, 
isolated bacterial clones from tissues did not produce pilin, as determined by Western blot 
analysis utilizing a pilin-specific monoclonal antibody as a probe, indicating that that this 
mutant did not revert to wild-type during infection (data not shown). 
To determine if the vaccination with LPS-free 1244 pilin could provide protective 
systemic immunity, the burned mouse model was employed.  Mice that were immunized 
twice with a mixture of 40 μg LPS-free 1244 pilin and Freund's Incomplete Adjuvant 
exhibited significant survival compared to mice receiving the control (P=0.0042; Fig. 5.3B) 
following an subeschar challenge of a lethal dose of strain 1244.47, indicating vaccine-
induced O-antigen specific systemic protection.  Because the challenge strain lacked pili, but 
expressed the same O-antigen as strain 1244, this suggests that immunization with LPS-free 
strain 1244 pilin can provide O-antigen-specific protection, and that the pilin glycan is a 
protective epitope. 
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Figure 5.3.  Survival after P. aeruginosa 1244.47 challenge following immunization 
with LPS-free pili in the acute pneumonia model (panel A) and burned mouse model 
(panel B).  Results are shown as Kaplan-Meier survival curves, and differences in 
survival were calculated by the log-rank analysis.  Panel A: Mice immunized i.n./i.n. with 
LPS-free strain 1244 pili exhibited significantly increased survival compared to mice 
immunized with PBS (control) following a lethal dose of the pilA mutant, strain 1244.47, 
P = 0.0375,*.  Panel B: Mice were immunized s.c. with either LPS-free strain 1244 pilin 
mixed with FIA, FIA, or were untreated.  Significant survival was observed when mice 
received the pilus vaccine compared to the adjuvant-treated, P = 0.0087, ** or untreated 
mice, P = 0.0001, ***.  It should be noted that significant survival was observed in 
adjuvant-treated mice compared to untreated mice likely due to an inflammatory 
response, and the attenuation of strain 1244.47 due to the absence of pili.  However, as 
survival of the mice receiving the pilus vaccine was significantly higher than the 
adjuvant-treated mice, this suggests that this additional protection was due to specific 
immunity. 
*
**, ***
 145
The current study established that LPS-free pilin provides O-antigen specific 
protection against a P. aeruginosa challenge in which the serotype corresponds to the pilin 
glycan.  Future studies should focus on expanding the application of this technology, by 
testing the protective efficacy of vaccines composed of strain 1244 pilin glycosylated with 
O-subunits from harmful pathogens, such as E. coli O157.  Fortuitously, O-antigen 
biosynthetic genes are clustered on bacterial chromosomes (196), allowing ease of cloning 
(82).  As previously shown, when P. aeruginosa 1244 expresses the E. coli O157 O-antigen 
biosynthesis genes in trans, the pili from the strain produced are decorated with the O157 O-
subunit (60).  Unlike the production of most chemically cross-linked glycoconjugate 
vaccines, in which dangerous bacteria must be grown in culture to obtain surface 
polysaccharide material, the strategy presented here involves the culturing of a relatively 
harmless organism, P. aeruginosa 1244.  Practically, the pilus vaccine technology would 
lower laboratory costs, as less stringent safety measures and minimal culture containment 
would be necessary.  
In current chemically cross-linked glycoconjugate vaccines, two purification steps 
must be performed including isolation of an appropriate carrier protein, in addition to 
refinement of the bacterial surface polysaccharide.  For gram-negative bacteria, this involves 
separating the LPS O-antigen from the lipid A portion.  Following purification, these 
molecules are subjected to coupling chemistry.  Altogether, these procedures are time-
consuming and expensive.  However, production of large amounts of glycosylated pili is 
quickly accomplished, relatively inexpensive, and only requires common laboratory 
procedures.  Moreover, it is well known that pili are immunogenic in humans.  In part, this is 
due to the polymeric display of subunits in the pilus fiber (184).  The arrangement of the 
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glycan in a polymeric form in both native pilus fibers and in reaggregated pilin subunits 
(241) might promote expedient B-cell proliferation due to the proximity of adjacent glycan 
epitopes.  Previous data indicated that the pilin glycan is exposed along the surface of the 
pilus fiber, and can easily be accessed by antibodies (210) and presumably by B-cell mIg.  If 
glycan recognition by mIg molecules led to internalization and MHCII presentation of pilin 
peptides, this may stimulate involvement of helper T-cells resulting in proliferation and 
differentiation of the B-cells producing glycan-/O-antigen-specific Ig. 
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Chapter 6. Discussion 
 
The presence of a covalently linked sugar to pilin of P. aeruginosa 1244 was one of 
the first examples of eubacterial protein glycosylation (32).  Since this discovery, there have 
been numerous accounts of protein glycosylation among prokaryotes, indicating that this 
type of post-translational modification is distributed among all biological kingdoms (213).  
Although the existence of protein glycosylation among bacteria has garnished widespread 
acceptance among scientists, little work has been conducted to understand the intricacies of 
this biological process, such as reaction specificities.  Using mutational analyses, works in 
this dissertation described the pilin and glycan specificities of the P. aeruginosa 1244 pilin 
glycosylation reaction.  A structure identical to this organism's O7 O-subunit (33) is bound 
by ether linkage to the β-carbon of Ser148, the pilin C-terminal residue in a reaction mediated 
by PilO (41).  Results from Chapter 2 suggested that the C-terminal Ser is the primary pilin 
glycosylation recognition structure, and that this residue cannot be substituted at its carboxyl 
group.   While no other pilin-specific recognition features were identified, results suggested 
that the pilin surface charge was important for compatibity with the reaction apparatus in 
order for glycosylation to occur.  Results indicated that unlike prokaryotic N-linked 
glycosylation (232), this O-linked modification does not require a specific sequence motif, 
but rather requires the target protein to possess only a C-terminal Ser or Thr and a charge-
compatible molecular surface.  Applying this information to manipulation of other non-pilin 
proteins could provide an efficient mechanism to develop glyconjugates for the use as 
vaccines. 
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An oligosaccharyl-transferase not only requires specificity for its target protein, but it 
must also specifically recognize its glycan substrate.  Chapter 3 detailed experiments that 
identified the reducing-end moiety of the glycan precursor as the sugar possessing 
recognition elements for glycosylation by P. aeruginosa 1244.  These findings have 
implications for utilization of the 1244 glycosylation machinery for vaccine design, as many 
gram-negative bacteria produce O-antigens with similar reducing-end sugars to β-D-FucNAc 
(129).  Future in vitro glycosylation experiments using structurally variant sugars as 
substrates will reveal the limits of this system with respect to the types of compatible 
saccharides. 
Many pathogenic bacteria express surface glycoproteins, in which the presence of the 
glycan enhances virulence (225).  The opportunistic pathogen, P. aeruginosa is a leading 
cause of hospital-acquired pneumonia.  One of the most important virulence factors for this 
organism is type IV pili.  The pilin subunit of strain 1244 and of many P. aeruginosa clinical 
isolates is glycosylated.  Previously, the function of this glycan was unknown.  Chapter 4 
detailed work indicating that loss of the pilin glycan did not disrupt normal pilus function.  
However, as this modification was found to be located along the entire surface of the pilus, it 
was likely that it influenced how this organism interacted with its environment.  
Concordantly, expression of glycosylated pilin subunits reduced pilus and whole-cell 
hydrophobicity.  These results suggested that the presence of the glycan might provide a 
selective advantage in a specific niche.  Therefore, pathogenicity was examined as a possible 
function.  A significant number of pulmonary P. aeruginosa clinical isolates expressed 
glycosylated pili.  Competition experiments using a respiratory mouse model comparing 
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strain 1244 and the pilO isogenic knockout strain, 1244G7 indicated that the presence of the 
glycan allowed significantly greater survival in the lung environment.  Altogether, these 
results suggest that the pilin glycan is an important virulence factor aiding in the 
establishment of pulmonary infection.  Because the pilin glycan is surface-located, and 
distributed along the fiber surface, this makes this structure a tempting vaccine target.  
Antibodies generated against the glycan will recognize the O-antigen (41), in addition to 
binding to the pilus inhibiting twitching motility (33), an important process for pathogenicity.  
Therefore, works presented in Chapter 5 were carried out to determine if the pilin glycan was 
a protective epitope. 
The LPS O-antigen is both a major structural outer-membrane component and the 
dominant immunological epitope of most gram-negative bacteria.  As previously mentioned, P. 
aeruginosa 1244 covalently attaches a single O-antigen repeating unit to each pilin monomer. 
Because antibiotic resistance among many bacterial pathogens (250) is becoming increasingly 
prevalent, it is necessary to turn to vaccination as a means to combat these disease-causing 
organisms.  The use of glycoconjugates produced by chemically cross-linking bacterial surface 
polysaccharides to carrier proteins is an important strategy for vaccine design (116).  Saccharides 
covalently bound to proteins invoke T-cell-dependent immunity (11), which involves a memory 
response, avidity maturation, and immunoglobulin class switching (248).  Conversely, bacterial 
polysaccharides unbound to proteins are usually associated with a T-cell-independent response, 
which does not involve the above mentioned immunological responses (161).  Results from 
Chapter 5 of this dissertation indicate that P. aeruginosa 1244 pili provide O-antigen specific 
protection in the murine acute pneumonia and thermal injury models of infection.  Therefore this 
system could be utilized as a means to develop numerous protective anti-gram-negative 
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bioconjugate vaccines.  It has been well established that pili are immunogenic in humans.  This is 
partially due to the polymeric display of pilin subunits in the pilus fiber (184).  The arrangement 
of the glycan in a polymeric form might promote rapid B-cell proliferation due to the proximity 
of adjacent glycan epitopes.  Data presented in Chapter 4 indicated that the pilin glycan is 
exposed along the surface of the pilus fiber, and can easily be accessed by antibodies (210) and 
also presumably by B-cell mIg.  If this glycan recognition by mIg molecules led to 
internalization and MHCII presentation of pilin peptides, this may stimulate involvement of 
helper T-cells resulting in proliferation and differentiation of the B-cells producing glycan- and 
O-antigen-specific Ig.  
 In Chapter 2, experiments suggested that the positioning of Ser at the pilin C-terminus 
is critical for recognition by the glycosylation apparatus.  Although there were no other 
apparent structures essential for recognition, the pilin surface charge must be compatible 
with the glycosylation machinery, i.e. PilO and the Und-PP-bound glycan precursor.  
Specifically, a negatively charged pilin surface was inhibitory for glycosylation, whereas 
positive surface charges were conducive.  The Und-PP-bound glycan precursor of P. 
aeruginosa 1244 has numerous negative charges in the form of a pyrophosphate group, and 
the carbohydrate moiety at the oxidizing end of the O-subunit, pseudaminic acid.  Therefore, 
it is possible that these negative charges were interfering with those of the pilin that had an 
acidic surface resulting in inhibition of glycosylation.  To test this, pilin genes on the 
plasmids, p103 P144S and p103 S146, were expressed in a P. aeruginosa clinical isolate that 
synthesized an uncharged O-subunit (serotype O11) and produced PilO (data not shown).  
Western blot analysis using a PA103-pilin specific antibody as a probe showed that pilin 
produced by p103 S146 was glycosylated, and p103 P144S-produced pilin was non-
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glycosylated (data not shown).  In Chapter 2, when these plasmids were expressed in 1244-
derived strains having an O-subunit with the negatively charged pseudaminic acid, pilins 
produced had the same glycosylation states as observed here (Figs. 2.4 & 2.9).  Therefore, 
pilin with a negative surface charge likely repels either the pyrophosphate group of the Und-
PP-bound glycan precursor, the portion of PilO that interacts with pilin, or both.  Conversely, 
recent evidence suggests that the protein targeted for glycosylation in bacterial N-linked 
glycosylation is required to have a residue with a negatively charged side chain (Glu or Asp) 
two residues to the N-terminal side of the glycosylation site (131).  Therefore, although there 
is much similarity between P. aeruginosa 1244 pilin glycosylation and the C. jejuni N-linked 
glycosylation, it is evident that mechanisms defining enzymatic recognition of the target 
protein in these systems are drastically different. 
 Chapter 3 of this dissertation details experiments showing that the glycan substrate 
recognition elements are within the carbohydrate moiety of the reducing end of the glycan 
precursor.  To this date, the only other prokaryotic protein glycosylation system in which the 
glycan specificity of an oligosaccharyltransferase was described was that of the N-linked 
system of C. jejuni (81, 240). To test the specificity of the C. jejuni transferase, PglB, genes 
encoding this glycosylation gene cluster were expressed in several bacterial strains of diverse 
serotypes and surface polysaccharide mutants (240), or synthetic Und-PP-linked 
disaccharides were tested for transfer in vitro (81).  The apparent glycan specificity of this 
transferase was consistent with that of PilO, in that both enzymes recognized a HexNAc 
carbohydrate moiety at the reducing end of the Und-PP-bound glycan precursor (240).  These 
data are also consistent with the specificity of oligosaccharyltransferases of eukaryotic N-
linked glycosylation (240) suggesting that these three protein glycosylation systems may be 
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related evolutionarily.  However, because investigators of the C. jejuni N-linked 
glycosylation system did not assay transfer of a single HexNAc monosaccharide, it is 
possible that structural aspects of additional sugars, or larger saccharide substrates in the 
glycan precursor may be involved in substrate recognition (81, 240).   
 Collectively, data from this study suggests that P. aeruginosa 1244 pilin 
glycosylation likely occurs by the mechanism outlined in Fig. 6.1.  Pilin is translated, folded, 
and the disulfide bond is formed in the periplasmic space (Fig. 6.1).  Subsequently, pilin, 
PilO, and the Und-PP-bound glycan precursor interact prior to glycosylation (Fig. 6.1).  This 
interaction is contingent upon the surface charge of pilin (Fig. 6.1).  Furthermore, PilO 
recognizes the C-terminal Ser of pilin as well as the carbohydrate moiety at the reducing end 
of the glycan precursor (Fig. 6.1).  PilO catalyzes the glycosylation of pilin in which 
hydrolysis of the pyrophosphate of the glycan precursor drives the reaction forward (Fig. 
6.1).  It is uncertain if glycosylation of pilin requires the formation of a pilin-PilO-Und-PP-
O-subunit ternary complex as shown in Fig. 6.1, or if interactions are successive.  Following 
glycosylation, pilin subunits are assembled into pili (Fig. 6.1).  By understanding the 
necessary pilin and glycan components necessary for glycosylation, it may be possible to 
engineer various non-pilin proteins for glycosylation with O-subunits from dangerous gram-
negative bacterial pathogens to be used as vaccines as mentioned in Chapters 2.5 & 3.5.  
However, it is necessary to fully explore the structural requirements for glycosylation by this 
system.  Since P. aeruginosa 1244 pilin glycosylation occurs in the periplasm (Qutyan and 
Castric, unpublished observations) engineering a non-pilin periplasmic bacterial protein, 
such as PhoA, to contain the glycosylation substrate may reveal if the minimal glycosylation 
motif described in Chapter 2 is sufficient for glycosylation.  Conversely, if pilin structures,  
 153
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1.  Proposed mechanism of pilin/ PilO/ Und-PP interaction and pilin 
glycosylation.  1. Pilin (red circle and green stem) is embedded in the cell membrane upon 
translation.  The globular head region (red circle) faces the periplasmic space where 
disulfide bond formation takes place.  2.  Folded pilin, and the glycan precursor (Und-PP-
bound O-antigen subunit; F X P inside hexagons represent the glycan, encircled Pi 
represents a phosphate group, and the serrated black line represents the polyisoprene carrier) 
and the oligosaccharyltransferase PilO (blue rectangle) are the necessary components of the 
glycosylation machinery.  3.  Interaction between pilin, the glycan precursor, and PilO takes 
place.  The positive surface charge of pilin is conducive for interaction with the 
glycosylation machinery.  PilO recognizes the C-terminal Ser of pilin, and the reducing-end 
moiety of the glycan precursor.  4. Glycosylation of pilin occurs (4a.), and energy input for 
this reaction is provided by hydrolysis of the pyrophosphate group of Und-PP (4b.).  5.  
Glycosylated pilin subunits are assembled into pili (not shown). 
Periplasm 
 
 
 
Cell 
Membrane 
 
 
 
 
Cytoplasm 
 
Periplasm 
 
 
 
Cell 
Membrane 
 
 
 
 
Cytoplasm 
 
 154
other than those outlined in this dissertation, are required for glycosylation deletion 
mutagenesis of coding sequence for the α-helix or globular head region will reveal which of 
these domains, if any, are essential.   
 Having a definitive glycosylation substrate specificity allows P. aeruginosa 1244 to 
exclusively display an oligosaccharide along the surface of its pilus.  Therefore, it was also 
important to determine the functional role of the pilin glycan.  The fourth chapter of this 
dissertation included a description of works suggesting that the strain 1244 pilin glycan was a 
virulence factor in the mouse respiratory model.  Future work should be focused on 
determining the mechanism by which the glycan enhances virulence.  For example, this 
modification may enhance virulence by increasing adhesion to epithelial cells.  By growing 
these host cells in culture and seeding with either strain 1244 or the isogenic pilO mutant, 
1244G7 followed by washing, one could assess differences in pilus-mediated adhesion.  
Another possibility is that the presence of the glycan may block interaction with pattern 
recognition molecules (125), such as toll-like receptors (149).  By treating epithelial cells 
with either glycosylated or non-glycosylated pili, one could assess levels of secreted 
inflammatory mediators and cytokines whose secretion is downstream of activation of these 
toll-like receptors.  Furthermore, as the pilin glycan was important for pulmonary virulence, 
it should be explored if this modification enhances systemic virulence, as was observed for 
P. aeruginosa flagellin glycosylation (10). 
 The noblest biological research seeks to understand the basic science underlying the 
intricacies of life in order to apply this knowledge toward the improvement of our own lives.  
In this dissertation, I showed that, in both the acute pneumonia and burned mouse models of 
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infection, that vaccination with LPS-free 1244 pilin provides O-antigen specific protection.  
Aside from application of this technology to develop vaccine strategies previously discussed 
in Chapter 5, immunization with glycosylated pili could possibly be utilized as a means to 
generate antigens that stimulate the production of O-antigen-specific antibodies in human 
volunteers. These LPS-specific antibodies could then be used in passive immunization.  In 
addition, the efficiency of producing glycosylated pili may be enhanced by generating a pilT 
knock-out, as these strains lead to hyperpiliation (42).  More boosts of glycosylated pili 
might increase the O-antigen antibody response, as is commonly observed chemically 
produced glycoconjugate vaccines (116).  Additional future studies should explore the use of 
a mucosal adjuvant, such as the oligonucleotide CpG1826 (254), in an effort to increase 
glycan- and O-antigen-specific antibody production and protection.  The essential glycan and 
pilin components for glycosylation were determined (Chapters 2 & 3), and data from Chapter 
5 suggested that the glycan is a protective epitope.  By integrating this information, it is 
plausible that other proteins, such as genetic toxoids, could easily be engineered for 
glycosylation which may greatly expand the breadth of protection provided by this 
technology.  Notably, many P. aeruginosa clinical isolates have been shown to produce 
group I, glycosylated pilin (Chapter 4, (136)).  Therefore the 1244 pilus vaccine, if applied 
toward P. aeruginosa vaccination, would target multiple P. aeruginosa surface components 
including the proteinaceous portion of the pilus, the pilin glycan (Chapter 4), and the O-
antigen, a scenario that would enhance protection.  Also, as seen in Chapter 2, group II pilin 
can be easily engineered to be glycosylated.  Therefore, if a vaccine was composed of a 
mixture of glycosylated group I and group II pilin, where the pilin glycans corresponded to 
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the most prominent clinical O-serotypes, protection against many P. aeruginosa strains 
would be expected.     
 In summary, work in this dissertation demonstrated the essential pilin and glycan 
components necessary for P. aeruginosa 1244 pilin glycosylation.  In addition, data 
suggested that the glycan functions to enhance bacterial pulmonary virulence.  Utilization of 
these pili as vaccines provides O-antigen specific protection due to the structural identity of 
the O-antigen and the pilin glycan.   
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